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Bayesian survival analysis has benefitted from the introduction of Markov Chain Monte
Carlo (MCMC) since the 1990s. However, MCMC has high computational cost and
requires tuning and convergence checking. These hamper its usefulness. Integrated Nested
Laplace Approximation (INLA) is a convenient alternative to MCMC due to its efficiency
and straightforward execution to obtain the posterior distributions of relevant survival
parameters such as the regression coefficients and Weibull shape parameter. This has
been demonstrated in parametric and semi-parametric proportional hazard and piecewise
constant hazard models. Nevertheless, it has not been possible until now to use INLA
when covariate data are missing since it neither can integrate out missing covariate data
nor is it satisfactory to use other subsidiary methods such as multiple imputation to
overcome this difficulty.
We therefore investigate the application of INLA to piecewise exponential constant
hazard models when covariate information is missing. We extend and modify the INLA
within MCMC method to circumvent the missing covariate data problem in survival
cases, assuming that the data are missing at random. We use both hierarchical and
autoregressive priors for the baseline log-hazard and covariate effects and compare the
results with those obtained by MCMC.
The methods are applied to three different data sets; Catheter-related kidney infection,
Scotland-Newcastle Lymphoma Group Non Hodgkin Lymphoma, and Malaysian Hospital
Universiti Sains Malaysia Advanced Lung Cancer data sets. The priors are constructed
based on the information obtained from the meta-analysis of results from previous studies.
The results obtained demonstrate that the developed methods are suitable for various sur-
vival data sets with reasonable numbers of missing covariate values, making this proposed
method a convenient alternative to standard MCMC algorithms for survival analysis.
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Introduction and Thesis Outline
1.1 Motivation
This research is concerned with the Bayesian analysis of survival data. The focus is on the
development of novel techniques to circumvent the problems with missing covariate data
in survival models when posterior inference is obtained using Integrated Nested Laplace
Approximation (INLA).
Classical analyses (such as Cox proportional hazard model with unspecified baseline
hazard function) are the usual choice among applied researchers when modelling continu-
ous time to event data. The reliance of these techniques on partial likelihood for parameter
inference has several limitations since they restrict the utilization of information from the
full likelihood and the complete estimation of unknown elements in the model. Survival
analysis using Bayesian methodology offers a better alternative and provides a complete
and accurate posterior inference for the parameters of the models.
Various techniques have been proposed in the Bayesian literature for the modelling of
time-to-event data to accommodate variations in dataset characteristics such as within-
group correlation, the effects of non-linear covariates and spatiotemporal differences. A
general overview of Bayesian survival analysis is given by Ibrahim et al. (2001). Some
research into Bayesian survival analysis has investigated the use of nonparametric and
semiparametric forms for the baseline hazard function. For example, Kalbfleisch (1978)
introduced piecewise constant hazard models which assume that the baseline log hazard
is constant over certain time intervals. Another active area has involved relating survival
to spatial location. Banerjee et al. (2003) used a parametric Weibull baseline hazard
with spatial component in their geostatistical model. Guo and Carlin (2004) investigated
1
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joint analyses of survival and longitudinal data. They demonstrated that longitudinal
and survival data are conditionally independent and postulated that a latent bivariate
Gaussian process was present in the model.
Markov chain Monte Carlo (MCMC) methods have been the backbone of Bayesian
modelling for the past three decades (Ashby, 2006). The two most widely used MCMC al-
gorithms, Metropolis-Hastings (Hastings, 1970) and Gibbs sampling (Geman and Geman,
1984; Gelfand and Smith, 1990), have provided approximations to previously intractable
posterior distributions in high dimensionality problems (“curse of dimensionality”). De-
spite the popularity of MCMC and a large number computational modalities such as
WinBUGS (Lunn et al., 2000) and R (R Core Team, 2018) that support MCMC execution
for broad classes of models, there are two main drawbacks:
1. high computational time (hours or even days for the computation of posterior
marginal distributions),
2. manual “tuning” by the users for convergence diagnosis and judgment on the accu-
racy of the approximation, especially when modelling spatial components or semi-
parametric (smooth) effects.
In order to address these difficulties, the INLA method has been proposed (Rue et al.,
2009). In recent years, Martins et al. (2013) introduced new features with INLA which
includes additional distributions for survival analysis that can be fitted by INLA. Jiang
et al. (2014) gave examples of INLA utility for geostatistical survival models for environ-
mental risk assessment using retrospective cohort data collected from Pickering Nuclear
Generating Station, Canada. Martins and Rue (2014) further extended INLA flexibility
to accommodate a class of near-Gaussian latent models such as those whose latent field
has a near-Gaussian distribution particularly those with a unique and unimodal mode,
finite first two moments and distributions with density that has full support on the real
line. In Muff et al. (2015), INLA was also extended and shown to be an efficient Bayesian
analytical approach for measurement error (ME) models.
In survival analysis, many of the Cox-type models in the literature may be viewed
as latent Gaussian models which are a large class of models with jointly-Gaussian latent
variables. Therefore, complex constituents of the models (spatiotemporal effects, an as-
sortment of frailty effects) can be included without difficulties since they can be regarded
as trivial changes to the Gaussian components of such a model. For Bayesian inferential
purposes, a quicker and more exact approximation to the posterior marginal distributions
can be made possible using INLA. The method uses a brilliant application of Laplace
2
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approximations and advanced numerical methods. These result in a significant reduction
in computational time (compared to standard MCMC methods). Besides, no significant
manual tuning or interaction is required from the users. This enables INLA to be used
like a“black box”. An R package is available (R-INLA) from http://www.r-inla.org to
aid the execution of INLA computation.
In medicine and public health, INLA methodology has been used for the modelling
of spatial and spatio-temporal models (Blangiardo et al., 2013), for a multi-state model
for pancreatic cancer progression (Alvaro-Meca et al., 2013), stomach cancer incidence in
Southern Portugal (Papoila et al., 2014) and others. In the field of ecological modelling,
Carson and Flemming (2014) further highlighted the usefulness of INLA. The authors
demonstrated that a more efficient technique of hierarchical spatio-temporal modelling
was developed when INLA was combined with a stochastic partial differential equations
(SPDE) approach for acoustic telemetry data, specifically for detecting or tagging of Sable
Island grey seals (Halichoerus grypus) at sea.
The nascent idea about INLA being a fast approximation method for posterior in-
ference in Bayesian statistics was expounded in a much earlier article, Rue (2001). The
author demonstrated that posterior marginal distributions for models that exhibit the
properties of Gaussian Markov Random Fields (GMRF), which is also known as condi-
tional autoregression (Besag and Kooperberg, 1995), may be efficiently computed since
they are straightforwardly amenable to numerical integration for sparse matrices. This
finding was further followed by an attempt to extend it to models that possess hidden
Gaussian Markov random field properties (Rue et al., 2004). The ideas contained in these
papers were taken one step forward by Rue and Martino (2007). The contributors devel-
oped a deterministic substitute to MCMC, which can be regarded as an INLA prototype,
utilizing the sparsity of the precision matrix Q in GMRF. This eliminates the need for
inversion of the precision matrix Q for computing marginal variances. This eventually
culminates in the seminal paper by Rue et al. (2009) which cemented the birth of INLA
as a fast deterministic approach for computing posterior distributions.
In their original contribution, Rue et al. (2009) had demonstrated that INLA is an
efficient technique for Bayesian inference for a subclass of structured additive regression
models called latent Gaussian models (LGM). In comparison to MCMC, INLA is superior
in terms of accuracy and speed in the computation of posterior marginals in LGM. This
is due to the additive errors of MCMC which implies that longer computational time is
required just to increase the precision of the estimate by a single digit. Apart from that,
the probabilities in the tail region are much harder to compute due to the additive errors
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of Monte Carlo estimates in MCMC. INLA is able to avoid these limitations since it has
only a relative error nature which permits the accurate approximation of tail probabilities.
Nevertheless, the robustness of the INLA scheme suffers from some limitations. Firstly,
the dependence on a Gaussian distribution for the latent field impairs its application to
other models that are not within the LGM class. For instance, a survival model with
gamma frailty (Ibrahim et al., 2001) whose random effects follow a log gamma distribu-
tion is not amenable to using INLA methodology. Martins and Rue (2014) attempted to
provide an alternative strategy to this problem by embedding the initial standard model
within a LGM framework to create a more flexible model. They then corrected the inde-
pendent non-Gaussian components of the latent field for asymmetry and kurtosis using
near-Gaussian distributions. However, this strategy is hampered by the unavailability of
clear diagnostics to identify which non-Gaussian distributions really have near-Gaussian
properties. Therefore, further strategies are required to extend the work of Martins and
Rue (2014) to permit a wider class of non-Gaussian models which can be computed using
the INLA scheme.
Secondly, the modest number of hyperparameters (m < 6) that can be accommodated
by INLA severely limits the application of this scheme. According to Rue et al. (2009),
even a moderate number of hyperparameters (6 ≤ m ≤ 12) may prove to be quite
taxing for INLA, resulting in an exponential rise in computing time. The low dimen-
sional hyperparameters and Markov random field are both underlying requirements for
the latent Gaussian field and INLA computation. Perhaps these are quite unrealistic in
many biological and medical applications (Wikle and Holan, 2009). More works are thus
required to expand the utility of INLA in models with high-dimensional hyperparameters
(m > 12).
Thirdly, the impact of missing covariates on the accuracy and flexibility of INLA
computation has not been investigated in the context of survival analysis. In particular,
work is required for dealing with non-Gaussian, especially categorical covariates, possibly
using further latent Gaussian variables.
1.2 Research objectives
The primary objectives of this research are:
1. Compare the performance of different computational approaches (MCMC vs INLA)
in Bayesian inference for survival analysis models.
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2. Investigate the construction of appropriate forms for the prior distributions of the
log hazard.
3. Assess the performance of INLA in missing covariates values and develop approaches
to improve the flexibility of INLA in this setting.
4. Apply the formulated approaches to practical problems using real medical datasets
and evaluate the strengths and limitations of each approach
Therefore, this research is concerned with answering these specific research questions:
 How can we fit piecewise constant hazard models using INLA and what is its effi-
ciency in obtaining posterior quantities of interest relative to MCMC approach?
 How can we resolve INLA’s deficiency in dealing with missing covariate information
in the most appropriate and efficient way?
 How can prior distributions for the log hazard be meaningfully constructed based
on the information from previous research?
 What are the advantages of INLA in the construction of prognostic indices for
different real medical datasets compared to MCMC?
1.3 Thesis outline
Chapter 2 introduces the fundamental ideas of survival analysis and Bayesian inference.
We give a brief introduction to survival analyses which is then followed by discussion of the
types of censoring and truncation. We then explain two commonly-used survival models:
the proportional hazard (PH) and accelerated failure time (AFT) models. Parametric
survival models are then introduced, with special attention given to deriving probability
density and hazard functions, survival time distributions and likelihood functions for
survival times that follow Weibull distributions. Frailty is subsequently introduced and the
derivations of the marginal survival time distributions and hazard function are illustrated.
In section 2.7, the piecewise constant hazard model is introduced and the methods used
for selecting the cut points for time intervals and the inclusion of time-varying covariate
effects are discussed in detail. In 2.8, the fundamental aspects of Bayesian inference in
a survival analysis context are succintly expounded and this is then followed by a brief
dicussion of Markov Chain Monte Carlo (MCMC) which includes illustrations of different
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variants of the Metropolis Hastings and Gibbs sampling algorithms. We then discuss
the data augmentation approach as a means to handle missing covariate values. The
computation of posterior quantities of interest is then illustrated using a catheter-related
urinary tract infection data set and this is performed using RJAGS.
In Chapter 3, we introduce latent Gaussian models (LGMs) and Gaussian Markov
random fields (GMRF). Firstly, the relationship between generalised linear models and
LGMs is discussed in detail. This is then followed by elaborations on GMRF characteris-
tics and proofs for the sparsity of the precision matrix, Q, are presented. Subsequently, we
demonstrate the derivations of the recursive formula for computing marginal variances for
each parameter of interest and conditional GMRF distributions in the presence of some
linear constraints. We then explicitly describe how a Bayesian hierarchical model can
be viewed as a GMRF. The GMRF approximation for non-Gaussian likelihood is then
illustrated.
In Chapter 4, the main ideas of the integrated nested Laplace approximation (INLA)
will be propounded in detail. The ideas behind the use of a Laplace approximation for
computing a posterior distribution are first described. We then present an outline of INLA
methodology which includes the use of the central composite design (CCD) approach to
tackle the problems with high numbers of hyperparameters. Next, we demonstrate INLA
implementation using two simple examples in 4.4. In 4.5, we show how piecewise constant
hazard models can be fitted using INLA. We then show how the missing covariate data
problem can be addressed with a new computational approach which is the INLA within
MCMC (INLA-MCMC) method. This is a novel approach which is introduced in this
thesis.
In Chapter 5, we introduce the three data sets used for application purposes: the kid-
ney infection data set, Scotland and Newcastle Lymphoma Group (SNLG) Non Hodgkin
Lymphoma (NHL) data set and a Malaysian lung cancer data set. For each data set, we
give the operational definitions and the characteristics of each covariate and explain how
the data were gathered.
In Chapter 6, we will give background information on how prior distributions can
be constructed for shape parameters in Weibull survival models, baseline log hazard,
coefficients of linear predictors and frailty variances. The constructions of two types of
prior for piecewise constant hazard models (hierarchical priors and autoregressive priors)
is then illustrated for the SNLG-NHL example.
In Chapter 7, the performance of the INLA-MCMC approach for dealing with missing
covariate information will be assesed and compared with standard MCMC by applying
6
Chapter 1. Introduction and Thesis Outline
the methods to the example data sets. In Chapter 8, we shall give conclusions and some






In this chapter, two main ideas shall be discussed: the fundamental approaches and results
in survival analysis and Bayesian Inference. In the first part, which consists of subsections
2.2 to 2.7, we will introduce the main ideas in survival analysis, truncation and censoring,
the two main models used in survival analysis: Proportional Hazard (PH) and Accelerated
Failure Time (AFT) models, parametric survival models, the effects of frailty on survival
time distributions and piecewise constant hazard models.
In the second part, the primary ideas and standard results in Bayesian inference will
be elucidated. This will include a brief introduction to Bayesian ideas where basic theory
and notation will be introduced. We will subsequently discuss survival analysis within
the Bayesian context, the use of the Markov Chain Monte Carlo (MCMC) approach for
computing posterior distributions and the strategies for dealing with missing data using
the data augmentation approach (Tanner and Wong, 1987). We will finally demonstrate
the application of Bayesian survival analysis via the RJags (Plummer, 2016) package using
a catheter-associated urinary tract infection dataset.
2.2 Introduction to survival analysis
Survival analysis is a statistical technique for the analysis of time-to-event data. This
data has the form of times from a specific origin until a certain event of interest occurs
(Collett, 2015). As an example, in a clinical trial, the time origin is usually at the time
when the patients were initially enrolled into the study and the events of interest are
9
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usually death, cancer progression or remission and other clinical events of interest.
For the analysis of survival data, the hazard function is usually employed to specify the
survival models. To aid discussion later on, the following notations are introduced; F (t)
is the cumulative distribution function (cdf) of the survival time, f(t) is the probability
density function (pdf) of the survival time and the survival function, S(t) is defined as




and F (t) = Pr(T ≤ t).
Hence, the survival function can be rewritten as
S(t) = 1− F (t).






Pr(t < T < t+ δt|T > t).









There are two additional features that should be considered in survival analysis: censoring
and truncation. These will be discussed in the next section.
2.3 Censoring and truncation
2.3.1 Types of censoring and truncation
The primary outcome in survival analysis is the time until the event of interest occurs.
Unfortunately, this is often incompletely observed and, as a result, censored observations
(observations with incomplete information on the event times) ensue. Several types of
censoring have been established and they are
Right censoring (the most common) - The censoring time for the subjects (Cr) is
less than the true survival time (T). Hence, it can be deduced that T is larger than
Cr.
10
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Left censoring - The true survival time, T, is known to be less than the left censoring
time (Cl). For instance, the event occurs before the commencement of the study
(T < Cl).
Interval censoring - The true survival time is not precisely known but is known to lie
between two censoring limits (Cl ≤ T ≤ Cr).
Truncation differs from censoring. Truncation is about the entry of subjects that have the
event times within the observational period or window of the studies. Truncated obser-
vations occur when only subjects whose event times are within the observation window
(Tl, Tr) are observed. Two types of truncated observations have been described:
Left truncation (also known as delayed entry) - occurs when Tr is limitless (Tr →∞).
Therefore, only those with observation times more than Tl are observed.
Right truncation - Tl = 0. The observation window is hence (0, Tr). Hence, only
individuals with event time less than a prespecified threshold of Tr are going to be
included in the study.
2.3.2 Independent and non-informative censoring
Independent censoring is one of the most critical assumptions in survival analysis. In some
cases it could be that the event that a patient is censored at time c is not independent of
the patient’s remaining lifetime. For example, patients who are ill and who have shorter
expected remaining lifetime may be more likely to drop out of a study and be censored.
When the independent censoring assumption is met, the actual survival time of a study
participant (patient) is independent of the censoring mechanism that causes his or her
observed survival time to be censored at time c (in this case, c < T ). In other words,
subjects who are censored at time c are still representative of other subjects who are still
at risk at that time point. As a result, the censoring and survival times can be treated
independently.
Suppose that each patient has a survival time T and a censoring time C. In some
cases C →∞. If C > T , then the patient is not censored and the event indicator δ = 1.
If C ≤ T then the patient is censored and δ = 0.
Let the parameters of the lifetime distribution be θT and those of the censoring process
be θC . The independence condition is:
Pr(T < t | C < s, θT , θC) = Pr(T < t | C ≥ s, θT , θC) for all t, s > 0.
11
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If this holds then the joint density of T and C given θT and θC is
fT (t | θT ) fC(c | θC).
Hence, if we make an uncensored observation at time t then the likelihood contribution is




since we observe that C > t.
Similarly, the likelihood contribution of a censored observation, censored at time c is
L0 = fC(c | θC)
∞∫
c
fT (t | θT )dt.
If, in addition, θT and θC contain no elements in common, then in terms of the likelihood
function of θT ,
L1 ∝ fT (t | θT ), L0 ∝
∞∫
c
fT (t | θC)dt = ST (c | θt) = 1− FT (c | θC) = Pr(T > c | θT )
(2.1)
and the censoring is said to be non-informative.
There are many scenarios where the assumption of independent censoring is not ten-
able. In the context of clinical trials, the violation of this assumption occurs when han-
dling drop-out cases. The reason for drop-outs occurring in clinical trials can be two-fold:
firstly, drop-out cases may reflect the study participants whose health is deteriorating
more quickly, resulting in failing to come for follow-up visits or discontinuation of the
drugs under investigation secondary to worsening physical condition. In a more extreme
scenario, the study participants might even have passed away undocumented and hence
are considered to be lost to follow-up and finally recorded as censored cases. As a result,
the study participants who are censored at time t are no longer representative of the
study participants who are still at risk at time t. This serious violation of independent
censoring will distort the findings obtained from survival analysis (e.g. inflated hazard
rate, obtaining survival time that is shorter than actual etc). However, for the purpose of
our future analysis, we shall assume that independent censoring holds. When censoring
occurs as a result of the end of the study, this is often a reasonable assumption.
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2.4 Linking the effects of explanatory vari-
ables and lifetime distributions
There are two major approaches for modelling the effects of explanatory variables on the
survival distribution: proportional hazard models and accelerated failure time models.
2.4.1 Proportional hazards (PH) model
Following the seminal paper by Cox (1972), the Cox proportional hazard model has been
at the forefront of survival data analysis based on the semi-parametric approach. Since
Cox’s proportional hazards model has been the most popular regression approach for
time-to-event problems used in many applications, only a brief account will be given
on this topic. For detailed discussion, the original paper by Cox (1972) is an excellent
exposition on this modelling approach.
According to Cox (1972), h(t) is a function of a baseline hazard function, h0(t), covari-
ates z1, z2, z3, . . . , zp and regression coefficients β1, β2, β3, . . . , βp. In a proportional hazard
model, this can be written as follows:
h(t|z1, z2, z3, . . . , zp) = h0(t) exp(z1β1 + z2β2 + z3β3 + . . .+ zpβp).
Thus, in a proportional hazard model, it is assumed that changing the value of a covariate
has a scaling effect on a hazard function of fixed form. Various types of proportional
hazard models can be produced with different kinds of distributional assumptions for
h0(t). For instance, if h0(t) is assumed to be constant over time, then an exponential
regression model will be obtained.
Suppose that there are P covariates (p= 1,. . . ,P ) and n subjects (i = 1, . . . , n).
The vector of the explanatory variables (covariates) for subject i is thus given by X i =
(xi,1, xi,2, . . . , xi,p)
T . Each explanatory variable can be one of these: discrete, continuous,
categorical or even mixed distribution covariates. For two subjects, which are denoted
as subject i and subject j, that have different values for the explanatory variables, their
respective hazards can be linked by the following equation:
hi(t) = λi,jhj(t).
We can regard subject j as the one having the baseline hazard h0 function. As a result,
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the hazard function for individual i can be said to be a multiple of the hazard of individual
j. Hence we can further express the equation above in the following relationship:
hi(t) = λih0(t).
Hence, λi is the hazard multiplier. Since the hazard cannot be negative, λi should thus be
constrained to be greater than zero. To ensure this condition is satisfied, the covariates
can be linked to the hazard multiplier through a logarithmic link function:
log λi = β1x1,i + β2x2,i + . . .+ βpxp,i.
If we set log λi = ηi, then ηi represents the model’s linear component. This quantity
specifies whether an individual has a higher (if ηi is unusually large) or lower (if ηi is
small) than average hazard of experiencing the event of interest. Hence, ηi is also known
as the prognostic index, or risk score (Collett, 2015), for the ith subject.
2.4.2 Accelerated failure time (AFT) models
The Accelerated Failure Time (AFT) approach uses a slightly different methodology com-
pared to the PH models. In the AFT modelling paradigm, the covariates act multiplica-
tively on the time scale. The effects of the covariates can thus be interpreted as an
acceleration factor: a rate at which an individual’s survival progresses on the time axis.
This approach has a highly instinctive appeal since AFT models can be regarded as a
way of measuring the speed of the progression of the event of interest (such as disease
progression based on some measured covariate values), making it attractive for application
in many scientific fields especially in medical research.
As a motivating example, let us consider a group of patients enrolled in a randomised
controlled trial. These patients were randomly allocated to either the standard or novel
treatment (denoted by S and N). The event of interest is death due to some fatal illness,
such as cancer. Within the context of an AFT model, the effect of the novel treatment is
assumed to either “accelerate” or “decelerate” the passing of time relative to the standard
treatment. To make things simple, we only consider a single covariate, which is the treat-
ment group, in this example. Based on this assumption, it can be said that the probability
of a patient who is allotted to the new treatment surviving beyond t is equivalent to the
probability of a patient who is randomised to the standard treatment surviving beyond
time t/φ. This φ is known as the acceleration factor and it is a positive constant.
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To illustrate further, let Ss(t) and Sn(t) be the survival functions for patients who
are on the standard and novel treatments, respectively. Under the AFT approach, the
relationship between Ss(t) and Sn(t) can be written in the following fashion:
Sn(t) = Ss(t/φ).
If φ lies between 0 and 1 (i.e. 0 < φ < 1), then the survival proportion of patients
who received the standard treatment is greater than the survival proportion of patients
who were on the novel treatment at time t (i.e. the novel treatment accelerates the
progression of the fatal disease). However, if φ is greater than 1, it means that the
survival proportion of patients receiving the standard treatment is less than the survival
proportion of patients who are on the novel treatment at time t (ie the novel treatment
“decelerates” the progression of the fatal disease). Hence, the novel treatment is better
than the standard treatment in prolonging a patient’s life if the acceleration factor φ > 0.
However, the interpretation should be reversed if the event of interest is, for instance,
cancer remission. If φ lies between 0 and 1, it means that the proportion of subjects
receiving the novel treatment who have achieved disease remission at time t is greater than
the proportion of recipients of the standard treatment (i.e. the proportion of recipients of
the novel treatment who still have active disease is less than the proportion of recipients
of the novel treatment with active disease at time t). On the other hand, the opposite
can be concluded if φ is more than 1.






the hazard and survival functions for patients in the standard and novel treatment groups
can be written as
fn(t) = φ
−1fs(t/φ) and hn(t) = φ
−1hs(t/φ).
If we define a new variable X as an indicator whether a patient is on the standard or





If we set xi = 0 in the equation above for patients on the standard treatment, we will
15
Chapter 2. Bayesian Survival Analysis
obtain the baseline hazard function, h0(t). Therefore, we can regard patients who receive
the standard treatment as having a baseline hazard function. It is hence obvious that the
hazard function of a patient who is on the novel treatment will be:
hN = φ
−1h0(t/φ).
Since φ should always be positive, we can reparametrise φ by writing: φ = eα. Hence, the




The AFT model can also be further generalised into models that include p covariates. We
can generalise the final form of the AFT hazard function for a single covariate case into
the following:
Si(t) = S0(t exp{−ηi})
hi(t) = exp{−ηi}h0(t exp{−ηi})
ηi = α1x1i + α2x2i + . . .+ αpxp.
Thus, S0(t) can be considered as a survival function for subjects with zero values for all
p covariates.
2.5 Parametric survival models
In an accelerated failure time model, we might specify the baseline survivor function as
S0(t) = S(t; θ0) = 1 − F (t; θ0) where F(t;θ) is the distribution function for a particular
family of survival distribution indexed by a parameter θ. Similarly, in a proportional
hazard model, we might specify the baseline hazard function as
h0(t) =
f(t; θ0)
1− F (t; θ0)
where f(t;θ) and F(t;θ) are respectively the pdf and distribution function for a particular
family of survival distributions indexed by a parameter θ. A survival model specified in
this way is known as a parametric survival model.
However we might prefer to allow more flexibility in the form taken by the baseline
survival or hazard function. A model where the form is not specified is known as a
16
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semi-parametric survival model. It is called semi-parametric rather than nonparametric
because the dependence on covariates is still specified parametrically.
2.5.1 Weibull distribution
2.5.1.1 Probability density, hazard and survival distributions
In this section, we shall borrow the notation used by Collett (2015). The Weibull dis-
tribution was named after a Swedish mathematician Waloddi Weibull, who thoroughly
elucidated it (Weibull, 1951). It was originally developed and used for reliability testing
in the industrial setting. However, it has now occupied a critical role in parametric
survival analysis due to its versatility and flexibility in adopting the characteristics of
other distributions by changing its shape parameter, α. The probability density function
















where α is the shape parameter, η is the scale parameter and ζ is the location (α > 0, η >


















In medical statistics, the Weibull distribution is often parametrised differently. The shape




















, λ > 0, α > 0.
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Hence, the cumulative distribution function of a Weibull distribution is





From these equations, we can easily deduce that, if we fix the shape parameter α = 1
(i.e. the failure rate is constant across time), the Weibull distribution reduces to the
exponential distribution











If α > 1, the hazard rate will be monotonically increasing and, when α < 1, the hazard
is monotonically decreasing.









Through the scale parameter, λ, we may include the covariate effects as
ηi = g(λi)
where g should be a monotonic function that can be differentiated. Usually g(λ)= log(λ).




where XTi represents the covariate values of patient i and β is a vector of regression
coefficients, βT = (β0, β1, β2, . . . , βp). We can relate λi with ηi as follows:
exp (XT β) = exp (ηi) = g
−1(ηi) = λi
For a subject with baseline covariate values (i.e. subjects with typical covariate pattern
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where λi = λ
∗
iλ0,
2.5.1.2 Likelihood function for Weibull survival times
In deriving the likelihood function for Weibull survival times, independent censoring is
assumed (for further details, refer to Section 2.2). Firstly, we shall define Ti and Ci
corresponding to survival time and censoring time, respectively. Then, the follow-up time
ti experienced by the patient will take the minimum of either Ti or Ci (i.e it is a realisation
of a random variable ψi = min (Ti, Ci)). We thus observe the paired quantity (ψi, δi),
where δi is an event indicator with value δi = 1 if the event is observed and δi = 0 if the







where θ contains α and the coefficients in the linear predictor.









For a Weibull distribution, there are two parameters that govern its scale and shape (λ
and α, respectively). Thus, θ = (λ, α)T . The likelihood function is given by

















































where R is a collection of X, n, S, T and δ (R = {X, n, S, T, δ}), E is the set of subjects
experiencing the event and C is the set of subjects with censored survival times and nD
is the number of subjects with the event of interest. For the collection of quantities in R:
 X is the n × (p+1) design matrix with the ith row representing the covariate values
for the ith individual. In other words, the ith row of X is (1, xi,1, xi,2, xi,3, . . . , xi,p)
 n is the total number of subjects;
 P is the number of covariates in the model;
 T = (t1, t2, . . . , tn)
T , where ti is the censoring or event time for individual i;
 δ = (δ1, δ2, . . . , δn)
T is the event indicator.
For easy algebraic manipulation, we take logs on both sides of the equation resulting in
`(λ, α) = log(L(λ, α | R)) =
∑
i∈E






However, we have previously shown that the linear predictors and the scale parameter λi
can be linked by
λi = exp(X
Tβ).
The log likelihood function can hence be rewritten as
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2.6 Random Effects in survival analysis (Frail-
ties)
2.6.1 Frailty: a succinct introduction
The concept of frailty originated in the innovative work of Greenwood and Yule (1920) who
conceptualised the idea that a negative binomial distribution of counts could be seen as a
mixture of Poisson random variables for “accident proness” and data on recurrent bouts
of disease attacks (Hougaard, 2013). The term frailty was firstly coined by Vaupel et al.
(1979) to denote the random effects of unknown or unmeasured covariates in univariate
survival data. However, frailty was applied to multivariate survival data a little earlier,
based on work by Clayton (1978) who assigned a gamma distribution to the frailty term.
When we investigate the risk factors for certain conditions, we always assume that the
individuals of interest have homogenous levels of risk factors (except for the ones that are
measured and included in the model) for a certain event such as death. However, this is far
from the truth since it is overwhelmingly implausible to consider, measure and include all
of the covariates associated with the survival time of subjects. This is particularly true
due to our limited knowledge with respect to the factors that are mechanistically and
prognostically relevant in influencing the time to the event of our interest. In fact, despite
taking into account all of the prognostic factors that are determinants of the differences in
survival times, there may still be heterogeneity in survival times among those who possess
similar covariate values. As a result, the non-observable variations in an individual’s risk
factors cannot be appropriately neglected. As a remedy, we require a random effect term,
known as frailty in the survival analysis context, to account for this survival heterogeneity
during the modelling process.
According to Aalen (1994), there are three possible sources of this unobserved hetero-
geneity. The first one is attributed to the differences in biological “fitness” from the start
of the period of observation. This can be explained by the fact that certain subjects or
patients may have weaker organ functions compared to other cohort members or have a
genetic predisposition that renders them more susceptible to the disease of interest. Sec-
ondly, the unobserved heterogeneity may also be caused by the stresses (both biological
and psychological stressors) experienced by those subjects in their lifetime. This therefore
portrays frailty as a dynamic process which changes as time progresses. The final cause
is due to whether the event of interest occurs at an early or late phase. For example, a
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protracted diagnosis of cancer may cause the cancer cells to be ubiquitously metastasised
all over the bodily systems. Consequently, such a person will be in an advanced stage of
cancer and this may cause him or her to have a higher frailty of death compared to his
or her cohort.
Before we proceed further, it is imperative to distinguish between the frailty term
used in a medical context and the frailty term used in biostatistics and demography. In
the former, frailty means the susceptibility of an individual to mortality or morbidity
associated with the disease of interest (Wienke, 2011). On the other hand, the statistical
frailty means random effects accounting for the unobserved heterogeneity between subjects
(Wienke, 2011). It is thus paramount not to confuse between these two types of frailty.
Another aspect that should be emphasised is that the frailty term only accounts for
unobserved heterogeneity between subjects, which is indeed a simplified concept in ad-
dressing the differences in survival times among individuals. For example, the concepts
of adaptation and debilitation are not captured by the frailty term (Wienke, 2011). In
the former, individuals are considered to be successfully adapting themselves to the stress
(i.e. the event of interest) after a period of exposure to the stress. Debilitation, on the
other hand, refers to the worsening of individuals’ stress response or physical health after
being exposed to the stress for a period of time. Hence, this is a fertile ground for future
research.
In the next section, we shall illustrate the utility of the frailty term in, firstly, uni-
variate survival data, followed by multivariate survival data. These are then followed by
the formal derivations of conditional and marginal cumulative hazard, hazard, survival,
probability density functions in the presence of a frailty term in the survival model.
2.6.2 The motivation behind the inclusion of a frailty
term
The frailty term in the univariate survival model is useful for making the model more
flexible. For instance, we can incorporate a frailty term with a proportional hazard model.
Contingent upon the type of distribution assigned to the frailty term, the assumption of
hazard proportionality can be relaxed and thus the model can now accommodate the
non-proportionality of hazard. Apart from that, the inclusion of a frailty term may also
rectify a survival model with an overdispersed error. We can also assign each subject his
or her own frailty and since frailty modifies the baseline hazard function multiplicatively,
each individual will thus have their own hazard. To obtain the population-level hazard,
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we can simply integrate out the frailty term and thus averaging the frailty over individuals
in the population (Wienke, 2011).
Neglecting the frailty term may have undesirable consequences. According to Hen-
derson and Oman (1999), forsaking the frailty term from the model may cause misspeci-
fication of a proportional hazard model to the correct marginal distribution. Henderson
and Oman (1999) also found that estimates of regression coefficients obtained might be
biased towards 0, depending upon the type of the frailty distribution and the level of
the unobserved heterogeneity operating on the individual subjects. For more examples
of frailty in univariate survival models, Hougaard (1995) provides extensive examples of
this.
On the other hand, frailty is more frequently used in multivariate survival models for
the purpose of modelling dependencies between observations (Hougaard, 2013). There are
four common scenarios where frailty is useful. The first one is when there is strong corre-
lation between two or more individuals, for instance twins, siblings or matched pairs. The
second is when modelling the effects of an intervention on related organs in an individual
or components in a machine. Thirdly, frailty is useful in modelling the dependencies of
recurrent or multiple events, for example when investigating the time to cerebrovascular
accident (i.e. stroke), heart attack or seizure associated with epilepsy in the same indi-
vidual. The final one is when an individual experiences multiple treatments in a designed
experiment and the time to an event of interest for each treatment regime is recorded.
For further information, refer to Hougaard (2013).
2.6.3 The derivations of conditional and marginal quan-
tities of interest
Before we proceed, we shall assume that the frailty term acts on the baseline hazard
function multiplicatively. Borrowing the notation used in Collett (2015) and Fung (2017),
we denote a frailty term as zi. In a proportional hazard model, the frailty term can be
incorporated as
hi(t | Zi = zi) = zi exp(βT xi) ho(t).
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The equation above gives the hazard function at t given the value of the frailty term zi
for individual i. We can take log on both sides of the equation to obtain
log hi(t | Zi) = log (zi) + βT xi + log h0(t).
There is one particular assumption that we made here. In contrast to the effects of other
covariates on survival time (i.e that they may change over time, hence possibly requiring
time-varying covariate effects), the effect of the frailty term is considered constant over the
time period. It means that the random risk experienced by the individuals will remain
constant as time progresses. This may or may not be true and hence there is room
for future research to develop a survival model that is not strictly dependent on this
assumption.
From here, we will proceed to deriving other quantities. To obtain the conditional
cumulative hazard, Hi(t | Zi), we integrate the hazard with respect to t, giving




Txi) Zidt = H0(t) exp(β
Txi) Zi.






we derive the conditional survival function as
Si(t | zi) = exp
{






where λi = exp(β
Txi). Then, by simple algebra, the conditional survival function is
obtained as





where S0(t) represents the baseline survival function. We can obtain the marginal survival
function by multiplying the baseline survival function with fZ(zi) and integrating out the





λizifZ(zi)dzi = EZ [S0(t)
λiZi ]
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where fz(zi) is the pdf of Z.





































As a simple example, we shall now elucidate gamma-distributed frailties with a con-
stant baseline hazard. In this example, we assume that each subject possesses a separate
value for the frailty term, zi, and these values are iid with Zi ∼ Ga (g,h∗). We also
assume S0(t) = exp{−t}, so the conditional lifetimes have an exponential distribution.
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which is not constant with respect to t unless λi = λj. The mean and variance of the























As we can see, (2.3) indicates the non-proportionality of hazards since the hazard ratio
changes with t.
2.7 Piecewise constant hazard model
2.7.1 Theory and basic notation
A flexible approach to relax the parametric assumption about the form of the baseline haz-
ard is a piecewise constant hazard model (Prairie and Ostle, 1961; Colvert and Boardman,
1976; Shaked, 1979; West, 1982; West et al., 1985; Gamerman and West, 1987; Gamerman,
1991; Ibrahim et al., 2001; Kim et al., 2007; Wilson and Farrow, 2017). We shall describe
the piecewise-constant proportional hazard (PCPH) models first before elaborating on the
alternative modelling approach which is needed when the proportional hazard assumption
is violated. In PCPH models, we assume that the hazard is variable over different time
intervals, albeit it is still proportional. In this case, the time axis is divided into disjoint
intervals by specifying several cut-off points.
We choose some fixed time points τ0,. . . ,τj, with τ0 = 0, τj > τj−1 and, typically,
τj → ∞. Then the jth time interval is Ij = [τj−1, τj). Next, we assume that the hazard
is constant within each time-interval, but variable between time-intervals. The hazard
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function can thus be represented as follows:
hi(t) = λij, for τj−1 ≤ t < τj
where τ0 = 0 and τj →∞
The covariates for individual i can be linked to λij by the relationship
λij = λ0jexp(x
T
i β) = exp(β0j + x
T
i β).


























λik(τk − τk−1) + λij(t− τj−1), t ∈ Ij.








λik(τk − τk−1) + λij(t− τj−1)
]}
, t ∈ Ij.
Hence, the probability density function of survival times is given by










for t ∈ Ij. Therefore, the conditional density and survivor function given that T ≥ τj−1
are
fi(t | T ≥ τj−1) = λij exp{−λij (t− τj−1)}
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and
Si(t | T ≥ τj−1) = exp{−λij (t− τj−1)}, for τj−1 ≤ t < τj.
If we consider the likelihood for the event time, t, we shall realise that the likelihood
can be factorised temporally. Based on Gamerman (1991), the likelihood for the event
time can be written as





Lj(tij | λj, Dj−1)
where D0 is an information set containing the event status for all subjects across all j
intervals, Dj−1 is the event status for subjects who survive into the previous interval Ij−1
and tij represents one of these three occurrences for each subject i in interval j:
 the ith subject experienced the event in the interval j. Hence, τj−1 ≤ ti < τj. So,
tij = ti and δij = 1
 the ith subject was censored in the interval j. Therefore, τj−1 ≤ ti < τj. So, tij = ti
and δij = 0
 the ith subject was still alive at the end of the interval j. Therefore, τj ≤ ti. So,
tij = τj and δij = 0
 the ith subject died or was censored before the beginning of interval j. Then tij =
τj−1 and δij = 0
where δij indicates whether the subject experienced the event of interest in Ij. Each
Lj(tij | D0, λ) is thus given by:




exp{−λij(tij − τj−1)} (2.4)
where δij = 1 if the subject dies in Ij and δij = 0 otherwise.
2.7.2 Methods of selecting the cut points for the time-
intervals in a piecewise constant hazard model
One of the requirements for the piecewise constant hazard model is that the time axis
should be partitioned. Several authors have recommended that the time intervals are
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between the start and end of the event times. However, Kalbfleisch and Prentice (1973)
proposed that the time intervals should be independently chosen without looking at or
being guided by the observed data. West and Berliner (1992) recommended that the time
intervals should be shorter in the beginning of the follow-up time for cancer datasets since
there is a higher number of deaths in the beginning than in the later time period. To
simplify things, we can attempt to choose the cut points so that a similar number of events
occur in every time interval. Nevertheless, caution is recommended since this approach
will not be suitable for all cases because events may occur in unequal proportions in each
time interval.
As an example, suppose we choose to have ten time intervals to model a cancer dataset.
Hence, we can aim to have about 10% of events occurring in each time interval. As an
approximation, we may assume that the event times are distributed exponentially. If
τ1 < τ2 < . . . < τJ−1 are the cut points and the exponential survival function with
parameter λ is given by S(t) = exp{−λt}, the probability that a subject survives until
time τj is given by
exp{−λτj} = 1− 0.1j.
This can be rearranged giving




The mean of the exponential distribution is ν = 1
λ
. Let ξ = 1
J
. Then the final form of the
equation will be
τj = −νlog(1− jξ).
This requires a prior evaluation of the mean lifetime. For instance, by applying the
equation above and based upon the evaluation of our prior beliefs for the mean survival
time for a typical patient with Non-Hodgkin Lymphoma (which is approximately about
3 years), we chose the cut points in Table 2.1 to obtain 10 survival time intervals.
Table 2.1: Nine cut points for constructing 10 survival time intervals for piecewise constant
hazard model for Scotland Newcastle Lymphoma Group (SNLG) data set
j 1 2 3 4 5 6 7 8 9
τj 0.316 0.669 1.070 1.532 2.079 2.749 3.612 4.828 6.908
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On the other hand, for a typical advanced non-small cell lung cancer (NSCLC) patient,
we assume the mean survival time is 13 months based on our prior belief. In this case, we
chose smaller number of time intervals since ten survival time intervals will result in a time
interval without event (i.e the time interval will only contain all censored observations).
The cut points are given in Table 2.2.
Table 2.2: Six cut points for constructing seven survival time intervals for piecewise
constant hazard model for advanced non-small cell lung cancer data set
j 1 2 3 4 5 6
τj 2.004 4.374 7.275 11.015 16.286 25.297
Each time interval is now assumed to have a separate baseline hazard. Those who
survive in one interval will enter the subsequent interval with a different baseline hazard.
2.7.3 Time-varying covariate effects
Despite the proportional hazard model being the most popular approach used for fitting
time-to-event data, it has several pitfalls. The most conspicuous drawback is its overde-
pendence on the proportional hazard assumption since this means that the hazard ratio
does not change over time. This assumption is sometimes unrealistic since we can imagine
real-life scenarios where this assumption is not tenable. For instance, let us consider a clin-
ical trial comparing the efficacy of bone marrow transplant (BMT) against the standard
chemotherapy regimen for acute myeloid leukaemia (AML) patients. In the earlier part of
the trial, AML patients who have undergone the curative BMT will have a higher hazard
of dying immediately after the BMT than the recipients of the standard chemotherapy
regimen. This observation can be attributed to the susceptibility of AML patients for
bacterial or viral infections secondary to immunosuppressive drugs that they received to
prevent BMT rejection. However, if they survived these early and serious complications
of BMT, their hazard of dying will start to decline at the later period of follow up before
it settles at a lower level than in those who received the standard chemotherapy regimen
due to the curative nature of BMT.
Another example to illustrate the non-proportionality of hazard is the hazard of dying
for non-Hodgkin lymphoma (NHL) patients who received the Rituximab, Cyclophos-
phamide, Hydroxydaunorubicin, Vincristine and Prednisone (R-CHOP) regimen which
is higher than that for NHL patients who received best supportive care (BSC) at the
beginning of the follow-up period in a clinical trial due to the side effects of the intensive
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chemotherapy regimes that they received to induce Non-Hodgkin Lymphoma remission.
However, as the time progresses, the R-CHOP NHL recipients will have lower hazard of
dying than those NHL patients who are treated with BSC since the R-CHOP recipients
are no longer on chemotherapy and the disease activity in this group of NHL patients
is now in complete remission. Consequently, the proportional hazard assumption is too
idealistic to be indiscriminately applied to the modelling of all survival data.
To relax the proportional hazard assumption, we can make the coefficients of covariates




where β(t) = (β1j, . . . , βpj)
T , for t ∈ Ij.
Besides, other alternatives have been proposed to remedy this. The most straightfor-
ward solution is to incorporate interaction terms between follow-up time and covariates in
the regression equation. One of the approaches that uses this methodology is the flexible
parametric models. These employ restricted cubic splines for the modelling of transformed
survival functions (Royston and Parmar, 2002). However, the simple inclusion of inter-
action terms between the spline function and time-dependent covariates is a rather crude
and less flexible technique since the pattern of changes in the function of the regression
coefficients is restrictively specified. Hence other more versatile and complicated functions
such as quadratic function cannot be fully implemented via the flexible parametric mod-
elling approach. Alternatively, the nonparametric smoothing spline approach (He et al.,
2010) and the piecewise constant hazard model (Kalbfleisch, 1978; Gamerman, 1991)
could also be used. Nevertheless, they also have their own disadvantages, for instance the
arbitrary selections of change points for the piecewise constant hazard model and the lack
of convergence of the MCMC sampler when greater degrees of the spline basis function
are used (He et al., 2010).
2.8 Bayesian inference: theory and notation
The goal of Bayesian inference is to quantify uncertainty about parameters θ = (θ1, θ2, . . . , θp)
T
using observed data y. Suppose y is modelled by some probability density function
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fy(y | θ). Then the likelihood is defined as




if y1, . . . , yn are conditionally independent given θ. The likelihood represents the prob-
ability or probability density of the data y as a function of the parameters θ. Prior
beliefs about θ are represented by the density π(θ) and Bayes’ Theorem provides a way
of updating these beliefs based upon observed data. The posterior density is therefore




which represents the updated beliefs about θ after observing the data y. Since the denom-
inator of (2.5) is not a function of θ, it can be regarded as a constant of proportionality
and hence
π(θ | y) ∝ π(θ)× L(θ | y)
Posterior ∝ Prior× Likelihood.
2.9 A brief introduction to MCMC and RJAGS
2.9.1 Fundamental elements of Markov Chain Monte
Carlo (MCMC) in Bayesian settings
Sometimes, it can be difficult to evaluate the integral in the denominator in (2.4) or other
integrals such as posterior expectations. Hence, numerical methods, such as Markov
Chain Monte Carlo (MCMC), are required. MCMC is an approach used to draw samples
from a target distribution by simulating from a specially constructed Markov chain with
stationary distribution equal to the target distribution π(.), Thus, providing that the
chain has converged, any value sampled will be from the density of interest π(.), here
the joint posterior density. Additionally, for a multidimensional chain, samples of each
component will be drawn from the marginal distribution of the respective component.
Let us assume that the distribution of interest is the posterior distribution, with density
π(θ | D) (known as the target distribution), where D = (y1, y2, . . . , yn). Here, we discuss
two algorithms to construct these chains, specifically the Metropolis-Hastings algorithm
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and the Gibbs sampler.
2.9.2 The Metropolis-Hastings (MH) algorithm
Metropolis et al. (1953) introduced the algorithm which was generalised by Hastings
(1970), leading to the name Metropolis-Hastings. Central to Metropolis-Hastings is the
idea of a proposal density, denoted q(.|.), which is some (arbitrary) transition kernel.
It can be advantageous to have a proposal density which is easy to sample from. The
Metropolis-Hastings algorithm is shown as Algorithm 1.
Step 2 generates a new value of the chain from the proposal density q(θ∗ | θ), which
in step 4 is either accepted (the chain moves) or rejected (the chain remains where it
was). Note that π(θ | D) enters the acceptance probability as a ratio, and hence it is
only necessary to know π(θ | D) up to a constant of proportionality. Therefore, by Bayes
theorem, A (in the acceptance probability of step 3) can be expressed as
A =
π(θ∗) L(θ∗ | D) q(θ | θ∗)
π(θ) L(θ | D) q(θ∗ | θ)
.
Given that we have complete freedom in the choice of the proposal density q(.|.), the nat-
ural question is, ‘What choices of q(.|.) might be good, or indeed useful?’ In particular,
a good choice of q(.|.) will lead to a chain which converges rapidly and mixes well; that
is, it moves often and well around the support of π(θ |D). We present the first algorithm
for the Metropolis-Hastings (MH) procedure as follows:
Algorithm 1: The Metropolis-Hastings Algorithm











where θ(0) is chosen from somewhere in the support of π(θ | D).
2. Propose a new value θ∗ using the transition kernel q(θ∗ | θ(i−1))
3. Evaluate the acceptance probability min(1,A), where,
A =
π(θ∗ | D) q(θ | θ∗)
π(θ | D) q(θ∗ | θ)
4. Set θ(i) = θ∗ with probability min(1,A), otherwise set θ(i) = θ(i−1).
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5. Set counter to i+1 and return to step 2.
2.9.2.1 Symmetric proposal
Suppose that we use a proposal distribution which is symmetric. That is
q(θ∗ | θ) = q(θ | θ∗), ∀θ, θ∗
and the proposal distribution can be, for example a Gaussian distribution
θ∗ | θ ∼ N(θ, σ2).





That is, the acceptance probability does not depend on the proposal density.
2.9.2.2 Random walk Metropolis
It is possible to use a random walk as the proposal distribution q(.|.) in step 2 of Algorithm
1. In this instance, q(.|.) takes the form
θ∗ = θ(t−1) + ωi
where ω1, . . . , ωp are independent and in many cases identically distributed. Typically
ω has a Gaussian distribution with zero mean vector. In this instance the Metropolis-
Hastings algorithm is known as a random walk sampler ( or random walk Metropolis).
The variance of the random variates ω will determine the mixing of the chain. Too low
a variance and the chain will explore the space slowly, but many proposed values will be
accepted. Too large a variance and few proposed values will be accepted. Reflecting the
correlation within θ in the covariance structure of ω is an important aspect in ensuring
the chain efficiently explores the space.
If the target distribution is Gaussian, Roberts and Rosenthal (2001) suggest that the
optimal acceptance probability is 0.234. Sherlock and Roberts (2009) extend this result
to ellipitically symmetric targets and subsequently Sherlock (2013) proposes a general set
of sufficient conditions for which the optimal acceptance probability is 0.234. Roberts
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where p is the number of dimension and Var (θ | D) is the variance matrix of the target
distribution π(θ | D). Typically though, Var(θ | D) will not be available and hence an
estimate from one or more pilot runs should be used.
We note that, for large p, sampling θ∗ from a multivariate Gaussian distribution may
be expensive. In these instances, an alternative approach is to take the components
of ω = (ω1, . . . , ωp)
T as independent and identically distributed (univariate) Gaussian
random variates. For example, ωi ∼ N(0, σ2i ), where
σ2i =




An independence sampler is a special case of a Markov chain. As the name suggests,
an independence sampler (or independent chain) proposes a new value θ∗ independently
of the current value θ. Hence, q(θ∗ | θ) = g(θ∗) for some density g(.). Whilst the form
of such a proposal may appear to disagree with the Markovian structure of the chain,
both θ and θ∗ feature in the acceptance probability, which means that a proposal still
depends upon the current state, and thus, the Markov property is preserved. Using such








Clearly, we can increase the acceptance probability by making g(.) and π(. | D) as
similar as possible. It is worth noting that, in the context of an independent sampler
(and in contradiction to the above on random walk Metropolis), the higher the acceptance
probability, the better the sampling is. Tierney (1994) suggests the avoidance of densities
g(.) with thin tails.
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2.9.3 Gibbs sampling
2.9.3.1 General Algorithm
The Gibbs sampler (or generically Gibbs sampling) originated in statistical physics before
it came into Bayesian statistics via image processing (Geman and Geman, 1984). It was
introduced by Geman and Geman (1984) before being generalised and brought to the
interest of the wider statistical community by Gelfand and Smith (1990). In essence, the
Gibbs sampler is an MCMC scheme in which the full conditional distributions (FCDs)
are used to form the transitional kernel.
Before we proceed further, we shall firstly define the FCD. Let θc be a component of a
parameter space θ. Hence, the FCD of θc is the distribution of θc given other components
of θ and data x. Mathematically, this is written as
π(θc | {θq : q 6= c},x).
For a Gibbs sampler, we assume that the FCDs for all components of θ are available and
can be sampled from. The Gibbs sampler is then given by Algorithm 2:
Algorithm 2: The Gibbs sampler



















from θ(i−1) using successive generation





θ1 | θ(i−1)2 , θ
(i−1)








θ2 | θ(i)1 , θ
(i−1)









θp | θ(i)2 , θ
(i)




3. Set iteration counter to i+1 and return to step 2.
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The chain approaches its equilibrium state as the number of iterations increases, and
once the chain has converged, a value of θi is a sample from π(θ | D). Thus the Gibbs
sampler is a way to sample from π(θ | D) when direct sampling is costly, complicated or
indeed impossible, but sampling from π(θi | θ−i, D) is possible. Algorithm 2 is known as
a fixed sweep Gibbs sampler. Whilst other versions of the Gibbs sampler are available,
such as the random scan Gibbs sampler, the fixed sweep is simple to implement, and thus
appealing. For details of other versions of the Gibbs sampler see, for example, Chapter 5
of Gamerman and Lopes (2006).
2.9.3.2 Blocking
Given that the components of θ can take the form of scalars, vectors or matrices, it can be
useful to block certain components that are strongly correlated in the posterior together in
multidimensional problems. Such a strategy is known as a block update and makes use of
multivariate sampling techniques. Blocking is a strategy used to improve the convergence
(and indeed mixing) of the chain, although it can come at a higher computational cost.
As discussed in Gamerman and Lopes (2006) it is not the case that the larger the block
update, the faster the convergence. Indeed for highly multidimensional problems a large
block update is likely to be highly detrimental. Instead, components of θ should be
blocked together such that the correlations between the blocks is low. Any conditionally
independent components should be updated on their own (a single-block update).
2.9.3.3 Component-wise transitions (Metropolis within Gibbs
Algorithm)
In practice, the construction of a suitable proposal density in a Metropolis-Hastings
scheme could be difficult. However, for many problems of interest, it may be possible
to sample from the full conditional distributions for a subset of θ. Let the full conditional
distribution for the ith component of θ be denoted by
π(θi | θ1, θ2, . . . , θi−1, θi+1, . . . , θp, D) = π(θi | θ−i, D), i = 1, . . . , p.
The algorithm for component-wise transitions is given by Algorithm 3 below. Note that
Algorithm 3 is actually just a special case of Algorithm 1 (Dellaportas and Roberts, 2003).
Besides, Algorithm 2 is a special case of Algorithm 3.
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Algorithm 3: The Metropolis-Hastings Algorithm: Component-wise Transitions
















2 , . . . , θ
(i)






θ1 | θ(i−1)2 , θ
(i−1)















θ2 | θ(i)1 , θ
(i−1)


















θp | θ(i)1 , θ
(i)











3. Set i+1 and return to step 2
If the full conditional distribution for the ith component of θ is available to sample
from directly, the resulting acceptance probability is 1. This method is also referred to as
Metropolis-within-Gibbs. If the full conditional distributions are completely known and
can be sampled from for all components of θ, we obtain the Gibbs sampler.
2.9.3.4 Analysing MCMC output
As mentioned above, a Markov chain Monte Carlo scheme will only give samples from
the target distribution provided convergence has been reached. It is therefore important
to monitor convergence carefully and ensure convergence truly has been reached. As the
number of iterations increases the distribution of the chain, θ(i) | D, tends to the posterior
distribution θ | D, and convergence is reached. Samples obtained before convergence,
when the distribution of the chain is not the posterior are discarded. This number of
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iterations is known as the burn-in period. Viewing the trajectory of the chain via a trace
plot can be used to check convergence informally. In this instance we are looking for the
chain to display the same qualitative behaviour after some initial burn-in period. Gelfand
and Smith (1990) (amongst others) suggest a number of informal checks for convergence.
More formal checks for ensuring convergence has been reached have been proposed by, for
example, Heidelberger and Welch (1983) and Raftery and Lewis (1992).
Samples of the MCMC scheme will be dependent, meaning successive draws are auto-
correlated. Autocorrelation at different lag times can be observed via an autocorrelation
(ACF) plot (Geyer, 2011). If samples are highly correlated then the chains may be thinned.
This involves retaining the sampled values from iterations m, 2m, 3m,. . . , where m is an
integer and m > 1. Thinning retains only n/m sampled values, resulting in an increase in
Monte Carlo variance. Nevertheless, the increase in Monte Carlo variance might be small
if there is a positive autocorrelation. Thinning is useful for evaluating convergence, as a
remedy to storage space problems and to reduce overall computational cost if expensive
computations are to be done on the sampled values (Geyer, 1992).
Once a chain has converged, the (suitably thinned) output can be analysed. It is
effortless to compute estimates of summary statistics (or standard statistical measures)
such as marginal means and variances. Joint and marginal distributions can be viewed
through the use of density plots (or histograms).
2.10 Missing Data and Data Augmentation
Approach
2.10.1 Missing Covariate Values
The analysis of survival data with missing covariate values will have serious consequences.
The posterior distributions may possess dissimilar properties if the analyses based on
complete cases only (i.e cases without missing covariate values) are compared with those
performed on all cases (i.e cases with missing covariate values are also included in the
analyses).
The general framework of missing data mechanisms is given by Little and Rubin (2002)
and they are as follows:
Missing completely at random (MCAR): Missingness is independent of the observed
and unobserved data. For example, we can divide the full data in a matrix x into
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two components: the observed component which is denoted by xobserved and xmissing
which represents the missing component. Using this missing data framework, the
conditional distribution of the missing data indicator can be written as:
f(mi | xobserved,xmissing, φ) = f(mi | φ)
where mi is the missing data indicator, mi = (mi,1, . . . ,mi,J)
T where mij = 0 if
xij is observed and mij = 1 if x is missing, φ is the parameter for the missing data
mechanism and xij is the value of the j
th covariate for the ith individual.
Missing at random (MAR): Missingness is conditionally independent of the unob-
served component given the observed data. The conditional distribution of the
missingness indicator can be written as:
f(mi | xobserved,xmissing, φ) = f(mi | xobserved, φ)
Since our inference about parameters of interest is only conditional upon xobserved,
MAR has an ignorable missing data mechanism provided that φ and θ are indepen-
dent in the prior, where θ is the collection of parameters of the data model.
Missing not at random (MNAR): Missingness is not conditionally independent of
xmissing given xobserved. This is a non-ignorable missing data mechanism that occurs
when the failure of observing the data values is dependent upon the missing data.
In survival analysis, the missing covariate data can be represented using the missing
data framework as follows. Let X∗ represent the covariate matrix and xi,j is the value
of covariate j for the ith subject. The survival time is represented by vector T , where T
= (t1, t2, . . . , tn)
T . Either X∗ or T is observed entirely (i.e. all subjects experienced the
event of interest (e.g death) by the end of the study, no missing values for all covariates)
or incompletely observed (i.e. several subjects did not experience the event of interest
(e.g death) and hence were censored by the end of a clinical trial, missing values for some
of the covariates). The missing indicator matrix is represented by M whose elements
mi,j denote the missing data indicator for covariate j for the i
th patient, where mi,j =
0 if the value for covariate j is fully observed or mi,j = 1 if the value is missing. The
model parameters are represented by θ and φ designates the parameter for missing data
mechanism. Hence, the joint distribution of a collection of X∗, M ,T conditional upon
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the θ and φ can be written as:
f(X∗,M ,T | θ, φ) = f(X∗,T | θ)f(M |X∗,T , φ).
If the covariate values are considered to be MCAR or MAR, the missing data models
are thus ignorable. In this research work, the missing data will be treated as MAR and
we shall assume θ and φ are independent a priori, and hence π(θ, φ) = π(θ)π(φ)). Our
approach for missing covariate data will hence be a fully Bayesian one and this involves
specifying the prior distributions for all parameters as well as specifying the distributions
for the missing data. There are several examples for this approach and one of them is
that demonstrated by Ibrahim et al. (2001) for forward conditioning and another is reverse
conditioning (Zhao, 2010).
2.10.2 Data augmentation
Certain models possess rather complicated likelihood functions which, if handled in a
direct fashion, would not be amenable to tractable algebraic manipulation. It is thus
occasionally feasible to make the likelihood more straightforward when extra variables,
known as auxiliary variables, are introduced. These variables could be considered as latent
observations, which, if they were actual observations, would result in the likelihood being
more manageable. These auxiliary variables could therefore be regarded as missing data.
This is known as the data augmentation approach (Tanner and Wong, 1987). MCMC
methods such as the Gibbs sampler are appropriate for this technique in handling missing
data in general.
We illustrate the use of the data augmentation approach for handling missing survival
data in censored observations. This approach makes the likelihood simpler since we as-
sume that all quantities are observed. In this approach, an auxiliary variable (denoted by
Tmissing) was introduced to represent the parameter by which the survival times for the
censored observations is generated (i.e. missing survival times). If we decompose T (all
survival times) into T observed and Tmissing, we can then compute the posterior distribution
of model parameters (denoted by θ) given the observed survival time T by integrating
out Tmissing as follows:
Pr (θ | T ) =
∫
Pr (θ,Tmissing | T )dTmissing
41
Chapter 2. Bayesian Survival Analysis
According to Bayes theorem, Pr (θ,Tmissing | T observed) is given by:
Pr(θ,Tmissing | T observed) ∝ L(θ,Tmissing) Pr(θ,Tmissing).
The likelihood can then be written as
fT,I(T observed, I | θ,ϑ) =
∫
fT (T observed,Tmissing | θ)f(I | T observed,Tmissing,ϑ)dTmissing
This is the likelihood of the data conditioned upon the augmented parameters and I is
the inclusion indicator where Ii = 1 if Tobserved and Ii = 0 if Tmissing in individuals with
censored survival times. Besides, f(I | T observed,Tmissing,ϑ) is known as the missing data
mechanism. If we assume that the priors for θ and ϑ are independent, then Pr(θ,ϑ) =
Pr(ϑ) Pr(θ). Hence, in this case the missing data mechanism is ignorable.
We can also use data augmentation approach to solve the problem with missing co-
variate data. This is implemented by iteratively sampling the conditional distributions of
the missing covariate information, Xunobserved given the parameters θ and observed data
Xobserved and subsequently the conditional distributions of θ given the augmented data,
Xaugmented = (Xobserved, Xunobserved). In this case, Xaugmented can be considered as an
augmented data set containing both the observed values and the sampled values for the




unobserved ∼ π(Xunobserved |Xobserved,θ
(k−1))
θ(k) ∼ π(θ |Xobserved,X(k)unobserved)
This approach is highly beneficial in the sense that it enables the sampling of θ when they
could not be sampled by conditioning them on Xobserved only. Besides, we may regard
that this algorithm is a special case of Gibbs sampling procedure whereby we sample
the joint posterior π (θ,Xunobserved | Xobserved) from their FCDs. We can then use the
sampled values of θ as if they are drawn from the marginal posterior, π (θ | Xobserved)
and these can be used to compute the posterior mean and variance of θ.
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2.11 Bayesian survival analysis computation
using RJAGS
In this short section, the fitting of an exponential survival model using a package called
Just Another Gibbs Sampler (JAGS) (Plummer, 2016) which is implemented in an R
environment as RJAGS (R Core Team, 2018) is used as an example. The kidney infection
dataset (Nahman et al., 1992) will be used as an example and this dataset consists of
survival time (time to kidney infection) and types of catheter insertion (either inserted
through surgery or under the patient’s skin). Let the model specification be given as
follows. We have
Ti ∼ exp(λi),
where for patient i (i = 1, . . . , 119), Ti is the time to the first catheter exit-site infection
(in days). The pdf of the survival time and the corresponding survival function are thus
given by
f(ti | λi) = λ exp(−λiti)
and
S(ti | λi) = exp(−λiti)
There is only one covariate, catheter placement status for each patient i (denoted by
x1i, and coded as -1 for surgically-inserted catheters and 1 for catheters inserted under the
patient’s skin), in this example. Hence, β = (β0, β1)
T , where β0 is the intercept and β1
is the coefficient for catheter placement (covariate trt). Therefore, λi = exp(β0 + x1iβ1).
The likelihood can then be written as










where λi = exp {β0 + β1x1i}.
For this case, we assume normal priors for β with mean µ0 and covariance matrix Σ0.
For illustration, let
β0 ∼ N(0, 20)
β1 ∼ N(0, 20)
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Hence, the posterior distribution for β can be written as
π(β | D) ∝ L(β | D)π(β | µ0, Σ0)











In rjags, dnorm (m, p) denotes a normal distribution with mean m and precision p. The
data is stored in a data frame named data. The data frame contains the following
 data$status: the censoring or event status (1 if the event occurs and 0 if censoring
occurs)
 data$time: the censoring or event time
 x: the covariate. in this case is the type of catheter placement received by the
patients (1:surgically, 2:percutaneously)
In this analysis, the dataset used by rjags contains the following vectors
 t: For this vector, the element i represents the time to event if the event was
observed for case i. If case i, on the other hand, is censored, then the element i of
t is NA. We can construct it as follows:
t=data$t
is.na(t)=data$status==0
 is.censored: This is a difference in terms of rjags code for survival analysis when
compared to other standard R survival and R-INLA packages. The survival indicator
should be coded as follows: 1 if the time is censored and 0 if the event time is
observed. This can be easily performed using the following
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is.censored=1-data$status
 t.cen: Element i is the censoring time for case i if this case was censored. If the
event was observed in case i, this censoring time should be set at a time greater
than the observed event time. This can be done as follows:
t.cen=data$t+data$status
 trt: A covariate.
x=data$trt
As we can see from the model specification, a special distribution was allocated to
is.censored.
is.censored[i]~dinterval[t[i],t.cen[i])
The missing values of t should be initialised. The reason for this is that the specifica-
tion of is.censored means that these cases are the censored ones. Hence, the unobserved
event time must be greater than the observed censoring time. If rjags is permitted to
select the initial values randomly, this may result in some of the chosen initial values for
the unobserved event times being smaller than the censoring time and this is inconsistent,
causing errors in rjags command execution. Therefore, we have to initialise the missing
values of t at greater values than the corresponding values of t.cen. For instance, the
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The command in the 4th line is for burn in and the last line command is for collecting the
samples from the posterior distributions for each model parameter. Using this code, rjags
will treat the censored event times as auxiliary variables and sample them. However, for
this exponential case, the likelihood could, of course, be easily and exactly written and
posterior sampling could be done without resorting to data augmentation.
This example is discussed in Section 7.2.1.2, where results are given.
2.12 Summary
In this chapter, we discussed the fundamentals of survival analysis in 2.1 - 2.3. In 2.4,
the methods of relating the explanatory covariates with the the lifetime distribution were
elucidated. In 2.5.1, the parametric Weibull survival models were introduced and further
elaborated. The motivations behind including the frailty effects in survival analysis were
explained in 2.6, together with the derivations of conditional and marginal survival and
hazard functions. The piecewise constant hazard model was introduced in 2.7 and the
theory of Bayesian inference was explored in 2.8. A brief introduction to MCMC was
elaborated in detail in 2.9, followed by a discussion on missing data and data augmentation
in the context of Bayesian survival analysis in 2.10. Finally, the implementation of an
MCMC scheme in RJAGS was demonstrated in 2.11.
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Latent Gaussian Models & Gaussian
Markov Random Fields
3.1 Introduction
The purpose of this chapter is to present the basic ideas and known results for latent
Gaussian models and Gaussian Markov random field (GMRF). We shall firstly discuss
the fundamentals of generalised linear models (GLM) and their extension, the latent
Gaussian models. We shall then elaborate on the standard results of Gaussian Markov
Random Fields (GMRF) and their relationship with Bayesian hierarchical models. The
paramount ideas discussed in this chapter will be implemented in later chapters and hence
this chapter is indispensable when elucidating the contents in subsequent chapters.
3.2 Generalised Linear Models and Latent
Gaussian Models (LGMs)
Latent Gaussian models (LGMs) are popular in statistical modelling due to their sim-
plicity and flexibility. LGMs treat observations, denoted here as y = (y1, y2, . . . , yn)
T ,
as depending on covariates (patient’s clinical characteristics, spatial locations etc). In
LGMs, observations are considered to be conditionally independent given a set of latent
variables and these observations have distributions based on the data types (e.g. Bernoulli
for binary data or Poisson for count data). These latent variables are then assigned a
Gaussian process (GP) prior, which can be defined as an ensemble of a finite number
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of random variables which follows a multivariate normal distribution (Rasmussen, 2004).
This implies marginal normality due to the properties of marginal distributions of multi-
variate Gaussian distributions. Then, the covariance structure of the latent variables is
parameterised by a set of hyperparameters which specifies the covariance function. Hence,
LGMs can be visualised to be hierarchical in nature, with hyperparameters conditioning
the latent variables, which in turn condition the observations.
LGMs can also be regarded as a type of Bayesian structured additive models with a
structured additive predictor, ηi. Before we proceed further, the much simpler generalised
linear models (GLM) shall be first described. There are two constituents in a GLM: the
conditional distribution of the outcome variable (Y) should be one of the members of the
exponential family and a link function should be specified to relate the mean of Y with
the linear combination of predictors, X1, X2, . . . , Xn(Dobson and Barnett, 2008; Faraway,
2016). For the distribution of Y to be considered as belonging to the exponential family
of distribution, its density should be expressible in the following form:





where φ is the dispersion parameter and θ constitutes the canonical parameter. As an
example, let Y be a Gaussian-distributed random variable. Hence the pdf of Y is









The pdf can then be rewritten in the following form:










We can then relate the mean of this distribution, E[Y]=µ to the linear predictors, X1, X2, . . . , Xn
using the link function g(.):
g(.) = η = β0 + β1X1 + β2X2 + . . .+ βpXp (3.1)
Some other types of link function are presented in Table 3.1. In the modelling approach
used in this thesis, however, we shall not restrict the distribution of Y to belong to the
exponential family.
We can relax the assumption of a known form of linear function in the linear predictor.
The framework for this model can be conceptualised as follows. The mean µi of this
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Table 3.1: The link functions for selected members of the exponential family of distribu-
tions used in the GLM (adapted from Faraway (2016))
Distributional Family Link Function Variance Function
Normal η = µ 1
Poisson η = log(µ) µ
Binomial η = log(µ/(1− µ)) µ/(1− µ)
Gamma η = µ−1 µ2
Inverse Gaussian η = µ−2 µ3
observation variable is connected to the structured additive predictor variables, ηi through
a link function, g(.), so that g(µi) = ηi. This can be represented as






βkzki + εi. (3.2)
In (3.2), β1, . . . , βnβ constitute the linear effects of covariates z, f
(.), . . . , fnf are the un-
known functions of covariates u which can be: i) non-linear effects of continuous covariates,
ii) time trends and seasonal effects, iii) frailty effects, iv) spatial random effects, v) i.i.d
random intercepts and slopes (Martino et al., 2011). The structured or unstructured
random errors are ε1, . . . , εn. Then, a Gaussian prior is allotted to each β0, . . . , βnβ and
f (j) with precision matrix Q(θ1) where θ1 is a vector of hyperparameters of the precision
matrix for the latent field x. In other word
x | θ1 ∼ N (0, Q−1(θ1)).
Let x be the vector of all the Gaussian-distributed quantities such as β0, β1,. . . ,βnp,
ε1,. . . ,εn, and f
(0),. . . ,f (nf ) whilst θ1 represents the vector of hyperparameters which are
not necessarily Gaussian.
The multivariate distribution of the observed y (i.e. y = {yi : i ∈ I}) is also dependent
on another set of hyperparameters θ2 (i.e. conditional on another set of hyperparameters
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that should not be confused with θ1). Hence, the likelihood is given by
π(y | x, θ2) =
n∏
i=1
π(yi | xi, θ2).
Therefore, the joint posterior density of the latent field x and hyperparameter θ = (θ1,θ2)
given the observed data y is




Exact inference for the parameters of a LGM is usually intractable analytically since
the likelihood of the observations,
n∏
i=1
π(yi | xi,θ) , is usually not the conjugate of GP priors
for the latent variables and neither can the hyperparameters be easily integrated out.
Attempts using deterministic approaches such as Laplace Approximation (LA) (Tierney
and Kadane, 1986) or refined Expectation Propagation (EP) (Cseke, 2011) have been
suggested to address such a problem. Rue et al. (2009) proposed the Integrated Nested
Laplace Approximation (INLA) as an approximate inference method for LGM. Basically,
INLA uses numerical quadrature based on a gridding scheme that can be applied to
problems with a relatively small set of hyperparameters and this method can be used to
find the posterior marginal distributions of the latent Gaussian field, π(xi | y), and the
hyperparameters, π(θk | y).
In the following subsections, further discussions will be made on Gaussian Markov
Random Fields (GMRF) which are a special case of Gaussian Random Fields. The
Markov assumption enables INLA to work efficiently but it is not strictly necessary since
a departure from this assumption is not an absolute hindrance for INLA to function sat-
isfactorily (Eidsvik et al., 2009). We will present a brief overview of INLA methodologies
as described in Rue et al. (2009) in Chapter 4.
3.3 Gaussian Markov Random Field (GMRF)
3.3.1 Introduction
The efficiency of INLA is dependent on the sparsity of the precision matrix. Therefore, the
sparse property of Gaussian Markov random fields (GMRFs) is essential to ensure INLA
efficiency since GMRFs allow fast and efficient computation of posterior summaries using
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numerical methods specific for sparse matrices (e.g. Cholesky factorisation). Therefore,
in this section, we give a discussion of GMRFs which will facilitate the understanding of
INLA methodology in subsequent chapters.
A Gaussian Random Field (GRF) is simply a finite-dimensional random vector, X=
(x1,x2,. . . ,xn)
T , that follows a multivariate normal distribution. A Gaussian Markov
Random Field (GMRF), on the other hand, is a special case of GRF in which we have an
adjacency relationship between elements of the vector X, such that two elements xi, xj
may or may not be neighbours, and an assumption of conditional independence between
non-adjacent elements given the elements in between.
The simple but powerful concept of conditional independence can be seen from the
following example. Let X = (X1, X2, X3)
T be a random vector. If X1 and X2 are condi-
tionally independent given X3, then once we know the value of X3, knowing X2 gives us
no further information about X1. To get a clearer picture, let the joint density of x be
π(x) = π(x1 | x2, x3)π(x1 | x3)π(x3).
If X1 and X2 are conditionally independent given X3,then
π(x) = π(x1 | x3)π(x2 | x3)π(x3).
To illustrate further, let us consider a first-order autoregressive (AR(1)) process with
standard Gaussian errors which can be expressed as follows:
Xt = φXt−1 + εt, εt ∼ N(0, 1).
The conditional independence assumption is not explicitly shown here. However, by
expressing the equation as:
Xt | X1, . . . , Xt−1 ∼ N(φXt−1, 1)
with t = 2,. . . , n, we see that Xt and Xs (with 1 ≤ s< t ≤ n) are conditionally independent
given {xs+1,. . . , xt−1} provided t - s >1. If | φ |< 1 and the marginal distribution of X1
is Gaussian with mean 0 and variance σ2 = 1 / (1 − φ2), then the process is stationary
and this marginal distribution is the stationary distribution for the process. Hence the
joint pdf of X can be expressed as follows:
π(x) = π(x1)π(x2 | x1) . . . π(xn | xn−1)
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−φ 1 + φ2 −φ
−φ 1

From the matrix Q above, we can clearly see that the zero entries occur outside the
diagonal and first off-diagonal elements. This tridiagonal feature of this matrix is due
to the conditional independence assumption: Xi and Xj are conditionally independent if
| i− j | > 1 given the rest of X (i.e. X−ij).
3.3.2 Fundamental characteristics of GMRFs
Consider a random vector X which has a multivariate Gaussian distribution with mean
µ and variance-covariance matrix Σ. An undirected graph G can be defined as a tuple
of ν and ξ; where ν represents the set of nodes from 1 to n in the undirected graph and
ξ are the edges. We define that there is an absence of an edge between node i and j if
and only if Xi ⊥ Xj | X−ij (⊥ denotes conditional independence, X−ij represents other
nodes than node i or node j). Hence, X has a GMRF property with respect to G. Let Q
= Σ−1 and i 6= j, then
Xi ⊥ Xj | X−ij ⇐⇒ Qij = 0
where Qij is the i, j element of Q.
The following results are also true if X is a GMRF with regard to G and has mean µ
= (µ1,. . . ,µr)
T and precision matrix, Q. The conditional expectation of Xi given X−i is
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The conditional precision of Xi given X−i is
P (Xi |X−i) = Qii.
The conditional correlation of Xi and Xj given X−ij
Corr (Xi, Xj |X−ij) =
Qij√
QiiQjj
, i 6= j
where j ∼ i indicates that node i and node j are neighbours. The proofs are given in section
3.3.3. Hence, the diagonal elements of precision matrix, Q are the conditional precisions
of Xi given X−i and the elements which are located off-diagonally are the conditional
covariance between Xi and Xj given X−ij (Rue and Held, 2005). The following Markov
properties of GMRF also hold:
The pairwise Markov Property:
xi ⊥ xj | x−ij, if {i, j} /∈ ξ and i 6= j
The local Markov Property:
xi ⊥ x−(i,ne(i)) | xne(i), i ∈ V
The global Markov Property:
xA ⊥ xB | xC
where xne(i) are the elements in the neighbourhood of i, A,B and C are disjoint non-empty
sets in which C separates A and B, V is the set of nodes in the graph and ξ is the set of
edges {i, j}.
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3.3.3 The proof for the properties of the precision
matrix Q
Let X = (X1, X2, . . . , Xn)
T be distributed as a Gaussian Markov random field. Let δij =






where S = (X − µ)T Q (X − µ) and µ = (µ1, µ2, . . . , µn)T . We can also write the joint




fi(xi | x1, . . . , xi−1)










fi(xi | x1, . . . , xi−1) ∝ e−
e2i
2νi
where ν1 is the marginal variance of X1 and νi (i > 1) is the conditional variance of
Xi | x1, . . . , xi−1. The last element, xn, only appears in fn(xn | x1, . . . , xn−1) and therefore
in en. Using the Markov property that Xn is conditionally independent of Nn given Nn,
where Nn =
{




xi : i < n and δin = 0
}
, we can write
en = xn − µn −
n−1∑
i=1
δinφin(xi − µi) (3.4)
for some coefficients φin.
Sparsity
Let the i, j element of Q be qij. From (3.3) and (3.4), we see that qni = qin = δin φin/
√
νn,
for i = 1,. . . ,n-1 and qnm = νn, and so the last row and column of Q only contain nonzero
elements corresponding to the neighbours of Xn. Of course, by rearranging the order of
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X1,. . . ,Xn, we can choose any to be the last.
Conditional Expectation
Now,
















Var(Xn |X−n) = vn = q−1nn .
Hence, the conditional precision is
P (Xn |X−n) = qnn.
Conditional Correlation
The last two elements Xn−1 and Xn, only appear in fn,n−1(Xn, Xn−1 | X1, . . . , Xn−2)
and fn−1(Xn−1 | X1, . . . , Xn−2) and hence in the joint density





















where ṽn is the conditional variance of Xn given X1, . . . , Xn−2, p is the conditional corre-
lation of Xn and Xn−1 given X1, . . . , Xn−2
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and




for some coefficients φ̃1,n, . . . , φ̃n−2,n. We can also write S̃ as
s̃ = (xn − µn)2qnn + 2(xn − µn)(xn−1 − µn−1)qn,n−1 + (xn−1 − µn−1)2qn−1,n−1 +R
where R contains terms not involving xn or xn−1. Thus
q−1nn = (1− p2)ṽn, q−1n−1,n−1 = (1− p2)vn−1
and
q−1n,n−1 = −p−1(1− p2)
√
ṽnvn−1.
Combining these, we obtain
p = − qn,n−1√
qn,n qn−1,n−1
.
3.3.4 Deriving the recursive formula for marginal vari-
ance computation
We can rearrange the order of the elements of X and reorder the rows and columns of Q
accordingly to make Q sparse. By considering what happens if we choose any element to
be the last element, we see that, for all i =1,. . . ,n and j = 1,. . . ,n, qij = 0 if δij = 0. In
other words, Q for any GMRF will have the following property: Qij = 0 for i 6= j if xi
and xj are conditionally independent given the other elements {xk: k6= i and k 6= j}. This
results in the sparsity of the structure of Q, making it convenient for fast computation
via Cholesky factorisation of Q
Q = LLT
where L is a lower triangular matrix. The beauty of this approach is that L also in-
herits the sparsity of Q since it also has global Markov characteristics. Consequently,
the computing time becomes more efficient since we do not have to compute and store
the zero terms. Hence, only the non-zero terms in L are computed and stored during
the procedures for posterior computation. This is thus the rationale behind the fast
computation of posterior summaries in the case of a GMRF.
To illustrate this further, let us consider a GMRF with a considerable size of 10000
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to 100000 nodes. By constructing a band matrix Q via permuting the indices of obser-
vation xi, the L matrix will be acquired. In this case, we classically use a band-Cholesky
factorisation method on Q to obtain L, which is a lower band matrix that possesses
similar bandwidth to Q (Rue and Held, 2005). As an example, let us consider an MCMC
procedure for obtaining posterior samples from a complicated hierarchical model that
possesses a GMRF structure with mean value of zero and precision matrix, Q. We can
do this by working out the Cholesky factor L for Q and thus subsequently obtaining z
which is a vector of independent standard Gaussian variables. The relationship between
L, x and z is given by
LTx = z. (3.5)
Specifically, (3.5) can be written (element-wise) as




To obtain the marginal variance
∑
ij, we multiply both sides of (3.6) by xj (j≥ i) and
divide by Lii which results in










LriΣrj, j ≥ i, i = n, . . . , 1 (3.8)
with δij = zizj. In this case, δij = 1 if i = j, and 0 if i 6= j. In the case where we are only
concerned with obtaining the marginal variance, only Σij whose Lij is not 0 should be
determined using the recursive formula (3.8). As a result, the computing costs to perform
this algorithm are efficiently reduced to O(n), O(n3/2) and O(n2) for temporal, spatial
and spatiotemporal GMRFs, respectively (Rue and Held, 2005).
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3.3.5 The derivation of GMRF distribution condi-
tional on a linear constraint
To derive the distribution of a GMRF with an additional linear constraint such as Ax
= e (i.e from π(x | Ax=e) and x∼ N(µ, Q−1), we can start with the joint Gaussian
distribution of x and Ax=e. In this case, A is a k × n matrix and of rank k, and e is a





















Using the formula for computing conditional expectation (µ∗ = µ1 + Σ12Σ
−1
22 (x2 − µ2))
and conditional covariance (Σ∗ = Σ11 −Σ12Σ−122 Σ21), µ̃ = E(x | Ax) can be derived as
µ̃ = µx +Q
−1AT (AQ−1AT )−1(e−Aµ)
= µx −Q−1AT (AQ−1AT )−1(Aµ− e) (3.9)
and Σ̃ = Cov(x | Ax) as
Σ̃ = Q−1 −Q−1AT (AQ−1AT )−1AQ−1. (3.10)
To take full advantage of the sparsity of Q matrix, we can then use a geostatistical
method called conditioning by Kriging (Ren et al., 2005). Using this method, samples
from the unconstrained GMRF, x ∼ N(µ̂, Q−1), are initially obtained. We can then
obtain samples from π(x | Ax = e) (denoted by x̃) by
x̃ = x−Q−1AT (AQ−1AT )−1(Ax− e). (3.11)
It is evident that x̃ has the correct conditional distribution if we compare its mean and
covariance with (3.9) and (3.10). Using algorithm 2.6 as elaborated in Rue and Held
(2005), samples from π(x | Ax = e) can thus be efficiently acquired.
3.3.6 GMRF and Bayesian hierarchical models
GMRFs are commonly used for Bayesian hierarchical models since they allow convenient
specification of stochastic dependence between unknown parameters. A common GMRF
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framework for this model type has a three-stage layout: hyperparameters θ specifying a
GMRF X, the field X is linked to data Y which are usually assumed to be conditionally
independent with one another given the field X, and finally the priors for the hyperpa-
rameters θ (in this case, θ represents a collection of θ1 and θ2). Using the most trivial
example, each Yi is only dependent on the corresponding i
th element in x, such that both
y and x possess the same number of dimensions. These three stages can be written as
θ ∼ π(θ) hyperparameter stage
X | θ1 ∼ N(0, Q−1(θ1)) latent field stage
Y | x, θ2 ∼ Ga(y | x,θ2) data stage
with data-stage density




The posterior distribution can thus be written as
π(x, θ1, θ2 | y) ∝ π(θ1)π(θ2)π(x | θ1)
n∏
i=1
π(yi | x, θ2)
or more succintly
π(x, θ | y) ∝ π(θ)π(x | θ)
n∏
i=1
π(yi | x, θ).
As an example, Yi is a Poisson random variable with mean µi. Suppose that we
assume that there is also information on covariate zi available for each yi. Hence, we can
assume that Yi now has a mean exp (β0 +z
T
i β) where β is a vector of unknown regression
parameters that has a multivariate Gaussian distribution with some mean and precision
matrix as its prior. We can also add independent normal random effects, νi with zero
mean to accommodate the random effects from unmeasured extra-Poisson variation and
hence Yi will have a mean of exp (β0 + νi + z
T
i β). This will also result in a GMRF that
still has a sparse structure which simplifies the computations of the posterior distribution
for the quantities of interest in the model. The exploitation of this feature will be crucial
when Bayesian posterior computation is performed using INLA methodology.
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3.3.7 GMRF approximation for non-normal likelihood
In certain models such as binomial models with logit or probit link functions, we can
employ a data augmentation strategy to obtain full conditional distributions (FCD) that
are still GMRF despite the non-Gaussian likelihood. However, there are cases where a
data augmentation strategy is not feasible to obtain FCDs that still possess a GMRF
characteristics. Fortunately, there is still a method to circumvent this difficulty.
In this scenario, the likelihood can be approximated using a Taylor series expansion
up to the second order. To illustrate this method, we firstly define the GMRF based on








where x ∼ Np(b, Q), with p as the number of dimensions, mean µ = Q−1b and precision
Q. Suppose that x represents the posterior density of GMRF latent field and it has the
following form










In this case, gi(xi) = log{π(yi | xi,θ)}, where θ is the hyperparameter. As an example,
log{π(yi | xi,θ)} might be the Poisson log likelihood. By expanding gixi using a Taylor
series up to the second order around an initial value, µ(0), we can derive its approximation
as follows:

















By expanding the quadratic term and simple rearrangement, we obtain








































If we set gi(µ
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i = bi and
−g′′i (µ
(0)
i ) = ci, the equation above can be rewritten as
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Then, we substitute (3.14) into (3.13) and this results in




(x− µ)TQ(x− µ) +
n∑
i=1








Since ai is a constant, this can be brought into the proportionality sign. By expanding
the quadratic form, removing any constant term (i.e µTQµ) and simple rearrangement,
we shall obtain

























This has the same form as (3.12), with x ∼ NW (Qµ+ b,Q + diag(c)). The mean, say








We can improve the approximation now by expanding about µ(1) and repeat the whole








In this chapter, we will introduce the Integrated Nested Laplace Approximation (INLA)
approach as an alternative to MCMC. In 4.2, we will explain the fundamental concepts of
the Laplace approximation in solving integrals. In 4.3, an overview of INLA methodology
will be given with emphases on the INLA steps for fast computation and exploration of the
posterior distribution and the use of the central composite design (CCD) approach when
the number of hyperparameters is moderately large. In 4.4, we will illustrate how INLA
works using a simple linear regression example. In 4.5, we will show how INLA can be
implemented in the survival analysis context, with particular attention given to dynamic
Bayesian survival models based on piecewise constant hazard models. Finally, in 4.6, we
propose a novel extension to the use of INLA which allows us to incorporate missing data
within the INLA framework. This extension greatly extends the applicability of INLA in
areas such as the analysis of survival data.
4.2 Laplace approximation
The Laplace approximation of an integral is the main building block for INLA methodology.
To illustrate this, consider that we want to solve this integral:
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where f(x), for instance, is proportional the probability density function (pdf) of a random
variable X. We can obtain an approximation to the function log f(x) using a Taylor’s series
expansion up to a second degree Taylor polynomial, assessed at x = x0. We write













If we let x0 be the mode of X (written here as x
∗), provided that log [f(x)] is differentiable




will be zero and the approximation will reduce to























The term exp[log{f(x∗}] can be factorised out, resulting in the final form
∫





















and which results in
∫











We can hence clearly see here that the integrand has the form of Gaussian density’s
kernel with mean x∗ and variance σ∗
2
. Therefore, an integrand whose limits are γ and κ
can be approximated by∫ κ
γ













where Φ(.) represents the standard Gaussian cdf.
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4.3 Overview of INLA methodology
4.3.1 INLA steps in a nutshell
For this subsection, we use x to represent n variables in the latent Gaussian random field
that include structured additive predictors ηi, the intercept β0, {βk} and the unknown
functions {f (j)}. The hyperparameters are represented by θ and y is the vector of random
observations (refer Eq 3.2). We want to compute the posterior marginal densities π(xi | y)
and π(θj | y) as
π(xi | y) =
∫
π(xi | θ, y)π(θ | y)dθ,
π(θj | y) =
∫
π(θ | y)dθ−j.
The INLA approach is dependent on constructing nested approximations π̃(xi | y) and
π̃(θj | y) using
π̃(xi | y) =
∫
π̃(xi | θ, y)π̃(θ | y)dθ
where
π̃(θj | y) =
∫
π̃(θ | y)dθ−j.
According to Rue et al. (2009), the posterior marginal for the latent field π(xi | y)
can be computed using the following three steps:
 Step 1: Approximate π(θ | y) using a Laplace approximation. The approximation
is represented by this notation: π̃(θ | y). It is derived as
π̃(θ | y) = π(θ, x | y)
π(x | θ, y)
=
π(θ, x, y)/π(y)
π(x | θ, y)
∝ π(θ, x, y)
π(x | θ, y)
∝ π(θ, x, y)




The denominator represents the Gaussian approximation to the FCD of x and x∗(θ)
represents the mode of the FCD of x given θ.
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This is performed by locating the mode θ∗ for π̃(θ | y) via the optimization of log
π̃(θ | y). A quasi-Newtonian method is employed to produce an approximation
to the second derivative of log π̃(θ | y) by using the difference between successive
gradient vectors. Next, the negative Hessian matrix, H, is computed at modal θ∗
using finite differencing. Then we take the inverse of the Hessian matrix to obtain
our covariance matrix Σ for θ. Subsequently, log π̃(θ | y) is explored by firstly
parameterising θ into a standardised variable z using a z-parametrisation. These
standardised variables, z are computed by firstly obtaining the spectral decomposi-
tion of our covariance matrix, Σ:
Σ = V ΛV T .
Then θ is parametrised as
θ(z) = θ∗ + V Λ1/2z
where θ∗ is the modal configuration. As a simple example, if π̃(θ | y) is a normal
density, z will then be a standard multivariate Gaussian variable, z ∼ N(0, I). This
z-parametrisation is required since the most efficient grid of evaluation points would
not be parallel to the untransformed axes. The z-parameterisation will thus rectify
the scale and rotation of a density which will make numerical integration easier
and more efficient (Smith et al., 1987). Subsequently, log π̃(θ | y) is explored in a
regular grid to locate the bulk of the probability mass.
To illustrate this, let us consider the case where the number of dimensions is 2. In
Figure 4.1, the subfigure on the left shows the new z-axes for z-values obtained via
the previous z-parametrisation and the modal position for a 2-dimensional case. To
locate the probability mass of log [π̃(θ | y)], we initially move along the positive
direction of z1 using a prespecified length of step of, for instance, 1 (denoted by δz
=1), provided
log[π̃(θ(0) | y)]− log[π̃(θ(z) | y)] < δπ
where δπ can be prespecified and take any value deemed appropriate. However, we
can use different values for step length, δz, such as 0.5 or 0.25 if more stringent
accuracy is needed for x. For δπ, Rue et al. (2009) chose δπ = 2.5 in his example.
We then change direction and move along the negative direction of z1 and the same
process is repeated for z2.
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Figure 4.1: Log [π̃(θ | y] exploration (Figure from Rue et al., 2009)
This results in the black dots seen in the subfigure on the right 4.1. To obtain the
intermediate values, we can take combinations of z1 and z2 values and these are
represented by the grey dots in the same subfigure and these values are retained as
long as the condition for πδ above holds. Since the points are placed in regular grids,
all area weights, ∆k, are equal. The posterior marginal of θj, π̃(θj | y), can then be
straightforwardly acquired from π̃(θ | y) by creating an interpolant with respect to
log π̃(θ | y) using the point obtained previously. We can then use this interpolant
to compute the posterior marginals, π̃(θj | y), via numerical integration. Besides,
these integration points (area weights) can also be used as area weights in step 3 of
the INLA for approximating π̃(θ | y).
 Step 2: π̃(xi|θ, y) is approximated by any one of these three methods: Gaussian
approximation, Laplace and simplified Laplace approximation. According to Rue
et al. (2009), the Gaussian approximation is the easiest to compute but the least
accurate due to errors in the location and skewness. The Laplace approximation
gives accurate results and this is computed using the relationship
π̃LA(xi | θ, y) ∝
π(x, θ, y)
π̃GG(x−i | xi,θ, y)
∣∣∣∣∣
x−i=x∗−i(xi,θ)
where x−i = x
∗
−i(xi,θ) is the modal configuration for the full conditional distri-
bution of x−i given xi and θ, and π̃GG(x−i | xi,θ, y) is the Gaussian approxi-
mation for the full conditional distribution π̃(x−i | xi,θ, y). However, note that
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π̃GG(x−i | xi, θ, y) is not the same as the Gaussian approximation for π(x | θ, y) [
i.e. π̃G(x | θ, y)]. Unfortunately this approach is quite expensive since π̃GG has to
be reevaluated for each xi and θ since its precision matrix, Q , is dependent upon
both xi and θ. There are several modifications that had been proposed by Rue et al.
(2009), which are beyond the scope of our discussion, to improve the computational
efficiency of this approximation strategy but the Laplace approximation is still con-
sidered to have the highest computational cost among those three approximation
strategies (Rue et al., 2009).
The simplified Laplace approximation is the best approximation in terms of optimal
computing efficiency due to the much reduced computational cost of the simplified
Laplace approximation. This is because the simplified Laplace approach approxi-
mates π(xi | θ, y) via a Taylor’s series expansion around the mode up to the third
order which will produce the linear and cubic correction terms for the standardized
Gaussian approximation (Rue et al., 2009). The multivariate skew-normal distribu-
tion is subsequently matched to the linear and cubic correction terms in the Taylor’s
series expansion of π(xi | θ, y) to rectify the errors in location and skewness of the
Gaussian approximation (Azzalini and Capitano, 1999; Rue et al., 2017). This is
considered to be the optimal choice despite a small reduction in computing efficiency.
 Step 3: π̃(xi | y) is obtained by combining the previous two approximations and
integrating out θ using a numerical integration technique called weighted finite sum.
This is represented as follows:
π̃(xi | y) =
∫




π̃(xi | θk,y)π̃(θk | y)∆k.
Here, θ1, . . . ,θk are the points selected in step 1 within the θ space and ∆i, . . . , ∆k
are the weights of integration. Using similar steps, the posterior marginal densities of
π̃(θj | y), j = 1,. . . , M can be computed. These two posterior marginal distributions can
be summarised using means, quantiles and variances. The deviance information criterion
(DIC) (Spiegelhalter et al., 2002, 2014) can also be produced for model comparisons and
assessing the model complexity.
To ensure the efficiency of INLA, additional conditions are required for the latent
Gaussian model. Firstly, the latent Gaussian field x is required to have a conditional
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independence property, making it a latent Gaussian Markov random field that posesses a
sparse precision matrix Q. Besides, the number, m, of hyperparameters (i.e. the unknown
parameters that are not included in the latent field x, for instance the shape parameter,
α, for the Weibull survival time distribution, the variance σ2 for normal observations y,
the overdispersion parameter for a negative binomial distribution etc.) should not be
excessively large (ideally m ≤ 6). However, Rue et al. (2009) demonstrated that using
an integral scheme called Central Composite Design (CCD), this limitation can be easily
circumvented and a larger number of hyperparameters can thus be easily accommodated
(m ≤ 20). In this approach, the integration problem is considered as a design problem and
CCD is used to choose the optimal selection of points to be laid out when approximating
the bulk of probability mass in the higher-dimensional posterior distribution.
4.3.2 INLA and the central composite design approach
(CCD)
As mentioned above, INLA is an efficient algorithm if the number of hyperparameters
is small (m ≤ 6). The efficiency of the algorithm starts to drop when m increases to
a moderate number (6 < m ≤ 12), signified by rising computing time. If we employ
the integration strategy shown in Figure 4.1, we need evaluation points of O(5m). If we
restrict our evaluation points to a lesser magnitude per dimension, the computational cost
is still unacceptably high. Hence, we require a new approach to overcome this impasse.
One way to do this is to consider this integration problem as an experimental design
problem where our task is to find the optimal number of points that should be placed in a
space of m dimensions. One particular approach is based on response surface methodology,
using a conventional design such as a central composite design (CCD) (Box and Wilson,
1951). A CCD is a factorial or fractional factorial design with some clever modifications:
the centre points (central black dot in Figure 4.2) are supplemented by additional design
points (black dots on the squares and corners of the cubes) and star points (the black
dots on the axes, away from the central points (eg. the points with (α, 0),(−α,0), (0,α),
(0,−α) coordinates for m = 2)). Using this approach, we can optimise the number of
evaluation points for numerical integration.
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Figure 4.2: Central composite design (CCD) for m = 2 (left) and m = 3 (right) (Figure
from Montgomery (2017))
As an example, for m = 5, the usual grid-search method requires 3125 evaluation
points if 5 evaluation points per dimension are used (55 = 3125), or at least 243 evalua-
tion points if only 3 evaluation points are placed in each dimension (35 = 243). However,
if the CCD approach is used, we only require 27 evaluation points for numerical integra-
tion. Hence, this approach will be definitely invaluable in preserving the computational
efficiency of INLA.
4.4 A Simple Example
4.4.1 Simple linear regression
In this example, we shall carefully describe how the algorithm works. This example is
adapted from Blangiardo and Cameletti (2015). In this example, we will use a simple
linear regression model with only an intercept. For further information on INLA code
used in this example, please refer to appendix A.10.
Firstly, we shall assume a vector Y to be a realisation of Gaussian random variables
that are identically and independently distributed with mean µ and variance σ2. For
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µ ∼ N (µ0, τ)
τ ∼ Ga (a, b).
In the original INLA notation (Rue et al., 2009), the observations can be represented by
the following
Yi | θ, τ ∼ N (ηi, τ) i = 1, . . . , n
where ηi = θ = µ and τ is the precision.
The initial stage of the INLA algorithm is to integrate out θ from the joint distribution
of θ and τ so that the marginal posterior distribution of the hyperparameter τ can be
obtained
p(τ | y) =
∫
p (θ, τ | y) dθ.
Since p(θ, τ | y) ∝ p(y | θ, τ) p(θ) p(τ), we can bypass the integration using the
following relationship
p(τ | y) = p(θ, τ | y)
p(θ | τ,y)
∝ p(y | θ, τ)p(θ)p(τ)
p(θ | τ,y)
and the distributions for each quantity are




θ ∼ N (µ0, σ20)
τ ∼ Ga(a, b)
















One particular point should be stressed here. Since the observations in this example
follow a Gaussian distribution, the quantity p(θ | τ,y) does not require Laplace approx-
imation. Besides, we do not need to perform Laplace approximation even though the
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posterior distribution, p(τ | y), does not have conjugate structure since the terms in the
numerator and denominator that are dependent on θ will cancel out. As a result, we may
opt for any θ values and the most sensible option is to equate this with the conditional
posterior mode, θ = θn. Hence, this results in











It should be noted that 4.1 is an unnormalised posterior distribution for τ . Hence, the
most possible values for τ were selected ({τ (z)})in order to appraise the the unnormalised
τ pdf. The value of the density function of each τ is computed using








p(θ = θn)︸ ︷︷ ︸
N (µ0,σ20)
p(τ (z))︸ ︷︷ ︸
Ga(a,b)
(4.2)












nτ (z) + 1
σ20
.
The quantities for 4.2 can be computed using the R code given in appendix A.10, starting
from line #1 until the last line in compute quantities section. The unnormalised τ pdf can
be normalised using the codes presented in normalise the tau density (precision) section.
In the next step, we have to analyse p(θ | y) for every τ value within the τ set, {τ (j)},
and for every θ within {θ(j)}. We can do this by assessing p(θ = θ(`) | y) based upon the
Gaussian distribution with mean θn and variance σ
2
n. Next, using a finite weighted sum,
we integrate out τ from the joint distribution p(θ, τ | y):
p(θ = θ(`) | y) ∝
∑
j
p(θ(`) | τ (j),y)p(τ (j) | y)∆j
with ∆j = ∆ =
1∑
j p(τ
(j)|y) . The R codes for this second step can be obtained in appendix
A.10 (starting from Select J Grid Points until normalising the density for marginal pos-
terior theta).
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4.4.2 Analysis of Piston-ring failures data
4.4.2.1 The data set characteristics and setup
This data was analysed as a simple INLA example. The data, which was originally
published in Davies and Goldsmith (1972), was obtained from Hand et al. (1994) which is
available for public access via “http://www.stat.ncsu.edu/research/sas/sicl/data/
piston.dat”. The data are on the number of piston-ring failures in three separate legs for
four different types of steam-driven compressors within a building. All compressors have
the same design and were positioned in similar fashion. The purpose of analysing this
data was originally to assess whether the probability of piston-rings failures was associated
with the different types of legs and compressors. Davies and Goldsmith (1972) initially
analysed this data using a simple chi-square test, but a Poisson regression model is also
a suitable alternative for answering this research question.
Table 4.1: Piston-ring failures data adapted from Hand et al. (1994)
Compressor no Leg
North Centre South Total
1 17 17 12 46
2 11 9 13 33
3 11 8 19 38
4 14 7 28 49
Total 53 41 72 166
4.4.3 The relationship between Poisson and multino-
mial likelihoods
The Poisson-multinomial relationship was shown by McCullagh and Nelder (1989) who
demonstrated that the conditional distribution of multiple Poisson random variates given
the total is equivalent to a multinomial distribution. To be more specific, consider counts
from individual groups or species as independent Poisson random variables, each with
mean µi. We can subsequently obtain the joint distribution of these independent Poisson
random variables which can be conditioned on the sum of the total observed count. Hence,
the sum of these independent Poisson random variables is also a Poisson random variable
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with a mean obtained by summing up their respective Poisson means (i.e. µ1 + µ2 +
. . . + µk). Hence, the total observations, N, will also be a random variable (since N =
Y1 + Y2 + . . .+ Yk).
Nevertheless, if we restrict or fix the total of the observations, N = n, then individual
Yi will no longer be independent Poisson random variables since the maximum count of
Y in group i cannot exceed the total observed count. Besides, the assumption of indepen-
dence will also be violated since the larger count of Yi in group i will make the observed
counts in other groups smaller. Hence, the distribution of Y1, . . . , Yk given
k∑
i=1
Yi = n is
no longer Poisson.
To derive it, we first write
























Since Yi, . . . , Yk are independent,
k∑
i=1




(Grimmett and Stirzaker, 2001). Hence, Pr(
k∑
i=1
Yi = n) = e
−M Mn
n!
So the conditional distribution of Y1, . . . , Yk given
k∑
i=1
Yi is given by
Pr(Y1 = n1, . . . , Yk = nk |
k∑
i=1
Yi = n) =

























































. Hence, the probability function obtained above is a multinomial probability
function. As a summary, the conditional distribution (i.e. conditioned on the overall
sample size) is a multinomial distribution. For two independent Poisson random variables,
X1 and X2, the distribution of X1 conditional upon their sum is a binomial distribution,
X1 ∼ Bin(n, µ1[µ1+µ2]).
4.4.3.1 Modelling strategies
For this scenario, the numbers of piston-ring failures are assumed to follow Poisson distri-
butions. Since the mean of Poisson distribution should be positive, the log-link function
is used to connect the mean number of piston-ring failures with the covariates. The mean







where xij is the number of failures according to the types of leg and compressor.
This is hence regarded as a generalised linear model with Poisson errors and log link.
Besides, a zero-sum constraint was also employed using orthogonal contrast. To achieve
this, the dataset was modified so that it will have the data structure as presented in Table
4.2.
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Table 4.2: The modified piston-ring failures data structure based on orthogonal contrasts
No. Leg Failures X1 X2 X3 X4 X5 X6 X7 X8 X9 X10 X11
One North 17 2 0 -1 -1 -1 -2 -2 -2 0 0 0
One Centre 17 -1 1 -1 -1 -1 1 1 1 -1 -1 -1
One South 12 -1 -1 -1 -1 -1 1 1 1 1 1 1
Two North 11 2 0 -1 1 1 -2 2 2 0 0 0
Two Centre 9 -1 1 -1 1 1 1 -1 -1 -1 1 1
Two South 13 -1 -1 -1 1 1 1 -1 -1 1 -1 -1
Three North 11 2 0 1 -1 1 2 -2 2 0 0 0
Three Centre 8 -1 1 1 -1 1 -1 1 -1 1 -1 1
Three South 19 -1 -1 1 -1 1 -1 1 -1 -1 1 -1
Four North 14 2 0 1 1 -1 2 2 -2 0 0 0
Four Centre 7 -1 1 1 1 -1 -1 -1 1 1 1 -1
Four South 28 -1 -1 1 1 -1 -1 -1 1 -1 -1 1
In this data structure, X1 and X2 represent the main effects for legs and X3, X4 and X5
are the main effects for compressors. The rest of the Xs represent the two-way interaction
effects between legs and compressors. Finally, the parameters are given independent
normal distributions and the values are given in Table 4.3.
Table 4.3: The prior means and variances for the intercept (α) and regression coefficients














The R codes for MCMC (using rjags) and INLA (R-INLA) are given in appendix
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A.3. The number of iterations for MCMC was fixed at 100,000 with a burn in of 1,000.
The posterior means and standard deviations are given in Table 4.4. The results are
presented as posterior means and standard deviations (in brackets). Figure 4.3 show
marginal posterior densities of the parameters computed using both methods.
Table 4.4: The comparisons of results for regression coefficients obtained via MCMC and
INLA
Parameter MCMC (Posterior mean (SD)) INLA (Posterior mean (SD))
α 2.5131 (0.0851) 2.5158 (0.0832)
β1 0.0067 (0.0589) 0.0092 (0.0580)
β2 -0.2934 (0.1054) -0.2927 (0.1036)
β3 0.0016 (0.0848) 0.0012 (0.0833)
β4 -0.0432 (0.0843) -0.0433 (0.0833)
β5 -0.1280 (0.0848) -0.1275 (0.0833)
β6 -0.0257 (0.0585) -0.0254 (0.0580)
β7 -0.0035 (0.0585) -0.0031 (0.0580)
β8 -0.0231 (0.0588) -0.0232 (0.0580)
β9 -0.2863 (0.1050) -0.2871 (0.1036)
β10 -0.1583 (0.1050) -0.1591 (0.1036)
β11 -0.0258 (0.1044) -0.0255 (0.1036)
As we can see from the results presented in both Table 4.4 and Figure 4.3, the poste-
rior means, standard deviations and densities are closely similar. However, the computing
time for INLA is much shorter than MCMC (0.87 seconds vs 16.83 seconds). This indi-
cates R-INLA is more than 19 times more efficient than RJAGS in obtaining posterior
distributions.
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Figure 4.3: Comparisons of posterior densities of α till β11 obtained via MCMC (red) and
INLA (blue)
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4.5 INLA and survival analysis
4.5.1 Weibull lifetimes
In survival analysis, the model under consideration can easily be visualised as a latent
Gaussian model (LGM). An example using a Weibull proportional hazard model will
be used to elaborate on the methodological aspects of INLA in the context of survival
analysis. Let us assume that we have survival times t1, t2, . . . , tn which are iid observations
from a Weibull distribution. Hence, the probability density function (pdf) for these
survival times, given the two Weibull parameters α > 0 and λ, can be alternatively
written as
f(ti | α, λ+) = αtα−1i exp{λ+ − exp{λ+}tαi }.
where exp{λ+} = λ (the scale parameter of a Weibull pdf).
For Weibull-distributed survival times, the survival function S(t) = Pr(T > t) is
S(ti | α, λ+) = exp{− exp{λ+tαi }}.
Hence, the likelihood for α and λ+ is
L(α, λ+ | D) =
n∏
i=1

















([(δi)(α− 1)log(ti)]− exp(λ+)tαi )}.
In the equation above, δi represents the survival status of the subject and hence will
be recorded as 1 if the event occurs (hence there is a survival time, Ti; the first term on
the right hand side exists, the second term is 1) or 0 if the observation is right censored
(Censoring time (Ci); second term on the right hand side of the equation exists, first
term is 1). Since λ+i = ηi, the covariates can be brought in to establish a regression
model. Hence log λi = z
T
i β; zi is the p × 1 vector of the covariates and β is the vector
of regression coefficients. From here, we can allow the predictor to have a structured
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additive form (equation 4.1). Then, Gaussian priors are allotted to each of the elements
on the right side of the equation:







βkzki + εi (4.3)
so that x will have a Gaussian field property and a precision matrix of Q(θ1). This is a
latent Gaussian model with a latent field, x, hyperparameters θ = {θ1, θ2}; θ2 = α. The
observed data, D, are the survival status and survival time of each subject (ti, δi) with i
= 1,2,3,. . .,n. It can hence be seen that the likelihood of the observed data is dependent
on the latent field x only via the predictor ηi. As a result, INLA can easily be applied in
this setting.
An INLA scheme could also be implemented for a piecewise constant hazard model.
Within the piecewise constant hazard model set-up, the log likelihood contribution of the
ith individual with survival time ti (where ti ∈ [τj−1, τj) is given by
log[fi(t)] = log[hi(t)




λik(τk − τk−1) + (t− τj−1)λij
}
(4.4)
where δij is either 0 if the i
th individual experiences the event or 0 if censoring occurs.
Equation 4.4 can be further rewritten as
log[fi(t)] = δijηij − (t− τj−1) exp{ηij} −
j−1∑
k=1
exp{ηik}(τk − τk−1) (4.5)
where λij = λ0j exp{XTi β} and λ0j is the baseline hazard function in the jth interval.
Since the log likelihood is only dependent on Gaussian Latent field via the predictors
η1, . . . , ηj(where ηj = log(λij) = log(λ0j +X
T
i β)), the INLA scheme cannot be directly
implemented for such model. Fortunately,the piecewise constant hazard model can still
be rewritten into a Poisson regression framework, through which the INLA scheme can
be directly executed.
Holford (1976), Holford (1980) and Laird and Olivier (1981) have demonstrated the
equivalence of piecewise constant hazard model and Poisson regression model and this
framework has been utilised by the previous researchers to fit a variety of survival models
using traditional statistical software such as GLIM(Aitkin and Clayton, 1980). To proof
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Since δij can only be 0 or 1, δij! can be safely disregarded and the log likelihood contri-












δij log(λij) + δij log(tij)− λijtij. (4.6)
Since δij log(tij) term does not involve any λij, it can be disregarded and therefore 4.6 is
proportional to 4.4 since the summation of over j intervals equals to the summation of
j(i).
Hence, from (4.5), we can clearly observe that the first two terms on the right hand
side of the equation, δijηij − (t− τij) exp{ηij} has the form of Poisson log likelihood with




exp{ηik}(τk − τk−1), has a k − 1 Poisson log likelihood with mean
exp{ηik}(τk − τk−1) since individual i survives at the end of each previous j − 1 interval
and therefore δij is always 0. Therefore, we can fit the piecewise constant hazard model
within the framework of INLA by treating each ti as “augmented data points” originated
from a Poisson distribution.
4.6 INLA and missing data: INLA within
MCMC (INLA-MCMC) approach
In this section, we propose to extend the INLA within MCMC (INLA-MCMC) method
proposed by Gomez-Rubio and Rue (2018) to survival analysis with missing covariate
values. In their paper, Gomez-Rubio and Rue (2018) used a multiple imputation scheme
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to fill in the missing covariate values for linear regression models before obtaining the
posterior estimates for model parameters. Our approach is different since we directly
sample the missing values and then apply this to various survival models. The overview
of this proposed method will be given in this section.
Let θ be a collection of unknown parameters and hyperparameters in a Bayesian
hierarchical model. In this case, θ represents all of the parameters of the latent effects, x,
and all the hyperparameters which include hyperparameter of the latent field x, where x
| θ1 ∼ (0, Q−1(θ1)] and the hyperparameter in the likelihood of the observations or data
[i.e. y | x, θ2 ∼
n∏
i=1
π (yi | x, θ2)]. To ensure that INLA can be used to fit the model,
we fix some of the model parameters. Hence, we split θ into θξ and θ−ξ, where θξ is
the collection of parameters we fixed and θ−ξ is the parameters we do not fix. Thus, by
conditioning on θξ, INLA can be used to obtain the posterior marginals of all parameters
in θ−ξ, π (θ−ξ | y,θξ), and the conditional marginal likelihood, π(y | θξ). In R-INLA, π(y
| θξ) is automatically stored and therefore can be easily called for and combined with the
prior distributions for θξ to obtain the posterior marginal distributions for each element
in θξ.
The Metropolis-Hastings algorithm (Gamerman and Lopes, 2006) can subsequently
be used to draw values for θξ so that its joint posterior distribution can be obtained. At
step i + 1 of the Metropolis Hastings algorithm, new values θ
(i+1)
ξ for θξ are proposed




















If the proposed value is not accepted, then θ
(i+1)
ξ is set to θ
(i)
ξ . Here π(y | θ
(i)
ξ ) and














ξ , are π(θ
(i)
ξ ) and π(θ
(i+1)
ξ )
respectively. Hence, at each step of the Metropolis-Hastings algorithm, only a model
conditional upon the proposal needs to be fitted. Besides, the INLA calculation will also
provide the posterior marginals π(θ−ξ | y,θ(i+1)ξ ) for all the parameters in θ−ξ.
After a suitable number of iterations, the Metropolis-Hastings algorithm will produce
samples from π(θξ | y), from which the posterior marginals of the parameters in θξ can
be derived. Apart from that, we will obtain a family of conditional marginal distributions
for all the parameters in θ−ξ. Their posterior marginals can be obtained by combining
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all these conditional marginals and integrating out over θξ using
π(θ−ξ,i | y) =
∫





π(θ−ξ,i | y,θ(j)ξ ).
Values { θ(j)ξ }Nj=1 represent N samples from π(θξ | y) obtained with the Metropolis-
Hastings algorithm. Thus, the posterior marginal of θ−ξ,i can be obtained by averaging
the conditional marginals obtained at each iteration of the Metropolis-Hastings algorithm.
4.7 Summary
In this chapter, we described the fundamentals of INLA and application of INLA to
survival data. We then showed how, by nesting INLA, with an MCMC scheme we can
efficiently calculate posterior marginal distribution of parameters in models even when
there are missing covariate values. In Chapter 7, we will evaluate the usefulness of this






In Chapter 4, we discussed the application of INLA to survival data. In particular, in
Section 4.6, we introduced a new method, INLA within MCMC, which allows the use of
INLA with survival datasets when there are missing covariate values. In Chapter 7, we
will illustrate the use of this method by applying it to a number of data sets. This will
also allow us to evaluate the method’s usefulness.
In this chapter, we present details of the data sets used for application purposes. In
sections 5.2 and 5.3, the characteristic details of the kidney infection and non Hodgkin
Lymphoma datasets will be respectively elucidated. In 5.4, the Malaysian lung cancer
dataset will be described.
5.2 Kidney infection dataset
The kidney infection data set arose from a study which was performed to evaluate the
time to the first exit-site infection in patients who required catheters for renal insufficiency
(Nahman et al., 1992). Forty three (36.1%) patients used catheters which were placed
surgically (Group 1) whilst for the other 76 (63.9%) patients, the catheters were placed
percutaneously (Group 2). The total number of patients is thus 119. This data set
contains no missing covariate information. There are three variables in the dataset:
 Infection indicator - 0: no, 1: yes
 Cathether placement - 1: surgical placement, 2: percutaneous placement
85
Chapter 5. Applied Datasets
 Time - Times to first exit-site infections (in months).
This dataset is used as a motivational example.
5.3 Non-Hodgkin Lymphoma
5.3.1 Introduction and classification
Non Hodgkin lymphoma (NHL) is a type of blood cancer. Its origin is from lymphocytes
(a subtype of white blood cells), primarily B lymphocytes (85-90% of cases) whilst the
rest are derived from T-lymphocytes. According to the recent statistics, 12,294 new cases
of NHL were reported in 2009 in the UK, with 4452 deaths in 2010 (Shankland et al.,
2012). The age-standardised incidence of NHL was reported to have risen by 35% in the
period 1988-2007. Fortunately, the survival of NHL patients in England and Wales has
considerably improved: 50.8% of NHL cases are expected to survive longer than 10 years,
a marked improvement compared to 21.8% 10-year survival rate for those diagnosed in
the 1970s (Shankland et al., 2012).
There are diverse classifications for non Hodgkin lymphoma but the 2008 WHO clas-
sification for NHL has been adopted based on the universal consensus of experts in this
field. See Table 5.1.
5.3.2 Development of NHL
The mechanisms by which lymphoma develops are complex. For B cell lymphoma, the
mutations that drive the development of B cell lymphomas occur primarily during the
recombination of genes responsible for the production of heavy and light chain antibodies,
made possible by enzymes that enable double strand DNA breaks (Shankland et al., 2012).
In normal B cell development, these breaks in the DNA strands are easily repaired by
DNA repair mechanisms. Nevertheless, these strand breaks may also trigger chromosomal
translocations which in turn result in proto-oncogene activation. This culminates in the
development of B cell lymphoma.
On the other hand, the pathogenesis of T cell lymphoma is less well understood. Most
subtypes are not associated with any well-characterised genetic or biological alterations
to the T cell normal development. Recurring chromosomal translocations are rarely seen
in the development of T-cell NHL (Shankland et al., 2012). Exposure to human T-cell
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Table 5.1: 2008 WHO classification of Non Hodgkin Lymphoma (Shankland et al., 2012)
Diseases
B-cell lymphoma
Precursor B cell Precursor B-cell lymphoblastic leukaemia or lymphoma
Mature B cell Chronic lymphocytic leukaemia/small lymphocytic lym-
phoma; lymphoplasmacytic lymphoma; splenic marginal-
zone lymphoma; extranodal marginal-zone B-cell lymphoma
of mucosa associated lymphoid tissue; nodal marginal-zone
B-cell lymphoma; follicular lymphoma; mantle-cell lym-




Lymphomatoid granulomatosis; post-transplantation lym-
phoproliferative disorders (polymorphic)
T-cell and Natural Killer (NK)-cell lymphoma
Precursor T cell Precursor T-cell lymphoblastic leukaemia or lymphoma
Extranodal mature
T cell and NK cell
Mycosis fungoides; cutaneous anaplastic large-cell
lymphoma; extranodal NK-cell or T-cell lymphoma;
enteropathy-type lymphoma; hepatosplenic lymphoma; sub-
cutaneous panniculitis-like lymphoma; primary cutaneous
CD8-positive lymphoma; primary cutaneous γ/δ T-cell
lymphoma; primary cutaneous CD4-positive lymphoma
Nodal mature T
cell and NK cell
Peripheral T-cell lymphoma, not otherwise specified; an-
gioimmunoblastic lymphoma; anaplastic large-cell ALK-
positive lymphoma; anaplastic large-cell ALK-negative lym-
phoma; adult T-cell leukaemia/lymphoma
leukemia virus 1 (HTLV-1) and Epstein Barr Virus (EBV) have been identified to be
one of the causes (aetiology) of T-cell lymphoma development (Rizvi et al., 2006). The
infections by these viruses are believed to result in the clonal rearrangement of T-cell
receptors, with evidence pointing towards clonal integration of HTLV-1 (Ohshima et al.,
1997). The prognostic outlook for T-cell lymphoma is poor with a median survival of 8
months following diagnosis (Rizvi et al., 2006).
The pathogenesis of NHL development for both subtypes and potential therapeutic
targets are summarised in Figure 5.1.
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Figure 5.1: Pathogenesis of NHL and therapeutic targets (Shankland et al., 2012)
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5.3.3 Method of data collection for SNLG dataset
The Scotland and Newcastle Lymphoma Group (SNLG) has maintained a database of
Non Hodgkin Lymphoma patients from Northern England and Scotland since 1979. So
far, data on 18000 NHL patients have been included in the database. The data collection
process was performed using Population Adjusted Clinical Epidemiology (PACE) method-
ology employed by the Northern Regional Haematology Group (NRHG). In brief, the core
methodology of PACE lies in the establishment and maintenance of a regional registry
for all NHL subjects that includes relevant clinical profiles on each subject (demographic
and clinical profiles; prognostic outcomes etc.) in a geographical area that pertains to the
census population of incidence cases (Proctor and Taylor, 2000). Figure 5.2 shows the
areas covered in the data collection process.
Figure 5.2: Areas of data collection
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5.3.4 Covariates and outcomes
The original SNLG dataset includes all types of haematological malignancy. For the
purpose of modelling, only subjects with Diffuse Large B Cell Lymphoma (DLBCL), a
subtype of B cell lymphoma, were selected and used. In total, data from 2025 DLBCL
patients were included in the dataset, with more than 150 prospective prognosticators and
2 outcome measures (overall survival (OS) and time to first relapse (TFR)) recorded for
each NHL subject (Zhao, 2010). The whole data collection process was conducted between
January 1990 and January 2004 (14 years). The data set was made available for use by
Professor Stephen J. Proctor (lead investigator), Dr Michal Sieniawski (co-investigator)
and Ms Jo White (data manager) who were several of the original investigators from the
SNLG research group.
Out of the 2025 DLBCL patients, 1391 patients received the standard Cyclophos-
phamide, Hydroxydaunorubicin (also known as doxorubicin hydrochloride), Oncovin®
(vincristine sulfate) and Prednisone (CHOP) chemotherapy regime. To remove the effect
of treatment heterogeneity on patient survival, only this subset of patients were included
in the analysis.
Fourteen covariates and one measured outcome were selected for the final dataset.
Based on the preliminary analysis of the dataset, only 636 (45.7%) of DLBCL patients were
found to have complete information on all 14 covariates. The numbers of DLBCL patients
experiencing the event of interest (death) and censored observations are 738 and 653
respectively. Only three covariates (age, gender and Ann-Arbor stage) were completely
observed. The operational definitions and descriptive summaries of each covariate are
given as follows:
 Age - Age of patient (in years) at diagnosis.
 Gender - Gender for each subject, recorded either 1 or 2 for male and female,
respectively.
 Stage - Refers to Ann Arbor Stage (Carbone et al., 1971; Shankland et al., 2012).
There are 4 categories for this covariate, each corresponds to an Ann-Arbor Stage
(See Table 5.2). The number of patients diagnosed with DLBCL stage I, II, III and
IV is 255 (18.3%), 386 (27.7%), 354 (25.4%) and 396 (28.5%) respectively.
 LDH - This was originally recorded as a continuous covariate representing the
patient’s serum lactate dehydrogenase level. This is recorded in U/L (units per
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Table 5.2: Ann Arbor staging system for Non Hodgkin Lymphoma
Stages Descriptions
I The lymphoma is only present in a single lymph node or
lymph node region
II The lymphoma is found in two or more than two nodal regions
on the same side of diaphragm
III The lymphoma is present in the lymph node regions on the
both side of diaphragm
IV Disseminated lymphoma that can be found beyond lymph
node regions affecting extranodal sites (e.g. pleura, bone mar-
row, liver etc)
litre). The LDH ratio was obtained by dividing the raw value of serum lactate
dehydrogenase with the upper limit of the reference range for LDH used by each
centre of data collection. For analytical purposes, we categorised this covariate into
three levels based on the recommendation by Zhao et al. (2014): 1 if LDH ratio ≤
1; 2 if 1 < LDH ratio ≤ 3; and 3 if LDH ratio > 3. The values within the normal
range of LDH were interval-censored.
 Haemoglobin - This represents the amount of haemoglobin (an oxygen carrying
compound in the red blood cells). It is a continuous covariate and measured in g/L.
 WBC - This represents white blood cell (WBC) count in human blood. The unit of
measurement is ×109/ L and it was recorded as a continuous covariate. The normal
range of WBC in a healthy human is between 4 to 10 × 109/ L.
 ECOG - This represents the Eastern Cooperative Oncology Group performance
status (Oken et al., 1982). The ECOG scale has 5 ordinal categories. It is utilised
for evaluating the fitness of cancer patients which, in turn, can be used for deciding
the most suitable therapies for the patients. The descriptions for each ECOG grade
are given in Table 5.3.
 Albumin - This is a continuous covariate representing the concentration of albu-
min (a type of protein produced by the human liver) in the serum. The normal
reference range for serum albumin in a healthy human is between 35 g/L and 50
g/L (Longmore et al., 2014). Since albumin is rarely above the normal range,
albumin is classified into two categories: -1 (normal values) and 1 (low values or
hypoalbuminaemia).
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Table 5.3: ECOG performance status grading system (Oken et al., 1982)
Grades Descriptions
0 Fully active,able to carry on all pre-disease performance with-
out functional limitations. Equivalent to Karnofsky perfor-
mance score of 90 and 100
I Restricted in physically strenuous activity but ambulatory
and able to carry out work of a light or sedentary nature,
e.g., light house work, office work. Equivalent to Karnofsky
performance score of 70 and 80
II Ambulatory and capable of all selfcare but unable to carry out
any work activities; up and about more than 50% of waking
hours. Equivalent to Karnofsky perfomance score of 50 and
60.
III Capable of only limited selfcare; confined to bed or chair more
than 50% of waking hours. Equivalent to Karnofsy perfor-
mance score of 30 and 40.
IV Completely disabled; cannot carry on any selfcare; totally
confined to bed or chair. Equivalent to Karnofsky perfor-
mance score of 10 and 20.
V Dead. Karnofsky performance score of 0.
 AP - This covariate represents the concentration of serum alkaline phosphatase
(AP). It is an enzyme that is present in the human body, predominantly in the
liver, bile duct, kidney and bone. The normal range is between 30 and 150 IU/L
(Longmore et al., 2014). Supranormal level of AP indicates increased disease ac-
tivities in the liver and bone of patients with NHL. For analytical purposes, AP is
categorised into normal (-1) or high (1).
 Urea - This represents the concentration of urea in a patient’s serum. The normal
range is between 2.5 and 6.7 mmol/L (Longmore et al., 2014). High serum urea
concentration indicates failing kidneys. In this dataset, serum urea concentration is
categorised into normal (-1) or high (1).
 Extranodal- This is a categorical covariate that indicates the presence of extran-
odal diseases. This means that lymphoma cells have already disseminated beyond
the lymph nodes. This is coded as -1 (absent) or 1 (present).
 Bulk - This represents the presence of bulky disease which is based on the size of
lymph node mass of 10 cm or more (in any axis) (Pfreundschuh et al., 2008). In
this dataset, it is coded either 1 (present) or -1 (absent).
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Table 5.4: The descriptive summaries of numerical covariates and percentage of missing
data for the SNLG data set (n = 1391)
Variable Min Max Mean (SD) nmiss (%)
Age 18 92 62 (14.21) 0 (0)
Haemoglobin 74 178 126.4 (18.86) 52 (3.7)
WBC 1.1 27.2 8.0 (3.5) 46 (3.3)
 Bone marrow - This is a categorical covariate recorded either as 1 (present) or
-1 (absent). It indicates DLBCL involving bone marrow which is confirmed by the
presence of lymphoma cells in the bone marrow under histopathological examination
of bone marrow aspirate or biopsy.
 Bsy - This indicates the presence of B symptoms which are: fever, night sweats
and weight loss, suggesting a poorer course of disease. This is coded as 1 (present)
or -1 (absent).
For outcome measures, the only variable used is OS. It is defined as follows.
 OS - Overall survival of the patients since diagnosis until death in months (also
known as time to death). The event status is recorded as either 1 (died) or 0
(censored). The time is calculated from the date of first diagnosis until the date of
death ascertained from the death certificates (event) or to the last date of follow up
if no death was noted (censored).
The descriptive summaries and percentages of missing data for the numerical, binary
and ordinal covariates are given in Tables 5.4 - 5.5. The pattern of missing covariates and
the number of DLBCL patients associated with them are presented in Table 5.6.
Table 5.5: The descriptive summaries of binary and ordinal covariates and percentage of
missing data for the SNLG data set (n = 1391)
Variable Value n (%) nmiss (%)
Gender Male 704 (50.6) 0 (0)
Female 687 (49.4)
Stages I 255 (18.3) 0 (0)
II 386 (27.7)
Continued on next page
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Table 5.5 – Continued from previous page
Variable Value n (%) nmiss (%)
III 354 (25.4)
IV 396 (28.5)
LDH ≤1 365 (26.2) 522 (37.5)
>1 - 3 339 (24.4)
>3 153 (11.9)






Albumin Normal / High 986 (70.8) 97 (7.0)
Low 308 (22.1)
AP Normal 983 (70.7) 78 (5.6)
High 330 (23.7)
Urea Normal 999 (71.8) 51 (3.7)
High 341 (24.5)
Extranodal Present 465 (33.4) 1 (0.1)
Absent 926 (66.5)
Bulk Present 678 (48.7) 109 (7.8)
Absent 604 (43.4)
Bone marrow Present 191 (13.7) 196 (14.1)
Absent 1004 (72.2)
Bsy Present 794 (57.1) 13 (0.9)
Absent 584 (42.0)
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Table 5.6: The number of missing covariates with the corresponding frequency of DLBCL
patients in the SNLG data set












5.4.1 Lung cancer- a global and Malaysian perspec-
tives
The worldwide incidence of lung cancer has rapidly risen since the turn of the 20th century.
For instance, 228,190 new lung cancer cases and 159,480 lung cancer-associated mortality
were estimated for the USA population in 2013. These account for 28% and 26% of
cancer-associated mortality for American males and females, respectively (Siegel et al.,
2013). In Malaysia, lung cancer was considered rare in the 1950s. The earliest study
conducted to estimate lung cancer prevalence in Malaysia was by Marsden (1958) that
demonstrated lung cancer was the 8th commonest malignancy in male and not even in
the top ten among females. In contrast, according to the Malaysian National Cancer
Registry 2006, it had become the 3rd commonest cancer among the Malaysian population
after breast and colorectal cancers. The peak incidence of lung cancer is in the 7th decade
of life with younger age at diagnosis for non smokers (mean age 54.7) than smokers (mean
age 61.7).
There are several putative epidemiological risk factors that have been identified for lung
cancer. Smoking remains the predominant risk factor, followed by exposure to environ-
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mental pollutants such as nickel, arsenic, asbestos and others. A few genetic susceptibility
loci have been identified to contribute towards increased risk of lung cancer among first de-
gree relatives of a proband with lung cancer. Individuals with inflammatory comorbidites
such as Chronic Obstructive Pulmonary Disease (COPD), asthma and emphysema are
found to have an elevated risk of developing lung cancer whilst hay fever was associated
with lower risk of lung cancer.
The lung cancer types can be divided into two large classes; small cell lung cancer
(SCLC) which is the more aggressive type, and non-small cell lung cancer (NSCLC). The
NSCLC type is further divided into three common subtytpes which are adenocarcinoma,
squamous cell carcinoma, and large cell carcinoma. Of these, squamous cell carcinoma is
deemed the more aggressive NSCLC subtype which results in poorer overall survival and
progression free survival.
5.4.2 Malaysian advanced non-small cell lung can-
cer dataset - Hospital Universiti Sains Malaysia
(HUSM)
Hospital Universiti Sains Malaysia (HUSM) is a major teaching hospital located in Kota
Bharu, the state capital of Kelatan (a Malaysian state that is located near the Thailand
and Malaysian border) (Figure 5.3). It is a tertiary medical centre receiving referrals
mostly from the Malaysian east coast region. The oncology service is provided by the
Department of Nuclear Medicine, Radiotherapy and Oncology which is a spin off from
the Department of Medicine since 1995. On the average, it receives 15-25 newly diagnosed
primary lung cancer cases per annum.
Based on an initial survey of the hospital records performed in August 2014, there are
approximately 600 lung cancer cases which were reported from 1996 until 2014. So far,
the data collection process is still ongoing and the data set now has 397 advanced lung
cancer cases. All of them received a platinum-based regimen as the first-line palliative
chemotherapy regime. Nevertheless, the data gathered so far should be independently
verified to ascertain the accuracy of the data.
Based on initial analyses, there are 241 (60.7%) patients that had experienced the
event of interest (death) and 156 (49.3%) censored observations. There are 157 (39.55%)
patients with complete covariate information. The covariates and measured outcomes of
interest are basically similar to the SNLG dataset except that there are several additional
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Figure 5.3: Malaysian map showing the location of HUSM (green arrow)
covariates and Ann Arbor stage, extranodal disease, bulky mass, bone marrow
involvement, B symptoms and urea were excluded since these only pertain to the
NHL prognostic index. Furthermore, stage was categorised into either IIIB (locally ad-
vanced unresectable lung cancer, coded as -1) or IV (metastasised to other organs, coded
as +1) since all lung cancer patients were at terminal stages. Besides, only advanced
lung cancer patients with ECOG score of 0-2 were included in the data set since higher
ECOG scores excluded the patients from receiving palliative chemotherapy and this would
definitely impact patient survival. The operational definitions for the eight additional
covariates and two other covariates (stage and histology) that have classification system
different from those used for the SNLG data set are given as follows.
 Race - The ethnicity of patients, recorded either 1 or 2 as Malays and non-Malays
respectively.
 Smoking - This is a categorical covariate representing the smoking status of the
advanced lung cancer patients at the time of diagnosis. It is recorded as 1, 2, 3 for
never smokers, ex-smokers and active smokers respectively. This classification was
based on the recommendations by Simonato et al. (2001).
 Stage - It is recorded as 1 and 2 which respectively correspond to Tumour, Node,
Metastasis (TNM) stage IIIB and IV (Rami-Portas et al., 2017).
 Weight loss - It is defined as more than 5% weight loss in comparison to the
patient’s baseline weight 6 months before the diagnosis of lung cancer (Scott et al.,
2002). It is recorded as 1 and 2 which correspond to the absence and presence of
pre-treatment weight loss.
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 Brain metastasis - The presence of lung cancer cells / mass in the brain indicates a
widespread disease, indicating poor prognosis (metastasis is defined as the spread of
cancer beyond the original / primary site of cancer). This is a categorical covariate
coded as : 1 (metastasis absent), 2 (metastasis present).
 Sodium - A continuous covariate representing the serum sodium concentration in
lung cancer subjects. The usual range is between 135 mmol/L and 145 mmol/L
(Longmore et al., 2014). A low serum sodium concentration indicates the presence
of Syndrome of Inappropriate ADH (SIADH) secretion, signifying poor prognosis.
 Neutrophil count - A continuous covariate that is measured in ×109 unit. The
normal range is between 2.5 and 7.5 × 109 cells/L (Longmore et al., 2014). A high
neutrophil count indicates the presence of intense inflammation inside the tumour
environment, indicating poor prognosis.
 Platelet count - A continuous covariate. Platelets are a type of blood cell that
is responsible for the formation of blood clot. The normal range is between 150
and 450 ×109 cells/L (Longmore et al., 2014). It has been documented that the
presence of cancer cells induces a hypercoagulable state resulting in an increase in
the platelet count. Both neutrophil and platelet counts are modelled as continuous
covariates.
 Histology - This is a categorical covariate representing the types of lung cancer.
There are four categories within this covariate which are coded as follows: 1 -
Adenocarcinoma , 2 - Squamous cell carcinoma, 3 - Large cell carcinoma,
4 - Small cell carcinoma.
 Epidermal Growth Factor Receptor (EGFR) mutational status - The pres-
ence of the EGFR mutation in lung cancer cells results in a higher response rate to
molecular targeted therapy such as gefitinib or erlotinib. Consequently, the survival
in those with these genetic features is superior to those without this mutation. It
was estimated by Pao et al. (2004) that approximately 35% of lung cancer subjects
of East Asian origin harbour this genetic mutation. Hence, this categorical covariate
should ideally be included in the development of the prognostic index for advanced
lung cancer patients. The data are recorded as 1 for positive EGFR mutation and
-1 for absent EGFR mutation.
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On further analysis, EGFR mutational status was excluded due to unreliable reporting
by the HUSM pathology department. As a result, EGFR was no longer considered in the
analysis.
The descriptive summaries of numerical, binary and ordinal covariates of the Malaysian
advanced lung cancer data set are given in Tables 5.7 - 5.8. The missing covariate patterns
and the corresponding frequency of advanced lung cancer patients are presented in Table
5.9.
Table 5.7: The descriptive summaries of numerical covariates and percentage of missing
data for the Malaysian advanced lung cancer data set (n = 397)
Variable Min Max Mean (SD) nmiss (%)
Age 41 88 58.9 (10.92) 83 (20.9)
Haemoglobin 72 180 122.9 (21.77) 93 (23.4)
WBC 1.3 11.4 6.2 (2.01) 95 (23.9)
Sodium 125 142 136.0 (3.6) 76 (19.4)
Neutrophil count 0.60 7.60 4.2 (1.40) 95 (23.9)
Platelet count 33.0 882.0 369.8 (139.53) 77 (19.4)
Table 5.8: The descriptive summaries of binary and ordinal covariates and percentage of
missing data for the Malaysian advanced lung cancer data set (n = 397)
Variable Value n (%) nmiss (%)
Gender Male 207 (52.1) 0 (0)
Female 190 (47.9)
Race Malay 276 (69.5) 96 (24.2)
Non-Malay 25 (6.3)
Smoking Never smokers 36 (9.1) 83 (20.9)
Ex-smokers 121 (30.5)
Active smokers 157 (39.5)
Stage IIIB 127 (32.0) 85 (21.4)
Continued on next page
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Table 5.8 – Continued from previous page
Variable Value n (%) nmiss (%)
IV 185 (46.6)
ECOG 0 44 (11.3) 71 (17.9)
I 196 (49.4)
II 86 (21.7)
LDH ≤1 88 (22.2) 95 (23.9)
>1 - 3 214 (53.9)
Albumin Normal 117 (29.5) 107 (27.0)
Low 173 (43.6)
AP Normal 159 (40.1) 91 (22.9)
High 147 (37.0)
Weight loss Present 208 (52.4) 83 (20.9)
Absent 106 (26.7)
Brain metastasis Present 104 (26.2) 95 (23.9)
Absent 198 (49.9)
Histology Adenocarcinoma 175 (44.1) 87 (21.9)
Squamous 89 (22.4)
Large cell 22 (5.5)
Small cell 24 (6.0)
100
Chapter 5. Applied Datasets
Table 5.9: The missing covariate patterns for the Malaysian advanced lung cancer data
set
















In this section, the detailed characteristics of each applied dataset have been described.




Prior Information and Prior
Distribution Construction
6.1 Introduction
In this chapter, the construction of prior distribution will be described for modelling
purposes. In 6.2, a short introduction on the conceptual underpinnings of prior elicitation
is given. In 6.3 we shall describe and summarise the relevant information obtained from the
previous literature for prior constructions for the SNLG data and present the meta analysis
results. In 6.4, the information relevant to prior construction for the Malaysian HUSM
advanced lung cancer survival model will be presented along with meta analysis results. In
6.5 and 6.6, prior elicitation and construction for Weibull and piecewise constant hazard
survival models will be presented, including both hierarchical and autoregressive priors in
the piecewise case. In section 6.7, we shall conclude our findings for this chapter.
6.2 A short introduction to prior elicitation
6.2.1 Preliminaries
The purpose of prior elicitation is to obtain and quantify information about uncertain
quantities in a probabilistic construction based upon the knowledge acquired from the
experts in the respective areas. In other words, the main objective of prior elicitation
is to appropriately capture the experts’ knowledge and represent it in proper probability
distributions. To make things clearer, we shall define experts as individuals whose know-
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how and knowledge are worth having for constructing coherent priors (O’Hagan et al.,
2006).
In statistics, there are two circumstances where eliciting prior information is important.
They are design of experiments (DOE) and Bayesian statistics (O’Hagan et al., 2006).
In the former, prior elicitation is important to identify variables whose uncertainty is of
considerable magnitude. This is to ensure that the experts’ prior knowledge will assist
in designing efficient experiments. In the latter, however, prior information is used to
augment or supplement the information contained in the data. It is the case, nevertheless,
that in Bayesian statistics the prior information may not be very influential since the
information contained in the data far outweighs the information represented by the prior.
Hence, methodical or systematic prior elicitation will usually be performed if the experts’
prior is noticeably very informative or when the amount of information conveyed by the
data is limited.
6.2.2 Types of uncertainty
According to O’Hagan et al. (2006), uncertainties can be classified into two groups:
aleatory and epistemic uncertainties. The term aleatory is derived from the Latin
alea, die, or aleator, dice player. Hence, we can straightforwardly deduce that aleatory
uncertainty is attributed to uncertainties that arise from randomness in a process. On
the other hand, epistemic uncertainty originates from experts’ incomplete mechanistic
knowledge of a process (the word epistemic is derived from a Greek word, episteme,
which means knowledge). To better distinguish the differences between these two, we
shall consider the following example.
Let us consider an example where we model survival times for some homogeneous group
of patients using an exponential (λ) distribution. Beliefs about the survival time, T, for a
future patient will involve aleatory uncertainty because, even if we know the value of λ, T
is still a random variable, and epistemic uncertainty because we do not know the value of
λ. Hence, for example, Var(T) = Eλ[Var (T| λ)]+Varλ[E(T | λ)]. In this case, the problem
which elicitation methods need to overcome is how to separate the epistemic uncertainty,
masured by Var(λ), from the aleatory uncertainty, measured by Var(T| λ) (and Varλ[E(T |
λ)]), which both contribute to Var(T). For Bayesian statisticians, both epistemic and
aleatory components of uncertainty can be represented by probability distributions.
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6.3 Prior information for the Non-Hodgkin
Lymphoma data set (SNLG)
6.3.1 Information from previous literature
To search for relevant literature that provides information for prior construction for SNLG
model parameters, we used the Patient (or Population), Intervention (or Prognostic Fac-
tor), Comparison and Outcome (PICO) search strategy (Schardt et al., 2007). Search
engines and databases such as Google Scholar, PubMed and Scopus were utilised to
obtain the relevant literature using the following keywords: Non Hodgkin Lymphoma,
survival, prognostic factor, prognosticators, survival determinants. Any article that was
not available online was manually searched and obtained from the university library (the
Walton Medical Library). Overall, 35 studies were reviewed to obtain the necessary
information for constructing the prior distributions of the survival parameters and 12 of
them had to be discarded due to the following reasons: 1) inadequate information on pre-
cision; 2) questionable research methodology and authenticity of data collection process;
3) unsatisfactory sample heterogeneity in unmeasured but important prognostic factors.
Only 23 studies whose results are deemed acceptable were used for prior construction for
the model parameters. Their hazard ratios and 95% confidence intervals (CIs) are given
as follows:
 Troppan et al. (2014): A retrospective analysis of 290 Austrian patients diagnosed
with DLBCL between June 2004 and April 2013 at the Division of Hematology,
Medical University of Graz, Austria. Cox proportional hazard model was utilised
to obtain the hazard ratios and their respective 95% confidence intervals for the
relevant survival parameters:
– Age > 60 years old: 3.52 (95% CI: 1.48, 3.58) [Multiple Cox model]
– Ann Arbor stage III and IV vs Ann Arbor Stage I and II: 2.38 (95% CI: 1.21,
4.68) [Multiple Cox model]
– LDH >200 IU: 1.62 (95% CI: 0.83, 3.16) [Simple Cox model]
 Zhao et al. (2014): Analyses of 1650 DLBCL patients diagnosed between June
2000 and December 2010 diagnosed at 7 National Comprehensive Cancer Network
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(NCCN) research centres, USA. The patients were followed up until the end of De-
cember 2011. The hazard ratios of the following survival parameters were obtained
using multiple Cox PH model:
– LDH ratio (LDH-R): ≤1: 1.0, >1-3: 2.1 (95% 1.9, 2.7), > 3: 3.3 (95% CI: 2.3,
4.8)
– ECOG performance status: 1-2 = 0, ≥2: 1.9 (95% CI: 1.5, 2.4)
– Ann Arbor stage: Stage III and IV = 1.5 (95% 1.1, 2.0)
– Extranodal disease: 1.5 (95% CI: 1.2 , 1.9)
 Slymen et al. (1990): A total of 105 DLBCL patients diagnosed at the Arizona
Cancer Center, USA between 1978 and 1987 were included in the analyses which is
based on Cox PH model
– Ann Arbor Stage III and IV: 2.63 (95% CI: 1.11, 6.25)
– B Symptoms: 1.98 (95% CI: 0.99, 3.95)
 Li et al. (2012): A total of 437 Chinese patients who were diagnosed with DLBCL
between January 2001 and May 2010 at 6 Shanghai hospitals, China were included
in the analysis.Analyses were based on Cox PH model. Separate regression coeffi-
cients were obtained for rituximab (R-CHOP) and non-rituximab-treated (CHOP)
patients:
R-CHOP group:
– Age >60 years: 1.011 (95 % CI: 0.987, 1.037)
– Extranodal sites >1: 1.572 (95% CI: 1.059, 2.334)
CHOP group:
– Age >60 years: 1.017 (95 % CI: 0.999, 1.034)
– Extranodal sites >1: 1.172 (95% CI: 0.915, 1.502)
 Flowers et al. (2013): In total, 701 DLBCL patients (533 Caucasians, 144 African
Americans) who were recipients of medical care at 2 research centers (Emory Uni-
versity and University of Alabama at Birmingham, USA) between 1981 and 2010
were included in this retrospective analysis. Cox PH method were utilised to obtain
the hazard ratios and 95% CIs for each relevant prognostic factor for DLBCL
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– Age> 60 years: 1.53 (95% CI: 1.17, 2.00)
– Gender (male) : 1.23 (95% CI: 0.97, 1.57)
– ECOG Performance status (≥ 2): 2.62 (95% CI: 1.97, 3.49)
– Elevated LDH level: 1.59 (95 % CI: 1.15, 2.21)
– No of extranodal sites involvement (≥ 2): 0.92 (95% CI: 0.66, 1.28)
– B symptoms: 1.20 (95% CI: 0.92, 1.58)
 Chen et al. (2012): DLBCL exclusive samples (n = 100). Period of recruitment:
Jan 2000-Dec 2009. Single institution (Taiwan). All patients were treated with
rituximab-containing regime. Three variables are significant on Multiple Cox PH
model and an additional four are found to be important prognosticators for overall
survival on Simple Cox PH model:
Multiple Cox PH:
– ECOG performance ≥ 2 : 4.936 (95% CI: 1.818, 13.403)
– LDH (defined as ≥ 206 IU\L): 3.400 (95%CI: 1.155, 10.007)
Simple Cox PH:
– Haemoglobin (defined as ≥120g/dL: 0.518 (95% CI: 0.239, 1.120)
– Albumin (<37 g / dL): 2.451 (95% CI: 0.471, 12.821)
– B symptoms: 2.952 (95% CI: 1.296, 6.726)
– Bone marrow involvement: 4.100 (95% CI: 1.526, 11.015)
 Song et al. (2010): A total of 96 Korean patients who were diagnosed with primary
extranodal DLBCL in 3 hospitals between April 2003 and October 2008. They
received 6 to 8 cycle of R-CHOP as their therapeutic regime. The only reported
hazard ratio reported is
– Tumor bulk (≥ 7.5 cm, in non GC only): 1.420 (95% CI: 0.542, 2.297)
 Carella et al. (2013): This study involves DLBCL patients who received rituximab-
containing therapeutic regime and recruited from 43 Brazillian and Italian Institu-
tions (n = 1793). Cox PH model was used with bootstrapping to accommodate for
confidence level error (nbootstrap = 1000).
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– Male: 1.60 (95% CI: 1.30, 1.96)
 Takahashi et al. (2012): A retrospective analysis of data on DLBCL patients who
were recruited from 47 Japanese institutions and treated with R-CHOP from 2003
until 2006 (n = 1221). Multivariate Cox PH model was used to obtain thehazard
ratios and their respective %95 confidence intervals for the following prognostic
factors
– Age > 60: 2.9 (95% CI: 1.5, 5.6)
– Stage III and IV: 1.70 (95% CI: 1.0, 2.9)
– Elevated LDH: 1.9 (95% CI: 1.1, 3.2)
– ECOG performance status ≥ 2: 1.7 (95% CI: 0.9, 3.1)
 Chung et al. (2007): A total of 489 DLBCL subjects who were diagnosed at Cross
Cancer Institute, Edmonton, Canada between 1986 and 1997 were included in this
study. The mean age at diagnosis is 68 years (range: 20-100). Fifty five subjects
(n = 55) have concordant bone marrow involvement out of a total of 489 subjects.
Male subjects predominates the sample (>97%).
– Concordant bone marrow involvement: 1.87 (95% CI: 1.25, 2.81)
 Carson et al. (2012): US army veterans diagnosed with DLBCL between 1st Oc-
tober 1998 and 31st December 2008 (n = 2534). Analyses were performed using Cox
PH model in these predominantly rituximab-treated subjects (80.8%). B symptoms
is a time varying covariate
– Age (continuous scale): 1.04 (95% CI: 1.03, 1.04)
– Stage: II: 0.97 (95 % CI: 0.62, 1.05); III: 1.18 (95% CI: 0.78, 1.76); IV: 2.42
(95% CI: 1.74, 3.36) (0-2 months post DLBCL diagnosis)
– Stage: II: 1.20 (95 % CI: 0.97, 1.48); III: 1.51 (95% CI: 1.23, 1.84); IV: 1.97
(95% CI: 1.65, 2.35) (> 2 months post DLBCL diagnosis)
– B symptoms: 0.621 (95% CI: 0.385, 0.859) (0 - 2 months post DLBCL diagno-
sis)
– B symptoms: 0.239 (95% CI: 0.104, 0.372) (> 2 months post DLBCL diagnosis)
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 Peyrade et al. (2011): A multicentre, single arm, phase II study involving 150
DLBCL patients from France and Belgium. The median age at diagnosis is 83
(range 80-95), with slightly more than a third are man (34%). All were treated with
a combination of rituximab with low dose CHOP (R-miniCHOP).
– Bulky disease (tumour mass ≥ 10 cm): 1.4 (95% CI: 0.6, 2.9)
– Serum albumin (≤35 g / L): 3.2 (95% CI: 1.4, 7.1)
– Number of extranodal sites > 1: 1.2 (95% CI: 0.6, 2.4)
 Dalia et al. (2014): This study involves a cohort of 124 American patients with
DLBCL, recruited between 2007 and 2010 from a single institution (Moffitt Cancer
Center, Tampa, Florida). The median age of the subjects is 58 years (range 20-84),
with 62% of them are males.
– Serum albumin (≤ 37 g / dL): 3.846 (95% CI: 6.250, 1.587)
– Elevated LDH (hazard ratio obtained from Simple Cox PH Model): 2.11 (95%
CI: 0.98, 4.52)
– Extrandodal Disease (hazard ratio obtained from Simple Cox PH Model): 1.28
(95% CI: 0.69.2.35)
 Frederiksen et al. (2012): A retrospective analysis of Danish Non Hodgkin Lym-
phoma patients whose data were obtained from The Danish National Lymphoma
Registry (LYFO) database (similar to our SNLG database). The sample size of this
study is 6234.
– WHO performance status (another name for ECOG performance status): Class
I: 1.80 (95% CI: 1.65, 1.95); Class II: 3.31 (95% CI: 2.91,3.76); Class III: 4.23
(95% CI: 3.53, 5.07); Class IV: 7.37 (95% 5.79, 9.39)
– Ann Arbor Stage: Stage II: 1.10 (95% CI: 0.81, 1.50); Stage III: 1.18 (95% CI:
0.93, 1.49); Stage IV: 1.35 (95% CI: 1.18, 1.53)
– Elevated LDH: 1.71 (95% CI: 1.55, 1.90)
– Extranodal lesion: 1.09 (95% CI: 0.98, 1.21)
 Ngo et al. (2008): The only study from South East Asia that provides the hazard
ratio estimates for the relevant prognostic factors in DLBCL. In total 279 Singa-
porean subjects with DLBCL were included in the analysis and most of them were
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treated with either R-CHOP or CHOP regimes. Therefore, two different estimates
per factor were obtained after subjects were stratified by the types of chemotherapy
regimes received.
CHOP group (n = 183):
– Age > 60 years: 2.882 (95% CI: 1.793, 4.631)
– LDH ( > 380 µ / L): 2.333 (95%CI: 1.181, 4.609)
– Albumin (<37 g / L): 2.294 (95%CI: 1.284, 4.099)
– Ann Arbor stage III and IV: 2.599 (95%CI: 1.526, 4.428)
R-CHOP group (n = 96):
– Male: 8.386 (95% CI: 1.848, 38.058)
– Ann Arbor stage III and IV: 6.364 (95% CI: 1.847, 21.929)
 Ziepert et al. (2010): Data from 1062 DLBCL patients treated with chemother-
apeutic regime containing rituximab were obtained from three databases of RCTs
(MinT, MegaCHOEP and RICOVER-60) and retrospectively analysed.
– Age(> 60 years): 2.4 (95% CI: 1.7, 3.4)
– Elevated LDH (based on upper limit of normality used by different trial pro-
tocols): 2.2 (95% CI: 1.6, 3.0)
– ECOG Performance status > 1: 1.8 (95% CI: 1.3, 2.6)
– Ann Arbor stage III / IV: 1.5 (95% CI: 1.1, 2.2)
– Extranodal disease >1: 1.3 (95% CI: 0.9, 1.8)
 Aaldriks et al. (2015): Data from a sample of 44 geriatric NHL patients (aged
70 years and above) who were recruited from 1 university and 3 general hospitals
in Netherlands. The period of recruitment is between May 2004 and February 2010
were included in the analyses. Tehy were all recipients of R-CHOP based treatment
regime. The hazard ratio estimates are
– Elevated LDH (≥ 250 U / L): 0.92 (95% CI: 0.27, 3.11)
– Albumin (< 35 g / L): 1.83 (95% CI: 0.81, 4.16)
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– Creatinine (A surrogate measure of renal function that is more specific than
urea. Hazard ratio estimate for this parameter is used as a substitute for urea):
1.84 (95% CI: 0.70, 4.86)
 Yan et al. (1995): DLBCL (n = 60). Not included since no estimates on hazard
ratio for prognostic covariates for DLBCL patients were reported.
 Oki et al. (2008): DLBCL (n = 221). One hundred and nineteen (n = 119) of
NHL patients were treated with CHOP regime whilst the rest (n = 102) received
R-CHOP. It is a single institution study conducted at Aichi Cancer Centre, Nagoya,
Japan).
– B symptoms: 2.37 (95% CI: 1.16, 4.83)
 Møller et al. (2003): Two hundred and twenty one (n = 221) low risk Danish
DLBCL patients from Western Denmark covering Jutland and Funen (obtained from
the population-based LYFO registry) with IPI score of 0 and who were recipients
of a mixture of treatments (anthracycline-based chemotherapy, locoregional radio-
therapy or surgery with curative intent) were included in the analyses. The median
age at diagnosis is 50 years. The data included in the analysis were restricted to
patients who were diagnosed with DLBCL from 1983 until 31st December 1998.
The subjects were then followed-up for three years (the last date of observation: 7th
January 2002 - 134 alive subjects at the end of the observation period).
– Ann-Arbor stage II vs stage I: 2.7 (95% CI: 1.5, 4.8)
– Age > 50 years: 1.8 (95% CI: 1.0, 3.3)
 Cox et al. (2008): One hundred and one (n = 101) Italian CD20+ aggressive large
B cell lymphoma (DLBCL: 89 patients; Primary mediastinal large B cell lymphoma:
12 patients; Developed from or associated with low grade lymphoma: 15 patients)
patients receving immunochemotherapy between January 2003 and March 2007 were
included in the analysis.
– ECOG Peformance Status ≥2: 5.004 (95% CI: 1.635, 11.754)
 Maartense et al. (2000): A cohort of 1028 Danish patients with NHL of different
histologies were included in the final analyses. Old REAL classification system for
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NHL was used to identify and group patients with different NHL histologies. The
subjects were included prospectively in the registry (NHL registry of the Compre-
hensive Cancer Center West (CCCW), Netherlands) from June 1981 until December
1989. Hazard ratio estimates were computed using Esteve’s relative survival prob-
ability model (Esteve et al., 1990).
– Elevated LDH: 2.39 (95% CI: 1.93, 2.96)
– Male: 1.235 (95% CI: 1.010, 1.515)
 Advani et al. (2010): Two hundred and sixty seven (n = 267) DLBCL subjects
aged 60 years and older (median age: 69 years (range: 60-92)) and randomised to
R-CHOP arm in the US E4494 intergroup trials (ECOG4494, CALGB9793) were
included in the analyses. Cox PH model was used and model fit was assessed using
AIC. Concordance index (area under ROC) was used as a measure of discrimination.
– Elevated LDH: 2.1 (95% CI: 1.4, 3.1)
– Extranodal sites >1: 2.3 (95% CI: 1.6, 3.2)
 Hirakawa et al. (2010): A retrospective analysis of 152 Japanese DLBCL patients
treated with R-CHOP like primary and maintenance therapies. The problem with
this study is the results reported as odds ratio (not hazard ratio) despite Cox PH
model was used for analysis of overall survival (OS) of this cohort. Only one prog-
nostic factor that is relevant to our study is included in here since no data on other
prognostic factors deemed important by the findings of this study such as relative
dose intensity of less than 70%, febrile neutropenia and prophylatic use of G-CSF
were recorded in our dataset.
– Albumin (< 35 g / L): 2.397 (95% CI: 0.793, 7.246)
 Hayward et al. (1991): This study is a retrospective analysis of 972 subjects
(n = 972) with NHL (the early SNLG cohort). The main problem with this study
is the heterogeneous subsets of patients were included in the analysis. Besides, the
hazard ratios for prognostic factors influencing the overall survival of NHL patients
were given but no 95% CI were reported.
– B symptoms: 0.42
– Leukocytes: 0.42
112
Chapter 6. Prior Information and Prior Distribution Construction
– Ann Arbor stage III and IV: 0.29
– Age - continuous: 0.02
 Christina et al. (2013): This study was conducted among transformed lymphoma
patients (from other types of lymphoma such as follicular lymphoma, marginal zone
and MALT lymphoma to DLBCL) (n = 81) who were identified from the Moffitt
Cancer Center Total Cancer Care Database, Tampa, Florida between January 2001
and December 2011. The median age at diagnosis is 60 years, with male to female
ratio of 0.72 (58 females). The median time to DLBCL transformation is 3.4 years.
– B symptoms: 3.1 (95% CI: 1.5, 6.4)
– Elevated LDH: 2.6 (95% CI:1.0, 6.6)
6.3.2 Meta analysis results for Non-Hodgkin Lym-
phoma prognostic factors
Ideally, standard Bayesian meta analysis technique should be used to synthesise the re-
sults. However, our purpose of performing this meta analysis was solely for obtaining
guidance for the choice of prior distributions for the regression coefficient for each Non
Hodgkin Lymphoma prognostic factor. Therefore a random effect meta analysis model
and an empirical Bayesian estimator were used to account for the heterogeneity of study
results. For more information, refer to Viechtbauer (2005, 2010). Meta analysis was
performed using the metafor package version 2.0.0 (Viechtbauer, 2017) which was im-
plemented in R. The forest plots for each NHL prognostic factors are given in Figure
6.1. The mean and variances for each parameter based on the meta analysis results are
presented in Table 6.1.
6.4 Prior information for the Malaysian-HUSM
Lung Cancer data set
6.4.1 Information from previous literature
In total, 19 prior studies have been identified as having adequate information on the
estimates of the regression coefficients for each prognostic factor for lung cancer. The
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Figure 6.1: Forest plots of NHL prognostic factors
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Table 6.1: The synthesised mean and variances for each regression coefficients for survival









medical literature was searched using the PICO method (Schardt et al., 2007) for relevant
literature using the following keywords: advanced lung cancer, prognostic factors, prog-
nosticators, survival determinants. The search engines and databases used were Google
Scholar, PubMed, and Scopus databases. Older articles that were not available online
were manually searched at the university library (Walton Medical Library, Newcastle
University).
We initially found 30 studies that were relevant for extracting information on prognos-
tic factors. However 11 studies had to be excluded for the following reasons: 1) inadequate
reporting of measure of precision; 2) poor research methodology; 3) article retraction due
to unethical misconduct such as plagiarism and data falsification. The studies that are
finally included are as follows:
 Hespanhol et al. (1995): This study involves 411 patients with advanced non-
small cell lung cancer (NSCLC) in Portugal, recruited between 1984 and 1990.
Twenty one clinical, anatomical, haematological and biochemical parameters were
assessed and the following were found to be statistically important prognostic factors
for lung cancer survival based on multivariate Cox model.
– Albumin (normal vs low): 0.588 (95% CI: 0.463,0.747)
– Weight loss: 1.624 (95% CI: 1.283, 2.056)
– Stage (IV vs IIIB): 1.576 (95% CI:1.445, 2.310)
– LDH (high vs low): 1.268 (95% CI:1.010, 1.592)
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– Gender (male vs female): 1.410 (95% CI: 1.048, 1.896)
 Simmons et al. (2015): This study involves 319 patients with advanced NSCLC at
2 university hospitals in Greece (University Hospitals of Heraklion and Larissa). The
patients were recruited between September 2006 and February 2010. The hazard
ratios for the following prognostic factors were found to be statistically important
for lung cancer survival based on Cox model:
– Gender (male vs female): 1.67 (95% CI: 1.14, 2.34)
– Weight loss: 1.49 (95% CI: 1.18, 1.88)
 Leung et al. (2012): This study involves 261 patients with surgically inoperable
NSCLC at Wishaw General Hospital, Lanarkshire, UK. The patients were recruited
and prospectively followed-up from May 2001 to November 2004. The hazard ratios
for the following prognostic factors were found to be important for lung cancer
survival based on Cox model:
– Gender (male vs female): 1.09 (95% CI: 0.85, 1.41)
– Weight loss (yes vs no): 0.86 (95% CI: 0.58, 1.28)
– WBC:1.23 (95% CI: 0.93, 1.61)
– Stage (IV vs III): 1.56 (95% CI: 1.21, 2.01)
 Maeda et al. (2000): Data on two hundred and sixty one (n = 261) Japanese
patients with advanced NSCLC , collected by Okayama Lung Cancer Study Group,
Japan between 1978 and 1992, were retrospectively analysed in this study. The
hazard ratios for the following prognostic factors were considered important for
advanced lung cancer survival based on Cox model:
– Albumin (normal vs low): 1.69 (95% CI: 1.19, 2.41
– Stage (IV vs IIIB): 1.71 (95% CI: 1.27, 2.30)
 Hsu et al. (2012): One hundred forty four (n = 144) Taiwanese patients with
advanced NSCLC were recruited from National Taiwan University Hospital between
January 2000 and February 2009. The median survival time of this study cohort was
14.7 months. The hazard ratios for the following prognostic factors were considered
important for advanced lung cancer survival based on Cox model:
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– Gender (male vs female): 1.70 (95% CI: 1.08, 2.68)
– Smoking status (ever smoker vs non smoker): 0.96 (95% CI: 0.65, 1.41)
– Weight loss: 2.72 (95% CI: 1.39, 5.30)
– Haemoglobin (low vs normal): 2.08 (95% CI: 1.15, 3.77)
– WBC: 1.62 (95% CI: 0.94–2.78)
– Platelet (high vs normal): 1.70 (95% CI: 1.00, 2.90)
– Albumin (low vs normal): 3.26 (95% CI: 1.69, 6.30)
– Stage (IV vs IIIB): 2.62 (95% CI: 1.50, 4.57)
 Ye et al. (2014): Data were collected from 300 Chinese patients with advanced
NSCLC attending 40 clinical sites in Mainland China as part of the B9E-AA-B004
clinical trial. The median overall survival time was 15.6 months (95% CI: 12.5, 17.4).
The hazard ratios for the following prognostic factors were considered important for
advanced lung cancer survival based on Cox model:
– Gender (male vs female): 1.211 (95% CI: 0.847, 1.733)
– Smoking status (Never smoker vs ever smoker): 1.08 (95% CI: 0.779, 1.50)
 Svaton et al. (2014): Five hundred and forty four (n = 544) Czech patients
with advanced stage NSCLC who were treated with Erlotinib at the Department of
Pneumology and Phthisiology, Pilsen University Hospital, Czech Republic between
2006 and 2013 were included in this study. The following factors were found to be
important determinants of advanced lung cancer survival in this study cohort and
their hazard ratios are:
– Gender (male vs female): 1.25 (95% CI: 0.98, 1.58)
– Smoking status (Ever smoker vs never smoker): 0.96 (95% CI: 0.70, 1.32)
– Stage (IV vs IIIB): 1.49 (95% CI: 1.12, 1.97)
– Sodium (low vs normal): 1.87 (95% CI: 1.47, 2.39)
 O’Mahony et al. (2016): Sixty two (n = 62) patients with advanced stage NSCLC
who received treatments at Rush University Medical Centre (RUMC), Chicago, USA
were recruited into this study. Patient’s age, which was recorded as a continuous
variable, was found an important determinant for overall survival and the hazard
ratio is:
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– Age (continuous): 0.94 (95% CI: 0.99, 1.09)
 Mandrekar et al. (2006): A data set containing the relavant determinants of
lung cancer survival were obtained from 1056 patients with advanced stage NSCLC
pooled from 9 North Central Cancer Treatment Group (NCCTG) trials in the USA.
The patients were recruited between 1985 and 2001. The hazard ratios for the
important determinants of overall survival in this study cohort are as follows:
– Gender (male vs female): 0.99 (95% CI: 0.84, 1.17)
– Stage (IV vs IIIB): 2.61 (95% CI: 2.04, 3.34)
– Weight loss (yes vs no): 1.82 (95% CI: 1.29, 2.60)
– WBC (high vs normal): 1.43 (95% CI: 1.22, 1.67)
– Haemoglobin (low vs high): 1.51 (95% CI: 1.28–1.78)
 Park et al. (2009): In total, 316 patients with recurrent NSCLC receiving sal-
vage gefitinib treatment at Samsung Medical Centre (SMS), Seoul, Korea between
January 2002 and December 2005 were included in this study. Their clinical and
laboratory test results were obtained from the SMS database. The median over-
all survival of this study cohort is 6.4 months and the researchers determined the
following prognostic factors were relevant for predicting lung cancer overall survival:
– Gender (male vs female): 1.51 (95% CI: 1.18, 1.94)
– Smoking status (current smoker vs never smoker): 1.34 (95% CI: 1.02, 1.75)
– Stage (IV vs IIIB): 1.07 (95% CI: 0.80, 1.43)
– Brain metastasis (yes vs no): 1.13 (95% CI: 0.85, 1.50)
– ALP (high vs low): 1.50 (95% CI: 1.13, 2.00)
– Albumin (low vs normal): 1.45 (95% CI: 1.10, 1.93)
– WBC (high vs normal): 1.38 (95% CI: 1.03, 1.86)
 Du et al. (2013): Overall, 258 advanced NSCLC patients who were diagnosed at
Kaifeng second people’s hospital, Henan, China between March 2001 and September
2011 were included in this study cohort. The median overall time is 20 months and
only high platelet count is a significant prognosticator for overall survival
– Platelet (high vs low): 4.15 (95% CI: 3.09, 5.59)
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 Kim et al. (2014): Data on 854 patients with inoperable advanced NSCLC di-
agnosed at the Seoul University College of Medicine between January 2007 and
September 2009 were retrospectively analysed in this study. The median overall
time is 340.5 days (i.e approximately a year) in those with high platelet counts and
569.5 days in those with normal platelet levels. The important prognostic factors
identified in this study and their hazard ratios are:
– Gender (male vs female): 1.55 (95% CI:1.30, 1.84)
– Stage (IV vs IIIB - estimated): 1.98 (95% CI: 1.45, 2.69)
– Platelet (high vs low): 1.51 (95% CI: 1.14, 2.00)
 Ulas et al. (2014): This study involves data which were retrospectively collected
from 462 advanced NSCLC patients who were treated at the Department of Medical
Oncology, Oncology Teaching and Research Hospital, Ankara, Turkey between 2000
and 2010. In this study cohort, the median overall survival time is 11 months with a
median follow-up time of 44 months. The important determinants of overall survival
for this study cohort are:
– Gender (male vs female): 1.18 (95% CI: 0.86, 1.63)
– Smoking status (Ever smoker vs non smoker): 1.16 (95% CI: 0.87, 1.55)
– Brain metastasis (yes vs no): 1.56 (95% CI: 1.26, 1.98)
– Haemoglobin (low vs normal): 1.13 (95% CI: 0.92, 1.39)
– WBC (high vs normal): 1.55 (95% CI: 1.27, 1.89)
– Platelets (high vs normal): 1.11 (95% CI: 0.88, 1.39)
– ALP (high vs normal): 1.51 (95% CI: 1.16, 1.97)
– LDH (high vs normal): 1.31 (95% CI: 1.00, 1.70)
– Albumin (low vs normal): 1.28 (95% CI: 0.98, 1.67)
 Zhang and Ran (2015): In total, 773 NSCLC patients at advanced stages who
were diagnosed and treated at Kimmel Cancer Centre, Thomas Jefferson Hospital,
Greater Philadelphia area, USA between 1998 and 2011 were included as this study
cohort. The median overall survival time is 7.0 months in the training cohort. The
important prognostic factors determined from this study and their hazard ratios
are:
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– Age (continuous): 1.005 (95% CI: 0.997, 1.013)
– Stage (IV vs IIIB): 1.53 (95% CI: 1.24, 1.89)
 Lim et al. (2018): In total, 217 terminal stage NSCLC patients with malignant
pleural effusion who were diagnosed and treated at 6 hospitals in Korea between
January 2012 and July 2016 were included in this study. The median overall sur-
vival time is 16.2 months and nearly two thirds of the patients (62.6%) received
conventional chemotherapy regimens as the first line of treatment whilst the rest
were recipients of targeted therapies directed against either Epithelial Growth Factor
Receptor (EGFR) or Anaplastic Lymphoma Kinase (ALK) translocational muta-
tions. The hazard ratios for the major determinants of overall survival in this study
cohort are:
– Gender (male vs female): 1.620 (95% CI: 1.057, 2.481)
– Smoking status (ever smoker vs never smoker): 1.166 (95% CI: 0.971, 1.399)
– Platelet (high vs normal): 1.523 (95% CI: 1.059, 2.191)
– Haemoglobin (low vs normal): 1.245 (95% CI: 0.810, 1.914)
– Albumin (low vs normal): 1.724 (95% CI: 1.039, 2.861)
 Matsunuma et al. (2014): In total, 69 terminal stage NSCLC patients who
received palliative care at the Palliative Care Unit of Komatsu Municipal Hospital,
Ichikawa, Japan in 2012 were included in this retrospective study. The median
overall survival time is 30 days, a very short survival time due to the terninal stage
of illness. The important prognostic factors determined from this study and their
hazard ratios are:
– Sodium (low vs normal): 2.17 (95% CI: 1.01, 4.68)
– Albumin (low vs normal): 2.37 (95% CI: 1.05, 5.36)
 Fiala et al. (2016): On the whole, clinical and laboratory data on 457 ad-
vanced stage NSCLC patients treated with erlotinib (a type of targeted therapy
directed against EGFR mutation) who were diagnosed and treated at Faculty Hos-
pital, Pilsen, Czech Republic between between 2005 and 2014 were retrospectively
analysed. The median overall survival time is 10.0 months. The hazard ratios of
important determinants of lung cancer survival in this study cohort are:
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– Gender(male vs female): 1.08 (95% CI: 0.87, 1.33)
– Smoking status (ever smoker vs never smoker): 1.16 (95% CI: 0.86, 1.56)
– Stage (IV vs IIIB): 1.29 (95% CI: 1.01, 1.64)
– Albumin (low vs normal): 1.66 (95% 1.16, 2.38)
 Teramukai et al. (2009): In total, 338 advanced stage NSCLC patients who
hadn’t received any chemotherapy and received usual care between March 2001 and
April 2005 from 45 institutions which were under the Japan Multinational Trial
Organisation LC00-03 were were included in this study. They then received two
separate regimens of chemotherapy. The hazard ratios of relevant overall survival
determinants are:
– Gender (male vs female): 1.35 (95% CI: 0.98, 1.85)
– Smoking status (current smoker vs never smoker): 1.56 (95% CI: 1.18, 2.06)
– Weight loss (yes vs no): 1.30 (95% CI: 0.96, 1.76)
– Stage (IV vs IIIB): 1.24 (95% CI: 0.88, 1.75)
– LDH (high vs normal): 1.57 (95% CI: 1.20, 2.05)
 Schad et al. (2018): This is a non-controlled cohort study involving 158 stage IV
NSCLC patients receiving mistletoe as an adjunct to conventional chemotherapy
regimes. The study participants were recruited from multiple centres in Germany
between February 2010 and June 2016 based on the data available from the German
Network Oncology registry. The median overall survival times were respectively
17.0 and 8.0 months in those receiving conventional chemotherapy and mistletoe
and conventional chemotherapy alone. The hazard ratios of the determinants of
lung cancer survival are as follows:
– Age (continuous): 1.00 (95% CI: 0.98, 1.03)
– Gender (male vs female): 1.65 (95% CI: 1.04, 2.62)
– Smoking status (current smoker vs never smoker): 1.41 (95% CI: 0.62, 3.22)
 Li et al. (2015): This is a retrospective analysis of a data set containing clinical
and pathological information on 64 stage IV NSCLC patients treated in Beijing
hospitals from August 2010 to July 2015. No detailed information was given on the
types of treatments received by the patients. The hazard ratios of the determinants
of lung cancer survival for this study cohort are as follows:
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– Gender (male vs female): 0.71 (95% CI: 0.345, 1.424)
– Brain metastasis (yes vs no): 1.754 (95% CI: 0.844, 3.647)
– ALP: 1.957 (95% CI: 1.082, 3.542)
6.4.2 Meta analysis results for Malaysian advanced
lung cancer prognostic factors
Ideally, standard Bayesian meta analysis techniques should be used to synthesise the
results. However, our purpose in performing this meta analysis was solely for obtaining
guidance for the choice of prior distribution for the regression coefficient for each advanced
lung cancer prognostic factor. Therefore a random effect meta analysis model was used
and an empirical Bayesian estimator was utilised to account for the heterogeneity of
study results. For more information, refer to Viechtbauer (2005, 2010). Meta analysis
was performed using the metafor package version 2.0.0 (Viechtbauer, 2017) which was
implemented in R. The forest plots for the NHL prognostic factors are given in Figures
6.2 and 6.3. The mean and variance for each parameter based on the meta analysis results
are presented in Table 6.2.
122
Chapter 6. Prior Information and Prior Distribution Construction









βWeight loss 0.28 0.0135




βbrain metastasis 0.38 0.0165
123
Chapter 6. Prior Information and Prior Distribution Construction
Figure 6.2: Forest plots of meta analysis results for advanced lung cancer prognostic
factors
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Figure 6.3: Forest plots of meta analysis results for advanced lung cancer prognostic
factors
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6.5 Prior construction for Weibull models
To obtain the prior distribution for each parameter in a Weibull survival model, we can
use the information such as that presented in Sections 6.3 and 6.4. Three types of priors
are required: prior for Weibull shape parameters α, prior for baseline log hazard (β0) and
prior for the coefficients of linear predictors in the Weibull survival model. A suitable
elicitation method can be based on the method proposed by Consul (2016).
In the remainder of Section 6.5, we will construct the prior distributions for the SNLG
non-Hodgkin’s lymphoma data as an example. This prior specification will be based on
information from published studies. In Chapter 7, we will use this prior to assess the
performance of our INLA method in these circumstances.
6.5.1 Prior construction for the shape parameter for
a Weibull survival model
In constructing the prior for a Weibull shape parameter, α, we will not be able utilise any
information from the previous literature since all of them utilised the semi-parametric
Cox Proportional Hazard approach. Nevertheless, we can construct the prior distribution
for α by considering the median survival time, tm, upper quartile, tq(3) and lower quartile,
tq(1) of survival times of a large imagined future sample. The probability of death before
the median survival time is given by
Pr(T < tm) = 0.5.
The individuals’ survival function at the median time of survival is
S(tm) = exp(−λtαm) = 0.5,







Similarly, we can use the same mathematical procedures to express the survival function
for both lower and upper quartiles. This will lead to
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To complete our prior specification for α, we have to elicit further information on tq(1) and
tq(3) from the experts (presumably from a group of oncologists with long experience in
managing non Hodgkin lymphoma patients) or introspectively based on information from
past studies. Since α is always positive, we might give this quantity a gamma distribution
(α ∼ Ga(gα, hα)). To construct a prior distribution for α, we have first to elicit a range of
values for tq(1) and tq(3) which can be performed by using the hypothetical future sample
(HFS) as expounded by O’Hagan et al. (2006).
We can start by firstly asking our expert to identify an average SNLG patient that is
usually seen at a clinical setting. This patient should be the one that has the minimum
uncertainty about his survival times, based on the expert’s opinion. Then, we can enquire
further by asking the expert to assess the median survival time, tm, by asking the expert
the time when there is an equal probability that the patient will die before and after it.
To elicit tq(1), we can ask the expert to further consider the case where an average
SNLG patient who died before tm. Then, we ask the expert to assess the time when such
a patient would die prior to and after this time with an equal probability, provided the
patient died before tm. This will be our point estimate for tq(1). We may also elicit the
point estimate for tq(3) by asking the expert to identify the time when an average patient
is equally likely to die before and after this time, provided that the patient is still alive
after tm. This should be our assessment for tq(3). We can then obtain an assessment for
ϕ = tq(3)/tq(1). Nevertheless, we still have to quantify the uncertainty about ϕ.
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To achieve this, we need to elicit ϕ1, ϕ2 and ϕ3 which corresponds to the first, second
and third quartiles of ϕ, the multiplier of tq(1). This can be converted to Q1(α), Q2(α)
and Q3(α) using (6.1). The parameters gα and hα are then chosen to suit Q1(α) and
Q3(α). Due to the fact that hα is the scale parameter for the gamma distribution, only
gα needs to be specified and this can be achieved using numerical iteration. Then, we can
find hα using the following relationship: hα = qgα(0.75)/Q3(α) and qgα(0.75) represents
the upper quartile of Ga(g, 1) distribution. For further details, see Consul (2016).
6.5.2 Prior construction for the baseline log hazard
The baseline hazard is a hazard experienced by a baseline patient. It is convenient to
choose as the baseline a patient with a typical, or roughly average, covariate pattern.
For instance, consider the SNLG data. In this case, we choose the baseline patient to
be an individual whose age is 60, who is female, and has normal values or categories for
each predictor. Let us consider that survival time approximately follows an exponential
distribution. That is γ ' 1. Based on the current literature and experience managing such
a cohort of non-Hodgkin Lymphoma patients, we can rationally deduce the survival time of
a baseline non-Hodgkin lymphoma patient (i.e low risk patients) to be more than 5 years
if they receive the current standard chemotherapy regime for non-Hodgkin lymphoma
patients (rituximab-based chemotherapy). Hence, we postulate that the plausible range
of median survival time for baseline non-Hodgkin lymphoma patients to be between 5
years and 10 years (i.e 60 months to 120 months). We can represent this by the inequality
60 < tm < 120.
That is exp(−120λ) < exp(−λtm) < exp(−60λ).
















and − 5.154005 < log(λ) < −4.460857.
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We might then give log(λ) a Gaussian distribution. We can obtain the mean value and
standard deviation for log(λ) by solving the two linear equations
E[log (λ)]− 2σ = −5.154005,
E[log (λ)] + 2σ = −4.460857.
The solution for these equations will be the prior mean and standard deviation for log
(λ). Hence
σ = 0.173287 and E[log(λ)] = −4.807431.
Since log(λ) = β0, this culminates in
β0 ∼ N (−4.807, 0.03003)
or, in precision form
β0 ∼ N (−4.807, 33.30−1).
6.5.3 Prior construction for the coefficients of linear
predictors
To obtain the prior means and standard deviations for coefficients of linear predictors,
we shall use the method proposed by Ren and Oakley (2014) and elucidated further by
Wilson and Farrow (2017). The derivations of prior means and standard deviations for
continuous and 2-level categorical covariates shall be demonstrated as examples on how to
elicit prior distribution parameters based on the information from the literature. We shall
also assume that the prior distributions of coefficients in linear predictors are Gaussian.
For continuous covariates, the age of the patient will be chosen as an example. For baseline




. Then, let us consider another patient k who is
10 years older than the baseline patient, with the same covariate pattern as the baseline
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In the non-Hodgkin Lynphoma case, we identified two previous studies that gave
estimates of βage: Carson et al. (2012) and Hayward et al. (1991). The estimates for βage,
according to these two studies, are 0.02 and 0.039. However, only Carson et al. (2012)
gave a 95% CI of the estimate, which is between 0.0247 and 0.0430, and therefore the
results could not be combined using meta analysis. The mean of βage, based upon these
estimates, is hence 0.0295. We can also obtain the standard deviation of this estimate
based on the upper and lower limits of the 95% CI
(0.0430− 0.0247)/4 = 0.004575.
Therefore, the prior distribution for βage is
βage ∼ N (2.950× 10−2, 2.093× 10−4).
For a 2-level categorical covariate, the prior distribution for βB−symptoms shall be shown.
Again, we compare the baseline patient i with patient j who has the same covariate pattern













From the previous literature, we identified 6 studies that gave estimates of βB−symptoms:
Christina et al. (2013), Slymen et al. (1990), Flowers et al. (2013), Oki et al. (2008),
Carson et al. (2012) (2 estimates) and Song et al. (2010). The estimates for βB−symptoms,
according the synthesis of results from these 7 studies is given in Table 6.1. We choose
that the mean of βB−symptoms, based upon this meta analysis result, is thus 0.26. Since
the variance of βB−symptoms is 0.1266 (Table 6.1), the standard deviation of βB−symptoms
is hence 0.3558. However, we may make the prior variance for βB−symptoms bigger to
account for the heterogeneous nature of our study population and therefore we choose a
prior variance double the one we obtained from meta analysis. Hence the prior variance
is 0.2532 (or a prior SD of 0.5032). Therefore, the prior distribution for βB−symptoms is
βB−symptoms ∼ N (0.26, 0.2532).
The prior construction for anm unordered categorical factor is as follows. Suppose that
we want to construct a prior for m unordered categorical covariates. For a model where
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an intercept term is included, the degrees of freedom would be m− 1. To ensure that the
parameters are identifiable, we can constrain them using a sum to zero constraint or assign
a zero value to one of the parameters which is usually the baseline or reference category.
If we choose to use a corner point constraint, this may indicate that our prior knowledge
is greater for this baseline category. As an example, let us say that we endeavour to build
a prior for a four-level categorical covariate. In this case, based on our prior knowledge
we may regard the first level of that categorical covariate as our reference level. The
structure of that categorical covariate with level 1 as the reference level is shown in Table
6.3.
Table 6.3: Corner constraint structure with level 1 as the reference category
Level Contrast
1 0 0 0
2 1 0 0
3 0 1 0
4 0 0 1
The consequence of using this prior structure is that a different prior variance is
assigned to the reference level in contrast with other levels. In practice, however, our
knowledge about the reference category may not be more substantial than our knowledge
about the other levels. Fortunately, other methods can be used to deal with this issue.
One of them is that we could use orthogonal contrasts to ensure that the parameters could
have the sum-to-zero property. Besides, an orthogonal contrast may also ensure that the
parameters are exchangeable. As a result, all the parameters might possess identical
means, variances and covariances between two parameters.
To demonstrate this, suppose we have a four-level factor and we aim to construct an
orthogonal contrasts with sum-to-zero constraint for the parameters. We can achieve this
by using this scheme of orthogonal contrast which is presented in Table 6.4.
However, it is more cumbersome to create a contrast scheme if the number of levels is not
a power of two. To address this problem, we could use the scheme presented in Table 6.5
for an m-level category.
As an example, an appropriate orthogonal constrast scheme for a 5-level factor is
depicted in Table 6.6.
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Table 6.4: Scheme of orthogonal contrasts with sum-to-zero constrain
Level Contrast
1 1 1 1
2 1 -1 -1
3 -1 1 -1
4 -1 -1 1
Table 6.5: An orthogonal contrast scheme for a category whose levels are not multiple of
two
Level Contrast
1 -1 -1 -1 .... -1
2 1 -1 -1 .... -1
3 0 2 -1 .... -1





m 0 0 0 .... m - 1
Table 6.6: Example of a scheme where the number of levels is 5
Level Contrast
1 -1 -1 -1 -1
2 1 -1 -1 -1
3 0 2 -1 -1
4 0 0 3 -1
5 0 0 0 4
To exemplify further, we might wish to build a prior structure for a categorical co-
variate where all levels of that covariate should be exchangeable based on the orthogonal
contrast with sum-to-zero constraint as shown in Table 6.5. To achieve this, we may
convert m − 1 uncorrelated random variables into m random variables that have the
zero-sum constraint. These random variables may serve as parameters for an m-level cat-
egorical covariate. For instance, let us say that we have m − 1 independent zero - mean
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random variables δ1, δ2, . . . , δm−1 with δ = (δ1, δ2, . . . , δm−1)
T and β = (β1, . . . , βm)
T . Let
Var(δj) = wj, β = Mδ where M represents a m × (m − 1) matrix (Table 6.5). In this
case, every column is a contrast such that the total is ensured to be zero.





For 1 ≤ i ≤ m, we need



























We are also required to demonstrate the equality of covariances by showing what the
values are. So







If i = 2, . . . ,m− 1
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Hence
covar(βi, βi−1)− covar(βi+1, βi) = iwi − (i− 1)wi−1 + wi
= (i+ 1)wi − (i− 1)wi−1










Clearly, for i = 3, . . . ,m and j = 1, . . . , i− 2
covar(βi, βj) = covar(βi, βi−1).
Therefore, for all i 6= j,




Besides, we may wish to weaken the exchangeability assumption and this can be
achieved by permitting the prior mean for each parameter to be dissimilar and this can be
achieved by making the differences between the parameters and prior means exchangeable.
A set of exchangeable parameters might be constructed if βj − E(βj) for j = 1, . . . ,m.
Besides, the variances might also be different whilst preserving m− 1 degrees of freedom.
Suppose that β∗1 , . . . , β
∗
m forms a set of exchangeable quantities that also has the sum-to-
zero constraint. We may then let βj = mj+sjβ
∗
j for some selection of mj, sj which permits
the prior mean to be non-identical. For a further exposition on the general structure of
prior construction for categorical covariates, refer to Farrow (2003).
6.5.4 Prior for the frailty variance
The specification of an appropriate prior distribution for the frailty variance poses a
difficult but fascinating question. This lies in the fact that it is cumbersome to visualise the
actual effects of frailties on the survival time, especially in the univariate case. One such
problem is that it makes the unconditional lifetime distribution for a given covariate profile
not be a Weibull distribution even though the conditional distribution of the lifetimes
given the frailty term is Weibull. However this fact itself offers the possibility of a way to
consider prior beliefs about the frailty variance.
134
Chapter 6. Prior Information and Prior Distribution Construction
Suppose that we consider individual frailties Zi to have a gamma distribution. So
Zi ∼ Ga(g, g). Now the marginal survival probability at time t is











If we write vz = g
−1 for the frailty variance, then
S(t) = (1 + vzλit
α)−1/vz .







Let us write Q1, Q2 and Q3 for the values of t corresponding to the three quartiles of









So, by eliciting values for two such ratios, we can obtain two simultaneous equations
which can be solved numerically to obtain values for α and g = v−1z . By eliciting distri-
butions, or at least quantiles, for the ratios, we can obtain a joint distribution for α and
g. Suitable ratios could be Q2/Q3 and Q1/Q2.
In practical terms, we might give both g and α gamma prior distributions, compute
the corresponding distributions of the ratios to see whether they seem reasonable and
then adjust the hyperparameters of the prior distributions accordingly. If it is preferred
to use a lognormal distribution for the frailties then the method above might still be used
as a reasonable approximation.
A possible alternative approach might be based on the fact that the presence of frailties
causes non-proportionality of hazard effects. Consul (2016) discussed elicitation of prior
distributions for covariate effects. This method could be adapted so that, as well as
considering patients from time t = 0, we compare the conditional survival distributions
of patients who are still alive at some later time. The presence of frailties will cause the
hazard ratios to be different at the later time.
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6.6 Prior construction for a piecewise con-
stant hazard model
The prior distribution for this model is the Gaussian process which specifies the joint
distribution of β1,. . . ,βp, where βj = β0j, . . . , βpj. Two types of priors will be discussed
here: hierarchical and autoregressive priors. These priors are based on the work by Fung
(2017). We shall describe the hierarchical priors first for the piecewise constant hazard
model.
6.6.1 Hierarchical priors
Here, we shall consider building hierarchical priors for the baseline log hazard, β0, in the
piecewise constant hazard model for the SNLG dataset.
Suppose that β0,j is the baseline log hazard at interval j and β0 is the mean baseline
log hazard. We can build the hierarchical prior for the baseline log hazard by conditioning
β0,j on β0. Then we can specify the hyperprior distribution for β0 with hyperparameters
m and ν2. This can be represented by
β0,j | β0 ∼ N (β0, ν1),
β0 ∼ N (m, ν2).
In this case, we can clearly observe that the marginal variance of β0,j is divided into two
separate components: ν1 is the variance of the conditional distribution, β0,j | β0, and ν2
is the variance of β0. The marginal variance for β0,j is hence ν = ν1 + ν2. In section
6.5.2, we assessed the variance of β0 to be 0.03002838. In this case, we therefore let the
marginal variance of β0j for every single time interval be 0.03002838. The inter-interval
covariance is given by
Cov (β0,j, β0,k) = ν2, j 6= k
and the correlation between time intervals is given by:
Cor (β0,j, β0,k) =
ν2
ν1 + ν2
, j 6= k
Since we judge that the correlation between the log hazards in different time intervals is
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high (0.95), we shall obtain
ν2 = 0.95 (ν1 + ν2). (6.5)
However, we know that ν1 + ν2 = ν. In the NHL example, we have ν = 0.03002838. We
can thus substitute this value into 6.5 and obtain
ν2 = 0.028526961
and
ν1 = 0.03002838− 0.028526961 = 0.001501419.
Hence, the hierarchical prior structure has the final form:
β0,j | β0 ∼ N (β0, 0.001501),
β0 ∼ N (− 4.807, 0.02853).
Assessment of Corr(β0,j, β0,k) can be done using a hypothetical future sample method.
Suppose that we have assessed prior means and variances for β0,j and β0,k where k>j.
Suppose that we are now told to imagine observing that, out of nj patients alive at time
τj−1, Xj die in interval Ij. We should then reassess our median for the number Xk of
nk patients alive at the beginning of interval Ik who would die in this interval. This
allows us to calculate E(β0,k | Xj) and, using Bayes linear kinematics, we can deduce the
correlation. For further details, refer to Wilson and Farrow (2010, 2017).
6.6.2 Autoregressive priors
Another approach to specifying a prior distribution for the piecewise constant hazard
model is by using an autoregressive process prior. This approach is more rationally
plausible since we can now specify the log hazards in time intervals that are closer together
to be more correlated than the time intervals that are further apart. We shall firstly
explain the fundamental aspects of autoregressive processes before demonstrating how we
can use this stochastic process for the construction of autoregressive priors.
Borrowing the notation used by Fung (2017), we shall denote {Yt} as a first order
autoregressive (i.e. AR(1)) process. This can be written as
Yt = µ+ φ(Yt−1 − µ) + εt
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with constants µ and φ, and white noise process, εt ∼ N (0, σ2), provided that | φ | < 1.
The term φ(Yt−1 − µ) + εt can be viewed as an infinite moving average (MA), since an






The expectation and variance of Yt are




if | φ |< 1 (based on the limit of the sum of a geometric progression). The lag-k autoco-








We can then use these results to construct autoregressive priors for the baseline log hazard
for the SNLG and Malaysian advanced lung cancer data sets. For the SNLG data sets,
the baseline hazards are denoted by β0,1, β0,2, . . . , β0,10. For j = 2, 3,. . .,10, the AR(1)
equation for the baseline log hazard is given by
β0,j = β0 + φ(β0,j−1 − β0) + εj, εj ∼ N(0, p−1).
Hence, the expectation and variance of the conditional distribution of β0,j | β0, β0,j−1 are
given by
E(β0,j | β0, β0,j−1) = β0 + φ(β0,j−1 − β0)
and




Hence, the conditional distribution of β0,j | β0, β0,j−1 is
β0,j | β0, β0,j−1 ∼ N(β0 + φ(β0,j−1 − β0), p−1). (6.6)
We can then specify a hierarchical prior for each parameter in (6.6). Firstly, we give
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Gaussian priors for β0 and β0,1 | β0







If we equate the variance obtained for β0,1 | β0 with the prior variance obtained previously,
( σ
2
1−φ2 ), since we assume the process is stationary, we obtain
p1 = p(1− φ2).
Hence, the marginal variance is




In the SNLG case, we obtain γ(0) = 0.03002838. The covariance between β0,j and β0,j+k
and the lag-k autocorrelation are given by



















νp(1− φ2) + φ|k|
νp(1− φ2) + 1
. (6.7)





Then we have to specify the value for φ. We can make the neighbouring time-intervals
more strongly correlated than those that are further apart, provided that φ > 0. In the




= 0.01501419. Then we can
calculate p1 and p as follows. We have
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The lag-k autocorrelation function can be utilised to prove that the adjacent time intervals
are more highly correlated than the ones that are further apart. Based on the values of










From the result, it is thus proven that the time intervals that are next to each other are
more highly correlated than the time periods that are more distant apart. This occurs
since our selected value for φ(0.95) is very near to unity.















β0,j | β0, β0,j−1 ∼ N
(
β0 + φ(β0,j−1 − β0), 0.001464
)





= 0.001464. For further details, refer to Fung (2017) and Chatfield
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The prior distributions for all coefficients of linear predictors for SNLG data set are
given in Table 6.7.
6.7 Prior construction for Malaysian advanced
lung cancer data set
To construct prior distributions for the Malaysian-HUSM advanced lung cancer data set,
we follow the same methodology. For the Weibull shape parameter, there is a paucity of
information with respect to tq1 and tq3 that is available from prior studies. To construct
the baseline log hazard for the piecewise constant hazard model for this data set, we
assume that the median survival time, tm for typical lung cancer patients is between 10
months and 36 months. Therefore
β0 ∼ (−3.301, 0.1025).
For coefficients of linear predictors and 2-level categorical variables, the prior mean and
variances are given in Table 6.2. However, we make the prior variances double the ones
that we obtained from meta-analysis to accommodate heterogeneity of patients’ charac-
teristics due to differences in population characteristics. Therefore, the parameters for
the prior distributions are given in Table 6.8.
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βWeight loss 0.28 0.0270




βbrain metastasis 0.38 0.0330
To construct a hierarchical prior for the piecewise constant hazard model, we know that
ν = 0.1025495 and we fix the correlation between the time intervals at 0.95. Therefore,
using equation (6.5), we obtain ν0 = 0.09742202 and ν1 = 0.00512748. Hence
β0,j | β0 ∼ N (β0, 0.005127),
β0 ∼ N (− 3.310, 0.1025).
For the autoregressive prior, using the same methodology as in section 6.6.2, we obtain
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β0,j | β0, β0,j−1 ∼ N
(
β0 + φ(β0,j−1 − β0), 0.004999
)





= 0.004999. For further details, refer to Fung (2017) and Chatfield
(2003).
6.8 Summary
In this chapter, we discuss the prior construction for both our survival models, primarily
for the SNLG data set. In chapter 7, we will use these prior distributions in illustrative







In this chapter, we shall demonstrate the applications of the INLA method expounded in
chapter 4 to the analysis of several data sets. In 7.2, we shall show the applications of
INLA to survival models for the kidney infection (7.2.1) and the SNLG (7.2.2) data sets,
both without missing covariate information. In 7.3, we show INLA-MCMC performance
with respect to a Weibull survival model (7.3.1) and a piecewise constant hazard model
(7.3.2) in the presence of missing covariate information using the SNLG data set. In 7.4
we will apply our INLA-MCMC algorithm to the Malaysian advanced lung cancer data
set using both a Weibull model and a piecewise constant hazard model.
7.2 Analysis without missing covariate in-
formation
7.2.1 Analysis of kidney infection data
7.2.1.1 Data setup
In this section, the differences in the data setup between those used for rjags and R-INLA
are demonstrated.
From the data setup, shown in Table 7.1, we can clearly see that the data setup for
R-INLA is similar to the usual data setup for survival analysis and GLM modelling. On
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Table 7.1: Partial display of the data setup for rjags and R-INLA when fitting survival
model for kidney infection data set
RJAGS R-INLA
Event Placement Survival time Censoring time Time Event Placement
0 1 0.05 1.05 0.05 1 1
0 1 0.05 1.05 0.05 1 1
0 1 0.05 1.05 0.05 1 1
0 1 0.15 1.15 0.15 1 1
0 1 0.35 1.35 0.35 1 1
0 1 0.45 1.45 0.45 1 1
0 1 0.45 1.45 0.45 1 1
0 1 0.55 1.55 0.55 1 1
0 1 0.85 1.85 0.85 1 1
0 1 0.85 1.85 0.85 1 1
0 1 0.95 1.95 0.95 1 1
0 1 1.05 2.05 1.05 1 1
0 1 1.15 2.15 1.15 1 1
0 1 1.55 2.55 1.55 1 1
0 1 1.65 2.65 1.65 1 1
0 1 1.85 2.85 1.85 1 1
0 1 2.35 3.35 2.35 1 1
0 1 2.65 3.65 2.65 1 1
1 1 NA 0.25 0.25 0 1
1 1 NA 0.25 0.25 0 1
1 1 NA 0.65 0.65 0 1
1 1 NA 0.65 0.65 0 1
1 1 NA 0.75 0.75 0 1
1 1 NA 0.75 0.75 0 1
1 1 NA 0.75 0.75 0 1
1 1 NA 0.75 0.75 0 1
1 1 NA 0.85 0.85 0 1
1 1 NA 0.95 0.95 0 1
1 1 NA 1.05 1.05 0 1
1 1 NA 1.15 1.15 0 1
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the other hand, the data setup for rjags requires that the event and censoring times are
split into two separate vectors. Besides, the censoring indicators used for rjags are also
different since the event is coded as 0 whilst in R-INLA, event is coded as 1. For censored
observations, they are coded as 1 in the rjags setup and 0 in the R-INLA setup. This can
be trivially achieved with a couple of lines R code to convert rjags data structure to the
other and vice versa.
7.2.1.2 Exponential proportional hazard model
The model specification for the exponential proportional hazard model for this data has
been shown in Section 2.11. We first fitted the exponential survival model using an MCMC
procedure (Section 2.11) as in Martino et al. (2011), implemented using the rjags package
(Plummer, 2016) in R environment (R Development Core Team, 2008) on a 3.20GHz Ergo
Desktop with Intel(R) Core (TM) i7-4790S CPU and 8.00 GB of random access memory
(RAM). Two parallel chains were used. The number of iterations was set at 105 per chain
with a burn-in of 103. In the case of INLA, three versions of the method were used,
using the Gaussian, Laplace and simplified Laplace approximations (Section 4.3.1, INLA
step 2). We also provided the posterior summaries of regression coefficients obtained by
numerical integration using a trapezoidal rule (Burden et al., 2015). The results of the
analyses are given in Table 7.2 and Figure 7.1.
From Figure 7.1, the MCMC trace plots indicate good mixing. The densities calculated
using MCMC and INLA are clearly very similar in the cases of both the treatment and
intercept terms, indicating both MCMC and INLA give similar mean and standard devi-
ations. This is supported by the results presented in Table 7.2 which show the posterior
means and standard deviations obtained via MCMC and INLA are close to each other.
However, the time taken to obtain results is much shorter for INLA than MCMC. We
also provide the results and time taken for simple numerical quadrature and it is clear
that INLA is almost as fast as numerical quadrature in obtaining the posterior means and
standard deviations of the model parameters.
7.2.1.3 Weibull proportional hazard model
The model specification for the Weibull proportional hazard model used for the kidney
infection data is given follows. The lifetime is
Ti ∼Weibull(α, λi)
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Figure 7.1: MCMC trace plots and comparisons of posterior distributions of regression
coefficients obtained via INLA and MCMC
Table 7.2: The comparison of results for β0 and βtrt obtained via different methods
Method β0 mean (SD) βtrt mean (SD) Time(seconds)
Prior 0 (4.4721) 0 (4.4721) -













Numerical quadrature -0.6647 (0.5936) -0.5415 (0.3936) 0.50
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with density
fi(t | α, λi) = αλitα−1 exp(−λitα)
and survival function
Si(t | α, λi) = exp(− λitα),
where
β = (β0, β1)
T and λi = exp(ηi) = exp(β0 + xiβ1).
Hence,











δi(α− 1) log(ti)− exp(zTi β)tαi
]}
.
We give β a bivariate normal prior
β ∼ N2(µ0,Σ0)
and
α ∼ Ga(α0, κ0),
independently of β0 and β1. The joint posterior distribution for α and β is thus given by
π(α,β | D) ∝ L(α,β | D) π(α | α0, κ0) π(β0 | m0, v0)π(β1 | m1, v1).
We assigned values











For the building of the Weibull regression model, the covariates are introduced via λ
through λi = exp(z
T
i β). Hence, the corresponding hazard function can be written as
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Figure 7.2: Comparisons of posterior distributions of regression coefficients obtained via
INLA and MCMC
hi(t | α, λi) = αtα−1λi. Therefore, the joint posterior density is








i β + δi(α− 1)log(ti))− tαi exp(zTi β)]− κ0α
−1
2
(β − µ0)TΣ−10 (β − µ0)
}
.
In this case we compare MCMC (Section 2.11) and the three INLA methods (Section
4.3.1, INLA Step 2).
The number of iterations of MCMC (in RJAGS code) was set at 105 per chain with a
burn-in set at 103. Two parallel chains were used. The trace plots and posterior means
and standard deviations are presented as Figure 7.2 and Table 7.3.
From Figure 7.2, the trace plots indicate good mixing. The densities calculated using
MCMC and INLA are clearly very similar, indicating both MCMC and INLA give similar
mean and standard deviations. This is supported by the results presented in table 7.3
which show the posterior means and standard deviations obtained via MCMC and INLA
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Table 7.3: The comparison of posterior summaries of β0, βtrt and α for obtained via
different methods
Method β0 mean (SDs) βtrt mean (SDs) α Mean (SDs) Time(sec)
Prior 0 (4.4721) 0 (4.4721) 1 (0.9535) -
















are close to each other. However, the time taken to obtain results is much shorter for
INLA than MCMC.
7.2.2 Analysis of Non-Hodgkin Lymphoma (SNLG)
data set
7.2.2.1 Basic notations
In this section, the basic notations used for covariates in the SNLG data will be expounded
and this is given in Table 7.4.
After labelling each covariate with the appropriate notation, we can then construct
a design matrix, V, with S columns. The total number of columns, S, is determined
by the total number of covariates and the total number of levels within the categorical
covariates. There are now two choices of constraints to use for the categorical variables:
1) corner point constraint, 2) zero-sum constraint. However, the corner point constraint
has one shortcoming. We assign a different prior variance to the baseline category (level
1) compared to the rest of the levels, as if we have better prior information about level
1 than the rest of the levels of that factor. Consequently, the alternative method, the
zero-sum constraint, is more rationally appealing since it allows all the parameters to
have similar means, variances and covariances.
For this model, we calculate the number of regression parameters (S) is 24, allowing
m-1 for a factor with m levels. The overall number of parameters is thus 25 after taking
into consideration an additional parameter, α, which is the shape parameter for Weibull
distribution.
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Table 7.4: The notations used for each covariate that may influence the survival time of
SNLG cohort
Covariates Notation Types of covariates
Age x1 Continuous (quantitative)
Haemoglobin x2 Continuous (quantitative)
White blood cell count (WBC) x3 Continuous (quantitative)
Sex (Gender) x4 2-level categorical covariate
Albumin x5 2-level categorical covariate
AP x6 2-level categorical covariate
Urea x7 2-level categorical covariate
Extranodal disease x8 2-level categorical covariate
Bone marrow involvement x9 2-level categorical covariate
B symptoms x10 2-level categorical covariate
Bulky disease x11 2-level categorical covariate
Stage x12 4-level ordinal covariate
ECOG x13 5-level ordinal covariate
LDH x14 3-level ordinal covariate
7.2.2.2 Modelling strategies
For the SNLG dataset, we assume that the survival times follow a Weibull distribution
with a shape parameter α and a scale parameter λ. We also centre the quantitative covari-
ates (haemoglobin, wbc and age) and used orthogonal contrast for categorical covariates.
7.2.2.3 Covariate centering
There are three continuous covariates in this dataset: age, haemoglobin level and white
blood cell count. To obtain proper prior specification, these quantitative variables can be
standardised. For example, we can centre age as follows, x1 = xA - 60 where xA is the
subject’s age.
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Table 7.5: An outline of zero-sum constraint for a 4-level factor
Level Contrast
1 1 1 1
2 1 -1 -1
3 -1 1 -1
4 -1 -1 1
7.2.2.4 Orthogonal contrasts with zero-sum constraint
As stated previously, we can use orthogonal contrasts with a zero-sum constraint to avoid
the shortcomings of a corner-point constraint scheme. When we use this strategy, we
are now able to make the parameters exchangeable, thus making them have the same
means, variances and covariances. As an example, the orthogonal contrast with zero-sum
constrain for a 4-level factor is given by Table 7.5. This zero-sum-constraint was employed
for Ann-Arbor stage, a 4-level categorical covariate in the SNLG dataset.
In this case, the effects of the four levels will sum to zero. Nevertheless, this is a trivial
example since this scheme is only effective for a factor where the number of levels is a
power of 2. The scheme will break down if this is violated. To generalise such a scheme
to factors whose total number of levels is not a power of 2, we present the form of the
generalised orthogonal contrast with zero-sum constraint in Table 7.6.
Table 7.6: The general outline for a factor whose levels are not a power of 2
Level Contrast
1 -1 -1 -1 .... -1
2 1 -1 -1 .... -1
3 0 2 -1 .... -1





m 0 0 0 .... m - 1
As another example, we present the outline of the zero-sum constraint for a factor
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with 5 levels in Table 7.7. This zero-sum constraint was then used for ECOG performance
status which is a 5-level factor.
Table 7.7: The orthogonal contrast with zero-sum constraint for a 5-level factor (ECOG)
Level Contrast
1 -1 -1 -1 -1
2 1 -1 -1 -1
3 0 2 -1 -1
4 0 0 3 -1
5 0 0 0 4
Finally, we provide the zero-sum-constraint scheme for LDH, a 3-level factor in SNLG
dataset. This is given in Table 7.8.
For further information on calculating the variances of factors that have been orthog-
onally constrained, refer to section 6.5.3 and equations (6.2)-(6.4).
7.2.3 Analysis of SNLG Data with full covariate in-
formation
Recall from subsection 2.5.1.2, the log likelihood for survival data that follows a Weibull
distribution is given by
` = log(β, α | R) =
∑
i∈E
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where E is the set of subjects who died and nD is the number of subjects who died. The
regression coefficients are represented by
β = (β0, β1, β2, β3, . . . , βK)
T
where the intercept term is represented by β0 and βk represents the coefficient of covariate
k. From Section 2.5.1.1, we see that the linear predictors are related to λi by




We can then assign multivariate normal prior distribution to β
β ∼ NK+1 (µ,W ).
In this case, µ represents the vector of prior means for the regression coefficients and W is
the (K+1 × K+1) variance-covariance matrix. The multivariate normal prior distribution
for β has pdf
f0(β) = (2π)






[(β − µ)TW−1(β − µ)]
}
.
If we take logarithms of the multivariate normal prior distribution and assume that
β0, . . . , βk are independent and the shape parameter α is also independent of β as well,















where W−1 is a diagonal matrix with diagonal elements, W0,W1,W2, . . . ,WK . In this
case, W0 represents the variance of the intercept term and Wk is the variance of the k
th
regression coefficient. Since the shape parameter α must be positive, we assign a gamma
prior for α with shape parameter a and rate parameter b
α ∼ Ga(a, b).
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Hence, the density of the prior distribution for α has the form




Then, the joint prior density of β and α is given by π(β, α). Therefore, using Bayes’
theorem, the joint posterior distribution of β and α is obtained by
π(β, α | D) ∝ Prior× Likelihood,
= Q π(β, α) L(β, α | D).
Using simple algebra and taking logs on both side, the log posterior density of β and α
has the following form
log
(































































Since the joint posterior density is analytically intractable, we have to use numerical
methods. We can use an MCMC algorithm to obtain the sampled values from the posterior
distribution. We apply a zero-sum constraint for categorical covariates in this SNLG
Weibull survival model. Hence, the linear predictor has the following form










with δ represents the variable for an orthogonal contrast. A Metropolis within Gibbs
sampling algorithm was used which was implemented using RJAGS. Two parallel MCMC
chains were employed with different starting values to ensure that the convergence had
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been satisfactorily achieved. After a burn-in period of 2000 iterations, 150,000 iterations
for each chain were obtained as posterior samples. The trace and autocorrelation plots
were examined for convergence and adequate mixing. INLA was also used to obtain the
posterior means and standard deviations of the parameters, using the simplified Laplace
option. The posterior summaries are given in Table 7.9.
As we can see from the results in Table 7.9, the posterior means and standard devia-
tions (and hence precisions) obtained using MCMC and INLA are closely similar to each
other. In this case, INLA is by far more efficient than MCMC (computation time: 3.58
seconds vs 17 minutes 26 seconds, Intel i7® single core 8 GB RAM). Apart from that, we
can also clearly observe that the posterior standard deviations of all parameters acquired
through MCMC or INLA are much smaller compared to prior standard deviations. This
signifies increases in precision due to the combination of our prior knowledge with infor-
mation contained in the data through likelihood. As a result, this causes decreases in our
uncertainty over all parameters.
The plots of posterior distributions obtained for each parameter (24 regression param-
eters and the shape parameter, α, for the Weibull distribution) with both MCMC and
INLA are given in Figures 7.3 - 7.5. As we can see, the posterior distributions obtained
via INLA (blue curves) nearly perfectly match the posterior distributions obtained using
MCMC (red curves).
7.3 Analysis of SNLG data with missing co-
variate information
7.3.1 Weibull lifetime distribution
We also fitted the Weibull survival model on the whole data set which includes those
cases with missing covariate information. The results are presented in Table 7.10. We
can clearly see that the posterior means and standard deviations obtained using MCMC
are very similar to those obtained via the INLA-MCMC algorithm. Figure 7.6 depicts
the prior (black) and posterior densities of selected regression coefficients obtained via
MCMC (red) and INLA-MCMC (blue) and it can be clearly seen that both match each
other. The times taken for MCMC and INLA-MCMC to obtain the posterior means and
standard deviations are 4200 seconds and 209 seconds, respectively.
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Table 7.9: The posterior means and standard deviations (SDs) for the unknown parame-









β0(intercept) -0.4843 0.1384 -0.4842 0.1401
β1(Age) 0.0275 0.0046 0.0275 0.0046
β2(HB) -0.0069 0.0032 -0.0069 0.0032
β3(WBC) 0.0287 0.0182 0.0288 0.0182
β4(Sex) 0.0576 0.0569 0.0579 0.0570
β5(Albumin) -0.0820 0.0699 -0.0820 0.0697
β6(Ap) 0.0568 0.0686 0.0561 0.0683
β7(Urea) -0.0154 0.0642 -0.0157 0.0639
β8(Extranod) 0.0289 0.0641 0.0289 0.0641
β9(Bulk) 0.1702 0.0570 0.1701 0.0570
β10(Marrow) 0.2308 0.0865 0.2308 0.0868
β11(Bsy) -0.0439 0.0616 -0.0438 0.0616
δ12,1(Stage) 0.0377 0.0481 0.0379 0.0481
δ12,2(Stage) 0.0964 0.0428 0.0966 0.0426
δ12,3(Stage) 0.0636 0.0405 0.0636 0.0406
δ13,1(ECOG) 0.0197 0.0379 0.0198 0.0378
δ13,2(ECOG) 0.0524 0.0390 0.0525 0.0389
δ13,3(ECOG) 0.0894 0.0458 0.0893 0.0457
δ13,4(ECOG ) -0.1236 0.0921 -0.1234 0.0910
δ14,1(LDH) 0.0567 0.0377 0.0569 0.0377
δ14,2(LDH) 0.1366 0.0408 0.1365 0.0407
α (Shape) 0.8454 0.0389 0.8452 0.0382
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Figure 7.3: Comparisons of posterior means (SDs) of β0 until βbulk using MCMC and
INLA
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Figure 7.4: Comparisons of posterior means (SDs) βbsy until δ2,LDH using MCMC and
INLA
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Figure 7.5: Comparisons of posterior means (SDs) of regression coefficients δ1,stage until
δ4,ECOG using MCMC and INLA
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Figure 7.6: Comparisons of posterior distributions of regression coefficients obtained via
INLA-MCMC (red) and MCMC (blue)
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Table 7.10: The posterior means and standard deviations (SDs) for the unknown param-









β0(intercept) -2.6998 0.1348 -2.7032 0.1350
β1(Age) 0.0390 0.0054 0.0390 0.0054
β2(HB) -0.0140 0.0036 -0.0140 0.0036
β3(WBC) 0.0557 0.0212 0.0559 0.0212
β4(Sex) 0.1076 0.0671 0.1086 0.0671
β5(Albumin) -0.3724 0.0858 -0.3738 0.0853
β6(Ap) 0.1825 0.0779 0.1817 0.0779
β7(Urea) -0.1295 0.0729 -0.1298 0.0727
β8(Extranod) 0.0059 0.06251 0.0048 0.0624
β9(Bulk) 0.2614 0.0667 0.2621 0.0669
β10(Marrow) -0.1859 0.1043 0.1881 0.1042
β11(Bsy) -0.1464 0.0697 -0.1469 0.0694
δ12,1(Stage) 0.0718 0.0495 0.0721 0.0496
δ12,2(Stage) 0.0948 0.0467 0.0949 0.0465
δ12,3(Stage) 0.2077 0.0414 0.2085 0.0411
δ13,1(ECOG) 0.0210 0.0386 0.0210 0.0386
δ13,2(ECOG) 0.0216 0.0418 0.0218 0.0417
δ13,3(ECOG) -0.0194 0.0530 -0.0200 0.0532
δ13,4(ECOG ) -1.1050 0.1194 -1.1040 0.1210
δ14,1(LDH) 0.0634 0.0388 0.0633 0.0387
δ14,2(LDH) 0.1076 0.0446 0.1075 0.0447
α (Shape) 0.8397 0.0406 0.8392 0.0397
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7.3.2 Analysis of SNLG Data with missing covari-
ate information using piecewise constant haz-
ard model
In this section, we fit a piecewise constant hazard model to the SNLG dataset. For this
task, all subjects including those with missing information were included (n = 1391). The











− λij {tij − τj−1}
}
where λij represents the hazard experienced by patient i at time interval j, δij is an
indicator whether patient i died in interval j. In each interval, there are three things that
may occur to patient i: surviving through that single interval, event (death) occurs in
that single interval or censoring occurs. For further information, refer to 2.7.1.
Besides, a frailty term was also included in the model to weaken the dependent effects
of covariates. In this case, we assumed the frailty term was log-normally-distributed, with
the prior for its variance having a gamma distribution. Full distributional specification of
the frailty term (denoted as Z) is given by
log(Z) ∼ N (0, σ2z) and σ2z ∼ Ga(1.1, 0.53).
The next step is to choose a sensible value for the autoregressive parameter that we
consider in 6.6.2. To do this, we have to judge how much variance of the parameters in
the next time interval is explained by the values in the preceding time interval. In this
case, it is assumed that 90% of the parameters’ variances in the subsequent time period are
explained by the value in the preceding period. Hence, our coefficient of determination,
R2 , 0.90. Consequently, our correlation, r, is 0.95. With respect to prior means and
variances, we used the same values that we used in Section 6.3.2 (Table 6.1).
From the results shown in Table 7.11, the age effect decreases temporarily before it
increases as the time progresses. Besides, we can clearly see, the mean and standard
deviations obtained via the INLA-MCMC algorithm are really close to the mean and
standard deviations obtained using MCMC only. This is more evident if we look at
Figures 7.7 - 7.8 which show clear matching densities of each parameter obtained using
MCMC and INLA-MCMC algorithms. The time taken for MCMC and INLA-MCMC
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Table 7.11: Posterior means and standard deviations (in brackets) in each interval of time
for some chosen covariates (n = 1391)
j τj β0 (MCMC) βage (MCMC) β0 (INLA-MCMC) βage(INLA-MCMC)
1 0.316 -0.8515(0.2177) 0.06324(0.0137) -0.8313 (0.2169) 0.0624 (0.0137)
2 0.669 -0.1731(0.1603) 0.0459 (0.0072) -0.1609(0.1360) 0.0458(0.0720)
3 1.070 0.0847(0.1537) 0.0292(0.0072) 0.0932(0.1517) 0.0291(0.0072)
4 1.532 -0.0045(0.1761) 0.0321(0.0720) 0.0075(0.1734) 0.0321(0.0072)
5 2.079 -0.7924(0.2024) 0.0220(0.0078) -0.7761(0.2007) 0.0220(0.0079)
6 2.749 -1.8137(0.2096) 0.1723(0.0083) -1.8076(0.2102) 0.1723(0.0083)
7 3.612 -1.9534(0.2501) 0.1477(0.0088) -1.9443(0.2503) 0.1477(0.0088)
8 4.828 -1.8861(0.2601) 0.1316(0.0089) -1.8785(0.2636) 0.1316(0.0532)
9 6.908 -1.8405(0.2820) 0.1177(0.0087) -1.8327(0.2842) 0.1177(0.0312)
10 ∞ -1.4652(0.2969) 0.1065(0.0091) -1.4581(0.2968) 0.1064(0.0091)
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to compute posterior means and SDs are 4650.33 and 191.11 seconds, respectively. This
shows that INLA-MCMC is the more efficient algorithm.
7.4 Malaysian advanced lung cancer data set
7.4.1 Weibull lifetime model with missing covariate
information
Now we turn our attention to the Malaysian advanced lung cancer data and fit a Weibull
model. From Table 7.12 and Figure 7.9, we can clearly see that posterior means and
standard deviations obtained via MCMC and INLA-MCMC are very close to each other.
The density plots clearly match each other and the posterior summaries of all covariates
for the MCMC and the INLA-MCMC are very close to each other. The computational
time for the MCMC algorithm is 5142 seconds whilst for the INLA-MCMC algorithm,
the computational time is 314.57 seconds. Therefore, the INLA-MCMC algorithm is more
efficient than MCMC algorithm for computing the posterior summaries of this data set.
7.4.2 Analysis of the Malaysian advanced lung can-
cer data set with missing covariate information
using piecewise constant hazard model
We also fitted a piecewise constant hazard model for the Malaysian advanced lung cancer
data set with the presence of missing covariate information. From the results presented
in Table 7.13, we can clearly see that the posterior summaries for β0 and βneutrophil for
each time interval are very close to each other. Besides, Figure 7.10 demonstrates that
the density plots for each parameter obtained using MCMC and INLA-MCMC algorithms
again clearly match each other. The computing time is 412 seconds for the INLA-MCMC
algorithm and 3972.19 seconds for the MCMC algorithm. Again, this indicates that the
INLA-MCMC is a much more efficient algorithm than MCMC.
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Figure 7.7: Plots of the effects of intercept and age across time intervals (J=1 to J=6)
obtained via MCMC(red) and INLA-MCMC(blue)
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Figure 7.8: Plots of the effects of intercept and age across time intervals (J=7 to J=10)
obtained via MCMC(red) and INLA-MCMC(blue)
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Table 7.12: The posterior means and standard deviations (SDs) for the unknown param-









β0 -1.8699 0.3950 -1.8573 0.3919
βAge -0.0044 0.0053 -0.0044 0.0053
βAlbumin 1.0813 0.0894 1.0794 0.0844
βBrainmets 0.0314 0.0635 0.0311 0.0631
βHb 0.0038 0.0129 0.0040 0.0128
βNeutrophil -0.0479 0.0255 -0.0487 0.0255
βPlatelet 0.0005 0.0059 0.0005 0.0005
βRace -0.0717 0.0904 -0.0719 0.0896
βSodium -0.0490 0.0041 0.0049 0.0032
βWBC -0.0036 0.0294 -0.0311 0.0292
αlung 2.8240 0.1265 2.8220 0.1278
Table 7.13: Posterior means and standard deviations (in brackets) in each interval of time
for some chosen covariates (n = 397)
j τj β0 (MCMC) βneut (MCMC) β0 (INLA-MCMC) βneut(INLA-MCMC)
1 2.003 -3.259 (0.1718) 0.0453 (0.0093) -3.2610 (0.1727) 0.0454 (0.0093)
2 4.374 -3.662 (0.1364) 0.0451 (0.0093) -3.6633 (0.1368) 0.0452 (0.0093)
3 7.275 -3.273 (0.1090) 0.0461 (0.0093) -3.2869 (0.1088) 0.0461 (0.0093)
4 11.015 -3.181 (0.0927) 0.046 (0.0092) -3.1994 (0.0933) 0.0466 (0.0093)
5 16.286 -2.732 (0.0814) 0.0486 (0.0092) -2.7332 (0.0816) 0.0486 (0.0093)
6 11.912 -2.539 (0.0774) 0.0485 (0.0092) -2.5400 (0.0774) 0.0486 (0.0092)
7 25.297 -2.546 (0.0762) 0.0488 (0.0092) -2.5463 (0.0763) 0.0488 (0.0092)
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Figure 7.9: Selected plots of posterior distributions for regression coefficients obtained via
MCMC (red) and INLA-MCMC(blue)
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Figure 7.10: Plots of the effects of neutrophil accross time intervals (J=1 to J=7)
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7.5 Summary
In this chapter, we have shown that INLA-MCMC performs as well as MCMC in ob-
taining posterior means and standard deviations of the parameters of our models based
on its performance in subsections 7.3 - 7.4. However, INLA-MCMC has a much shorter
computing time than MCMC and thus is the more efficient algorithm. We have thus been
able to demonstrate the usefulness of INLA in fitting models to survival data, even when
there are many cases with missing covariate values. This significantly increases the range
of problems where INLA may be used efficiently since large reductions in computing time
can be achieved using the new INLA-MCMC algorithm.
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Conclusion and Future work
8.1 Thesis summary
The main contribution of this thesis is an extension of the applicability of INLA by
developing the capability to deal with missing covariate information in survival analysis.
We successfully extended the INLA-MCMC algorithm (Gomez-Rubio and Rue, 2018)
to deal with the situation and applied it to parametric Weibull survival models and
the semiparametric piecewise constant hazard models, with and without frailties. In
the piecewise constant hazard case, we used both hierarchical and autoregressive prior
structures.
In Chapter 2, we introduced the fundamentals of survival analysis and Bayesian ap-
proaches. In Chapter 3, we demonstrated the fundamental properties of Gaussian Markov
random fields (GMRF). We also proved the sparsity of the precision matrix, Q, and de-
rived the recursive formula for computing the marginal variances and GMRF distribution
conditioned on linear constraints. We then demonstrated how the GMRF can be seen as a
Bayesian hierarchical model and how to modify the GMRF to accommodate non-normal
likelihood functions
In Chapter 4, we introduced the basic concepts of INLA. We gave two examples, a
simple regression model with intercept term and a Poisson regression model for the piston
failures data set, to show how INLA can be used as a fast approximation for computing
posterior distributions. The basic concepts of the INLA within MCMC approach were
introduced in Section 4.6. We gave an overview of the INLA within MCMC algorithm
and how this algorithm can be modified to circumvent the missing covariate problem in
survival analysis.
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In Chapter 5, we gave an overview of the three data sets used for modelling purposes.
In Chapter 6, we showed how prior information can be obtained from previous studies
and combined using meta analysis. In Section 6.5, we showed how prior distributions
were constructed for Weibull shape parameters, baseline log hazards, coefficients of linear
parameters and a frailty variance. In Section 6.6, we demonstrated how hierarchical and
autoregressive priors could be constructed for piecewise constant hazard models.
In Chapter 7, we showed how INLA-MCMC performs for three different kinds of data
sets, the kidney infection, SNLG and Malaysian advanced lung cancer data sets. We
also demonstrated that INLA-within MCMC is superior to MCMC in handling missing
covariate information for models with reasonable numbers of parameters and hyperparam-
eters. In our case, the performance of INLA was more efficient when fitting the piecewise
constant hazard models compared to Weibull survival models. Nevertheless, INLA is
still faster than MCMC, especially when computing the marginal likelihood which when
combined with the conditional posterior distributions of model parameters would yield
the marginal posterior distributions of our parameters.
8.2 Discussion and Limitations
8.2.1 Introduction
In this section we identify points where there are limitations in the findings so far and
where further work would strengthen the findings of the thesis, throw more light on the
questions addressed or provide extra information useful to potential users of the methods.
8.2.2 Simulation study
In the context of Bayesian inference, given the combination of a particular model, prior
specification and data set, there is a posterior distribution for the model parameters
which is obtained by applying Bayes’ rule. In this thesis, we have been concerned with
how to calculate summaries of the posterior distribution in the case of survival models,
particularly when some values of covariates are missing.
We have compared the performance of INLA and our proposed INLA-within-MCMC
method with more conventional MCMC in terms of computational speed and in terms
of the ability of the INLA methods to reproduce the results obtained using MCMC.
The comparisons have been done using real data sets and, in the examples where some
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covariate values were missing, the missingness was the actual missingness in the real data
sets. It is possible that the ability of the INLA methods to reproduce the results obtained
using MCMC, and the relative computational speed might be affected by changes in the
proportion of missing covariate values. This was not investigated in the thesis. To inves-
tigate this question, we might analyse data sets with different missingness proportions,
increasing in steps from no missingness up to a high proportion of covariate values missing.
It may be that, rather than just the proportion of missing values, the configuration
of missingness, that is which values are missing, or other features of the data might
have an effect. Therefore we might randomly generate data sets with randomly allocated
missingness and use a number of such data sets at each level of missingness. This whole
simulation experiment would be likely to be computationally time-consuming so it might
be best to use a relatively simple problem. In the case of a simple problem with few
unknowns, we could also compute the posterior using numerical quadrature to provide a
deterministic comparison rather than assuming that MCMC accurately gives the correct
values of posterior summaries. However, this would be impractical with missing covariate
values.
Another area for further investigation is sensitivity to the choice of prior distribution.
It may be that, with models of the type which we investigate here, the posterior, or aspects
of it, may be sensitive to the choice of prior. It may also be that there are particular types
of prior distribution, for example very imprecise priors, which cause difficulties for either
the INLA methods or MCMC and may lead to discrepancies between the results obtained.
This will be discussed further in Section 8.2.3.2.
8.2.3 Bayesian meta analysis and sensitivity analysis
8.2.3.1 Meta analysis and prior distribution construction
In Chapter 6, detailed information from previous studies on Non-Hodgkin Lymphoma
and advanced lung cancer has been presented, including the estimated values of coefficients
of prognostic factors for Non Hodgkin Lymphoma. However, we only used an empirical
Bayesian technique to synthesise the results which is an unsatisfactory method since we
did not use a full Bayesian meta analysis. This information could be used in a more
meaningful way by considering the following approaches.
Firstly, we could implement a standard Bayesian meta analysis of information obtained
from previous literature combined with full prior elicitation from the experts. In this way,
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better prior distributions for our parameters of interest could be obtained. For more infor-
mation, refer to O’Hagan et al. (2006). Besides, we could also improve the construction of
our prior distribution by extracting the individual patient data (IPD) from the published
Kaplan-Meier curves using the Guyot algorithm (Guyot et al., 2012). These recreated
data sets could then be used to generate prior distributions for the Weibull distribution
parameters, for instance, by fitting Weibull models to these recreated data sets. However,
the poor quality of the image for the available Kaplan-Meier curves published in older
journals might hamper the process of IPD extraction since it is dependent upon the
ability of the digital software such as DigitizeIt (Bormann, 2012) to establish accurately
the coordinates of published survival curves (Guyot et al., 2012).
To account for differences in the studies over time, we could use a meta-regression
technique to obtain, for instance, the prior means of our covariates of interest (Thompson
and Higgins, 2002). It has been demonstrated in a number of studies that the mean
covariate effect may vary across the time when the study was conducted as represented
by the year of the publication of the study (Berkey et al., 1998; Bollen et al., 2007; Fiocco
et al., 2012). This temporal heterogeneity of effect may be attributed to improvements
in treatment modalities, changes in the characteristics of the patient cohort and other
changes (Berkey et al., 1998; Bollen et al., 2007; Fiocco et al., 2012). This is particu-
larly true in our case since there had been several published works which demonstrated
pronounced temporal heterogeneity of covariate effects for the non-Hodgkin lymphoma
and advanced lung cancer cases (Gao et al., 2002; Matakidou et al., 2005). Besides,
meta-regression technique can also be used to adjust the other sources of heterogeneity
such as study sample size, types of studies (e.g. case control vs cohort studies), different
cut-off values used to classify the covariate of interests that may affect the accuracy of our
prior summary and the construction of prior distributions in general (Castillo et al., 2014;
Zhang and Ran, 2015). Hence, the results obtained from meta-regression analysis can
clearly facilitate the construction of more accurate prior distributions for our covariates
of interest.
We could also use multivariate meta-analysis methods to take into account the corre-
lations induced by the same (within-study correlation) and different (between-study cor-
relation) studies contributing to potentially a number of different covariate meta-analyses
(Bujkiewicz et al., 2013). The within-study correlation could be assessed using the IPD
obtained from other observational cohort studies or clinical trials whilst the between-
study correlation could be evaluated using the summary statistics from individual studies.
However, caution should be exercised since the use of multivariate meta analysis methods
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might inflate the degree of uncertainty around the studied outcomes instead (Cooper
et al., 2011). Possible causes include the heterogeneity in treatment effects, baseline
characteristics of study participants and study designs (Song et al., 2001).
We could also perform random effect meta-analysis using the combination of IPD and
the summary statistics from previous studies to generate posterior predictive distributions.
Ades et al. (2005) and Dias et al. (2013) reasoned that, in the presence of heterogeneity
of effects between studies, the predictive distribution of a future study is a more cogent
description of the degree of uncertainty around the effect of interest than the distribution
of mean effect. As a result, the predictive distributions obtained from prior studies can
subsequently be used to derive the prior distributions for the analyses that had been
undertaken in our study.
Alternatively, we could also use the power prior distributions for regression models
as proposed by Ibrahim and Chen (2000) to construct informative prior distributions.
Briefly, suppose that historical data from previous studies is given by D0 = (n0, y0, X0),
where n0 represents the sample size of the previous study, y0 is the n× 1 response vector,
X0 is the n×p matrix for covariates and θ represents the indexing parameters. The power
prior distribution of θ for the present study is then given by
π(θ | α0, D0) ∝ L(θ | D0)α0 π0(θ | c0)
where c0 is the hyperparameter for the initial prior (before knowing the existence of the
historical data), α0 is the scalar parameter representing the weights of the historical data
relative to the likelihood of the current study, L(θ | D0) is the likelihood of θ in the
current study given the historical data, D0. This hierarchical power specification can be
made complete by assigning a prior distribution for α0, resulting in the joint power prior
distribution for θ and α0 that is represented by
π(θ, α0 | D0, α0) ∝ L(θ | D0)α0 π0(θ | c0) π(α0 | γ0)
where γ0 is the hyperparameter vector. One of the candidates for π(α0 | γ0) is a beta
prior. Nevertheless, priors that have either truncated gamma or truncated normal form
may also serve as alternatives since all of them possess the same computational and
theoretical consistency (Ibrahim and Chen, 2000).
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8.2.3.2 Sensitivity to prior distribution
The results obtained using the informative priors should be evaluated with respect to
their sensitivity to changes in prior specification (sensitivity analyses). We could repeat
the analyses, starting with very imprecise priors and increasing the prior precision in steps
to assess the effects. However, the effects on the results might depend on the combination
of particular features of the data with the degree of precision in the prior. Therefore,
as in Section 8.2.2, multiple simulated data sets should be generated and by these, the
sensitivity of results obtained to the different prior specifications could be adequately
investigated.
8.2.4 Predicted survival curves
Using the analyses of Chapter 7, we could compute predicted survival curves for patient
groups with a specific covariate profile. In fact, since we have a missing data model, we
could obtain the predicted survival curves without specifying the full covariate profile. For
instance, if we would like to obtain a predicted survival curve for a male Non-Hodgkin
Lymphoma (NHL) patient aged 60, we could do this by integrating over the conditional
distributions of the unspecified covariates. This can be done easily in MCMC and INLA-
MCMC since we can use MCMC sampling for the missing covariate values. In both
cases, a “dummy patient” could be included in the analysis and a survival function could
then be computed at a range of time points for this patient. We could then sample the
survival function values and since the survival function is a probability, and therefore an
expectation, we could subsequently find the posterior mean of the survival function at
each of the time points. These could then be plotted against time to obtain the predicted
survival curve for that particular patient.
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8.3 Future work: Multi-state survival mod-
els
8.3.1 General overview of multi-state survival mod-
els
The inspiration to use a multi-state model for lung cancer patients comes from the
seminal work of Armero et al. (2016) on a disability model for lung cancer. Multistate
models are a class of stochastic models that involve the probability of occupying a number
of discrete states in continuous time. These natural stochastic models are practical for
the modelling of discrete systems’ evolution. There are two main types of multi-state
models: K-progressive model and illness disability model (also known as disability model)
(Meira-Machado et al., 2009). For the former, the simplest case will be a model with two
states such as dead and alive state with merely one transition probability. Nevertheless,
this can be generalised to k-states as shown in Figure 8.1.
Figure 8.1: K-progressive model (Meira-Machado et al., 2009)
As an example, let us consider a three-state model for a hypothetical scenario of
survival of breast cancer patients which is illustrated in Figure 8.2.
Figure 8.2: Breast-cancer three-state model (adapted from (Meira-Machado et al., 2009))
One possible approach is to decouple the whole multi-state model into a variety of
survival models. This is achieved by fitting distinct hazard functions for all possible
transitions using proportional hazard regression models whilst at the same time making
suitable adjustment to the risk set. The effects of covariates can be assumed to act linearly
on the log hazards. However, this is a very simplified version of modelling multi-state
survival models and this makes it less useful if the covariate effects do not have constant
linear effects on the log hazards.
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Another alternative is dependent on whether the Markov assumption is completely
fulfilled. This will result in two different models: Cox-Markov model or Cox semi-Markov
model. In the former, the Markovian assumption is completely fulfilled, by which the
future states that an individual will occupy will only depend on the current state. Within
this fully Markovian framework, we may assume that the hazard function, hvj (t;(Z)) =
hvj0(t) exp (β
T
vjZ), where hvj (t;(Z)) is the hazard function for transitions from state v to
state j with covariate vector Z, hvj0(t) is a non-negative baseline hazard function and βvj
is a vector of regression parameters. The number of covariates, which may be, continuous
or categorical, is p.
Nevertheless, the complete Markov assumption is not truly tenable in the real-life
setting. Under a full Markovian framework, we assume that the future health of patients
who were recently afflicted with breast cancer is similar to that of breast cancer patients
who have been sick for a long time. Besides, for patients who experience recurrent breast
cancer (exemplified by state 2 in Figure 8.2), we may be interested in the sojourn time
of patients in state 1 (alive and healthy). Hence, the Cox semi-Markov model may be
used for the modelling purposes. The difference with this approach from the previous
full-Markovian approach is really subtle: the future of the states is not dependent on the
absolute time at the current state (i.e. the time lapsed since the entry of a subject into
the initial state), but rather on the time duration spent in the current state (Foucher
et al., 2007). Hence, the difference lies in the way we model the transition from state 2
to state 3. The hazard functions are given by




h23(t− T12;Z) = h230(t− T12) exp(βT23Z)
where T12 is the time when a patient enters into state 2 and t− T12 is the time duration
spent in state 2. This is similar to resetting the clock since, when a patient enters a new
state, the clock time is reset to zero again.
To address the possible non-linearity effects of covariates on the hazard function, we
may employ additive multi-state models, by which the transition of individuals from one
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where fi,hj(.), i=1,2,3,. . .,q represent smooth functions of the covariates for breast cancer
survival. This approach is more useful than the previous one since we relax the assumption
of a linear effect of covariates on breast cancer survival. Hence, we assume such covariate
effects may affect the breast cancer survival via unspecified smooth functions.
For the second type of model (illness-disability model, also known as illness-death
model), the individuals or patients were disease-free initially. Subsequently, they con-
tracted the disease (state 2) and died (state 3) later. For non-lethal diseases, the patients
may return to state 1 again after receiving successful treatments. If this is a possibility,
the model can be styled as a bi-directional model. Apart from that, patients may also
experience death instantaneously, thus bypassing state 2. Figure 8.3 illustrates an example
of an illness-disability model with three states.
Figure 8.3: Illness-disability model (Meira-Machado et al., 2009)
As a further example, let us consider an illness-disability model for surgically-operable
cancer patients who later experience recurrence, distant spread (metastases) and death.
For clarity, Figure 8.4 gives a further example of such a model.
8.3.2 Multi-state models for lung cancer survival
Borrowing the methodological framework used by Armero et al. (2016) a stage IV lung
cancer patient will occupy the following three states at a specific time t during the course
of their diseases:
181
Chapter 8. Conclusion and Future work
Figure 8.4: Multi-state model for surgically-operable cancer patients (Putter et al., 2007)
 State I: Stable disease (defined according to Response Evaluation Criteria in Solid
Tumor version 1.1 (RECIST) criteria (Eisenhauer et al., 2009)).
 State II: Progressive disease (increase in diameters of the tumors based on RECIST
criteria).
 State III: Death.
Hence, we can consider state 1 and state 2 to be transitory states and state 3 as an
absorbing state. The illness-disability model for this simplified version of a lung cancer
multi-state model can be further elucidated by Figure 8.5.
Figure 8.5: Multi-state model used by Armero et al. (2016)
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For this scenario, we can assume that transitions between states are determined by a
parameter vector, θ and covariates x. For individuals in state 2, the transition probability
from state 2 (progressive stage IV lung cancer) to state 3 (death) is also contingent upon
residence time in state 1 (symbolised by T12). These can be represented by the equations
p1j = (s, t | x,θ) = P(Z(t) = j | Z(s) = 1,x,θ), s ≤ t, j = 2, 3
and
p23 = (s, t | x,θ, t12) = P(Z(t) = 3 | Z(s) = 2,x,θ, T12 = t12), t12 ≤ s ≤ t.
To determine these two probabilities, the hazard function for times between transition,
Tij, may be employed since it is congruent with inter-state transition intensities. These
can be represented by the two equations
h1j(t | x1j,θ1j) = lim
δt→0
{
P(T ≤ T1j < t+∆t | T1j ≥ t,x1jθ1j)
∆t
}
, j = 2, 3
and
h23(t− t12 | x23,θ23, t12) = lim
δt→0
{
P(A | B,x23,θ23, T12 = t12)
∆t
}
where A is the event t − t12 ≤ T23 < t − t12 + ∆t and B is the event T23 ≥ t − t12. For
a homogenous illness-disability model that posesses a semi-Markovian property (v to j
transition intensity at a time point is also dependent upon sojourn time at state v), the
relationships between the hazard functions and the transition probabilities can be linked
via the equations





[h12(u | x12,θ12) + h13(u | x13,θ13)]du
}
,





h23(u− t12 | x23, t12)du
}
,
p12(s, t | x,θ, t12) =
∫ t
s
p11(s, u | x,θ)h12(u | x,θ12)p22(u, t | x,θ, u)du,
p13(s, t | x,θ) = 1− p11(s, t | x,θ)− p12(s, t | x,θ),
p23(s, t | x,θ, t12) = 1− p22(s, t | x,θ, t12),
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and
p33(s, t | x,θ) = 1.
Nevertheless, a fourth state can be added to the original ideas of Armero et al. (2016).
The fourth state is called a responsive disease state (can be either Partial Response (PR)
[defined as 30 percent reduction in the sum of diameters of target lesions, using the baseline
diameters as reference] OR Complete Response (CR) [defined as total disappearance of
the target lesion](Eisenhauer et al., 2009; Schwartz et al., 2016). The fourth state can
be anticipated to occur quite frequently in Malaysian advanced lung cancer cases since
the use of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs),
which is a form of molecularly-targeted therapy for lung cancer that specifically targets
the highly expressed cellular growth-promoting signalling cascades, resulting in a total
disappearance of target lesions (primary tumor mass in the lungs) in those harbouring
EGFR mutations, may cause a dramatic improvement in the survival of the subjects.
Therefore, for the Malaysian advanced lung cancer dataset, the following rearrangement
of the state space is proposed.
 State I: Responsive disease:A minimum reduction of 30% in the total diameters of
target lesions compared to their baseline measurements (Eisenhauer et al., 2009)
 State II: Stable disease: An inadequate reduction or increase in diameters of the
tumors to qualify for responsive disease or progressive disease (Schwartz et al., 2016)
 State III: Progressive disease (RECIST 1.1 criteria)
 State IV: Death (absorbing state)
Therefore, states I, II and III are considered as transient states and state IV as an ab-
sorbing state. The movements between states are governed by the patient’s health status.
The jump from state I or II to state III occurs when cancer progresses, from state III
to IV when cancer patients die because of disease progression, from state I or II directly
to state IV if the patient dies because of other reasons (not due to disease progression).
There can also be reverse jumps from state III to either state II or I since cancer may stop
progressing if new therapeutic regimens are given to the patients who have failed the first
line regime (which they might also have previously responded to), resulting in a second
complete or partial response period. There will be no jump from state I to state II since
they are mutually exclusive. Figure 8.6 summarises the four-state space.
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Figure 8.6: State space for the advanced model
8.3.3 Renewal process and non-homogenous Poisson
process in survival analysis
Much of the time-to-event modelling for cancer data assumes a non-repairable system.
This type of system can only experience a single failure and a parametric time-to-event
model using a Weibull distribution will aptly summarise the distribution of the time
when the system fails. In contrast, a repairable system presumes that failed items can be
restored back into service. For instance, a damaged car can be repaired and refitted back
into service, whilst severely damaged cardiac tissues are no longer repairable, requiring a
new organ transplantation for such patients. Hence, models for repairable systems have to
give allowances to a full sequence of repeated failures and it must also have the capability
to reflect the alterations in the system’s reliability as time progresses. A counting process
approach is thus suitable for modelling a repairable system in survival analysis.
Let N(t) represent the number of failures of a repairable system in one interval [0,
t]. Since N(t) is non-negative integer valued, the difference between N(t) and N(s) is
the number of failures occurring in the time interval between s and t (provided s < t)
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(Engelhardt and Bain, 1992). An alternative specification can also be made with re-
spect to sequential failure times: T1,T2,. . .,Tn (Lindqvist et al., 2003). If a system is
fully repairable into a new condition, this system can thus be modelled using a para-
metric assumption with independent and identically distributed survival times (renewal
process). However, the modelling of time-to-event data for cancer cases is far more com-
plicated. For instance, the time to chemotherapeutic failure between successive regimes
of chemotherapy becomes shorter due to the mutation in cancer cells that confers further
selective resistance towards different combinations of chemotherapy. Besides, for curable
cancer types, the times between relapses become progressively shorter as evident from the
shorter time to relapse for non-Hodgkin lymphoma patients who are cured by the second
chemotherapeutic regime, compared to their survival time when they were treated with
the first chemotherapeutic regime. Therefore, the repairable system in cancer cases can
be assumed to have a profound decrease in its reliability as time progresses (ie. as the
system ages).
To illustrate further, we may view the general condition where the renewal process of
a series of events is observed for every patient such that the the inter-event times Xj, j
= 1,2,. . . for a patient are iid. Hence, we may imagine a number of individual renewal
processes which are censored at possibly different times. Thus, the following scenarios for
censoring times may occur (Aalen and Husebeye, 1991):
 The censoring times can be considered to be fixed in advance. The example is at
the cessation of a fixed observation period.
 The censoring time itself can be considered as a random variable which is not de-
pendent upon the renewal process. Hence, every patient can be considered to have
distinct censoring times or one censoring time that is shared by several patients.
 Censoring time occurs after each patient has completed a predetermined number of
renewal periods.
 Censoring time happens when the individuals have completed a certain number of
periods or the observation times have exceeded certain limits.
 Censoring time occurs at the first event occuring after a predetermined time-interval.
The other alternative to a renewal process, which can be considered as a generalised
homogeneous Poisson process, is to use a non-homogeneous Poisson process (NHPP) to
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model cancer survival data. Engelhardt and Bain (1992) showed that this process has a
non-constant intensity function as given by
ν(t) = (β/θ)(t/θ)β−1.
An intensity function should not be confused with a hazard function since the former is
the absolute rate of failure for a repairable system whilst the latter is the relative rate
of failure for non-repairable systems (Deshpande et al., 1999). A Weibull process has a
mean value function, M(t), given by
M(t) = (t/θ)β; θ > 0, β > 0
where θ is the scale parameter whilst β is the shape parameter (Engelhardt and Bain,
1992). Besides, Engelhardt and Bain (1992) also demonstrated that M(t) can be alter-
natively reparameterised as
M(t) = λtβ.
If the second parametrisation of M(t) is substituted into the intensity function, ν(t), this
leads to parameterisation of ν(t) as
v(t) = λβtβ−1
To model cancer survival data that have the properties of a non-homogenous Poisson
process (NHPP), we could use a semiparametric model as proposed by Sinha (1993) based
on the conditional intensity function,
h(t|zi, wi) = I(t)h0(t) exp(βT zi)wi
where wi is a frailty effect that is patient-specific, zi is a vector of covariates for the i
th
individual, βT is the vector of unknown parameters, h0 is the baseline intensity function
and I(t) is the indicator of the censoring process. Therefore, wi can be considered as a
multiplicative random effect on the hazard function for a specific patient or individual.
The baseline hazard function can be modelled using a piecewise constant hazard function.
However, there are a few difficulties in computing the posterior distributions for this model
under the INLA framework. Firstly, frailty is usually regarded to be an iid gamma random
variable of mean 1 and unknown variance κ
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Wi ∼ Ga(κ−1, κ−1),
for each individual i = 1,. . .,N. As a result, this creates a cumbersome situation if INLA
is used for obtaining the posterior distributions. To circumvent this, several alternatives
such as using the log normal distribution for frailty could be explored so that the Weibull
process can be rewritten into a latent Gaussian model, a prerequisite for Bayesian inference
using INLA methodology.
8.4 Conclusions
The main goals of this research were as follows:
1. Compare the performance of different computational approaches (MCMC vs INLA)
in Bayesian inference for survival analysis models.
2. Investigate the construction of appropriate forms for the prior distributions of the
log hazard, Weibull shape parameters and frailty.
3. Assess the performance of INLA in missing covariates values and develop approaches
to improve the flexibility of INLA in this setting.
4. Apply the formulated approaches to practical problems using real medical data sets
and evaluate the strengths and limitations of each approach
In Chapter 7, we compared the performance of MCMC and INLA and we showed that
INLA was superior to MCMC when obtaining the posterior means and standard deviations
of our parameters of interest. In Chapter 6, we showed that the appropriate forms of prior
distributions for the log hazard could be computed for both the SNLG and Malaysian
advanced lung cancer data sets. We also showed in 6.6, the methods used to construct the
prior distributions for the log hazard, Weibull shape parameters and frailty variance. We
fulfilled objectives 3 and 4 in Chapter 7 by showing that INLA-MCMC can appropriately
handle missing covariate data problems in different kinds of real medical data sets and the





A.1 Standard Distributions Used in Survival
Analysis
To facilitate better understanding of the model structures developed in this research
project, standard distributions used in survival analysis will be elaborated.
A.1.1 Weibull and Exponential Distributions
The Weibull and exponential distributions are the two most commonly distributions used
in analysing the lifetimes of subjects. The two-parameter Weibull distribution has the
following form:











with b > 0 is the shape parameter and a> is the scale parameter. If k < 1, this means
that the failure rate declines as time progresses. If k> 1, the failure rate increases over
time. A special case occurs when the failure rate is a constant over time (k =1), where
the Weibull distribution is reduced to exponential distribution:








Then we substitute 1
a
= λ, resulting in;






with λ > 0 as the rate parameter.
A.1.2 Lognormal distribution
Let X is a random variable whose logarithm has a Gaussian distribution. Hence, Z = log
X is distributed normal. The pdf of this continuous distribution is given by:










where σ2 > 0, −∞ ≤ µ ≤ +∞. This distribution is useful for an alternative to gamma
distrbution if X ∈ (0, ∞).
A.1.3 Gamma distribution
Let Y is a random variable that has a positive support and follows a gamma distribution,
with a scale parameter,h, and shape parameter g. Hence, the pdf of Y is given as follows:






where g and h > 0. Γ (g) is a gamma function. This distribution is usually employed for
a parameter that has a strictly positive support. One of the examples is the variance of
a normal or log-normal distribution.
A.1.4 Log-logistic distribution
Let R is a random variable that has only positive support. Hence the pdf is given by:












where both α and β are strictly positive. This distribution is usually used in survival
analysis for modelling events whose rate escalates initially and diminishes eventually. As
an example, mortality rate may follow this kind of distribution.
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A.1.5 Multivariate normal distribution
This distribution is a Gaussian distribution that has been generalised from one-dimensional
univariate Gaussian to multi-dimensional Gaussian distribution. Let say X is a p-dimensional
random vector. The pdf of this distribution is thus given by:
f(x | µ,Σ) = 1
(2π)
p







where E[X] = µ and Var[X] = Σ, which denotes the positive-definite covariance matrix.
A.1.6 Beta distribution
Let V is a continuous random variable whose support is between 0 and 1. Hence, V follows
a beta distribution that has a pdf as follows:
f(v | α, β) = v
α−1(1− v)β−1
B(α, β)
where α and β are shape parameters that are strictly positive. B represents the beta
function that has the following form:
B(α, β) =
Γ (α) Γ (β)
Γ (α + β)
Beta distribution is popular with respect to Bayesian inference because it is a conjugate
prior distribution for binomial and geometric distributions.
A.1.7 Multinomial distribution
It is a generalised version of binomial distribution. In n number of multinomial trials
that are independent, there are k possible outcomes having fixed success probability.
Hence, multinomial distribution is hence the distribution of the outcomes determined
by multinomial trials. Let Q1, Q2, . . . , Qk with N =
∑k
i=1Qi = 1.The probability mass
function (pmf) of multinomial distribution is given by:
Pr(Q1 = q1, Q2 = q2 Q3 = q3, . . . , Qk = qk) =
n!












i=1 qi = n. Two special cases of this distribution should be noted; a) in a single
trial (n = 1) with k = 2 outcomes, this distribution is reduced to Bernoulli distribution,
b) in n independent trial with k = 2 outcomes, this multinomial distribution is reduced
to binomial distribution.
A.1.8 Dirichlet distribution
This distribution plays a very special role in Bayesian inference, it is a conjugate prior

























It can clearly be seen that if d=2, this distribution will be reduced to the beta distribution.
A.2 The Structure of SNLG dataset
The SNLG dataset has the following format (structure):
Table 1A: The structure of partial SNLG data
"t" "t.cen" "is.cen" "age" "hb" "wbc""gender""albumin"
0.0164 1.0164 0 12 -4.706 -6.069 1 2
0.2502 1.2502 0 3 -17.706 -5.970 1 1
0.1689 1.1689 0 -2 -25.706 -5.770 2 1
0.1945 1.1945 0 -8 -42.706 -4.970 2 2
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The negative signs for age, haemoglobin level (hb) and white blood cell (wbc) count are
attributed to the centering of the continuous quantitative covariates.
A.3 RJAGS and INLA codes for piston-ring
failures poisson regression model
---------------------------------------------------------------









































A.4 R function for the numerical quadra-
ture method used for the analysis of
kidney infection data set using expo-
nential proportional hazard model
kidney2<-function(eta1,eta2,t,status,placement,prior,alpha=1)
# Evaluates posterior density etc for Weibull model for kidney dialysis data.
# Exponential model is obtained when alpha is set to 1
# prior is mean0, mean1, var0, var1, covar for beta
# placement is 1 for surgical and 2 for percutaneous




































































A.5 Bayesian Weibull Survival Model for SNLG
























beta.ecog[1]<- -delta.ecog[1] -delta.ecog[2] -delta.ecog[3]
-delta.ecog[4]


































































































































A.6 R functions for splitting the survival
time of SNLG subjects into 10 time in-
tervals
#-------------------------------------------------------------
















































































A.7 Bayesian piecewise constant hazard model
using hierarchical priors for baseline haz-
ard for the SNLG data set (including
missing covariate information)
#Bayesian piecewise constant hazard for the SNLG data set (complete
covariate information) using age, sex, albumin, extranod, bulk, marrow















































#Priors for all beta coefficients
#----------------------------------






























A.8 Bayesian piecewise constant hazard model
with frailties using autoregressive pri-
ors for the SNLG data set with missing
covariate information
#Bayesian piecewise constant hazard model for the SNLG
data set using all 14 covariates
#---------------------------------------------------------














































































































































































































































# DYNAMIC PART D: ITERATIVE STEPS
#---------------------------------------------
for (j in 2:10)
{











































































































A.9 An example of user-written Metropolis-
Hastings sampler code for Weibull Sur-
vival Model
-----------------------------------------
METROPOLIS HASTINGS CODE FOR WEIBULL MCMC
-----------------------------------------




































































































































































A.10 User-written INLA code for intercept-
only simple linear regression example
#-----------------------------------------------





















formula <- y ~ 1
inla.output <-inla(formula, data = data.frame(y = y),
control.family = list(hyper = list(prec =list(prior =
"loggamma", param = c(a, b)))),control.fixed = list(

























theta.n<- sigma2.n <- lik <- num <- den <- prior <- c()
for (h in 1:H) {
theta.n[h] <-(tau.grid[h]*n*ybar+mu0/sigma2_0)/(tau.grid
[h]*n + 1/sigma2_0)
sigma2.n[h] <- 1 / (n*tau.grid[h] + 1/sigma2_0)
prior[h] <- dnorm(theta.n[h], mu0, sd=sqrt(sigma2_0))
lik[h] <- prod(dnorm(y, theta.n[h], sd=1/sqrt(tau.grid[h])))
num[h] <- hprior[h] * prior[h] * lik[h]
den[h] <- dnorm(theta.n[h], theta.n[h], sd=sqrt(sigma2.n[h]))
}
#---------------------------------------




#Normalise the tau density (precision)
#-------------------------
f.tau <- approxfun(tau.grid, post.tau,yleft=min(tau.grid), yright=max(tau.grid))
















for (j in 1:J) {
for (h in 1:H) {





































































#POSTERIOR SAMPLES FOR INTERCEPT
summary(marg.post.theta.plot.final)
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